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Aging is usually characterized by impairments in physiological functions 
increasing its susceptibility to dementia and neurodegenerative disorders. In this 
dissertation, the mechanisms of dementia-free aging were investigated. The use of an 
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human aging was shown to result in a significant decrease in the levels of oxidative 
stress. A proteomic analysis of these brains also demonstrated a significant decrease in 
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which correlated with improved learning and memory. 
 We show that following TBI key mitochondrial-related proteins undergo 
extensive oxidative modification, possibly contributing to the severe loss of 
mitochondrial energetics and neuronal cell death previously observed in experimental 
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Taken together, these findings support the role of oxidative stress in the 
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CHAPTER ONE 
 
Introduction and Research Aims 
 
The studies presented in this dissertation research were geared towards 
elucidating biochemical mechanisms associated with successful aging, improved learning 
and memory following treatment with an antioxidant fortified diet and a program of 
behavioral enrichment and also in gaining insights into mechanisms of protein oxidation 
in traumatic brain injury. Aging is defined as the gradual alteration in structure and 
function that occurs over time, eventually leading to an increased probability of death not 
associated with disease or trauma (Ashok and Ali, 1999; Gonos, 2000). Aging, and age-
related disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), 
Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) are usually 
accompanied by a significant increase in oxidative stress with an eventual decline in 
memory and cognitive function (Butterfield and Kanski, 2001; Poon et al., 2004a). 
Though various mechanisms for neurodegeneration have been put forth, the progressive 
accumulation of oxidative damage has been thought to play a significant role in the 
development or accumulation of neuropathology typically observed in these 
neurodegenerative disorders.  
The significant increase in oxidative stress and generation of free radicals 
observed in these neurodegenerative disorders are mediated through a wide range of 
mechanisms. Mitochondria play a key role through the generation of superoxide anion 
O2· -, which undergoes various reactions leading to the production of key ROS such as 
hydroxyl radical (OH·), peroxynitrite (OONO- ), and hydrogen peroxide (H2O2) among 
many others (Melov, 2000). For AD, our laboratory has proposed that the significant 
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increase in the levels of oxidative stress are mediated by amyloid-beta peptide (Aβ 1-42) 
through methionine 35 (Met-35)-related chemistry (Varadarajan et al., 2000; Varadarajan 
et al., 2001; Butterfield and Kanski, 2002). These ROS/RNS have been shown to mediate 
oxidative modification of proteins, lipids and DNA as observed in AD brain when 
compared to age-matched controls. Oxidative attack to peptides and proteins usually 
leads to alteration in protein structure (Subramaniam et al., 1997), and a possible loss in 
function contributing to the pernicious effects on cellular functions (Levine and 
Stadtman, 2001; Halliwell, 2006).  
The mechanisms involved in being able to achieve extended longevity while still 
maintaining cognitive function are still unknown. However, it has been proposed that the 
mechanism of successful aging is a product of an interaction between genetic, 
environmental and lifestyle factors (Petropoulou et al., 2000; Perls et al., 2002a; Perls et 
al., 2002b; Snowdon, 2003). Significantly, until the present dissertation research, the 
protein profiles in these groups of individuals have not yet been established. As a result, 
this dissertation research provides a proteomic expressional profile for the non-demented 
nonagenarian compared to demented age-match controls, providing possible biochemical 
pathways towards successful aging. 
With an increase in age-related oxidative stress and cognitive dysfunction as 
reported for neurodegenerative disorders such as AD and models thereof, the use of 
antioxidants, antioxidant-related compounds and exercise programs have been found to 
provide beneficial and protective effects against these age-related deficits (Mates et al., 
1999; Bickford et al., 2000; Milgram et al., 2002b; Drake et al., 2003b; Farr et al., 2003; 
Adlard et al., 2005b). These beneficial effects include a reduction in the levels of 
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oxidative stress, improvements in learning and memory and a delay in the development 
of age-related cognitive deficits. However, the mechanisms that underlie these effects in 
the aging brain are still not well established. It has been reported that there is a significant 
improvement in cognitive function in the canine model of human aging undergoing a 
program of behavioral enrichment and having a diet fortified with a broad range of 
antioxidants (Milgram et al., 2004; Milgram et al., 2005). We propose in this dissertation 
research that this improvement in cognitive function observed is due to a decrease in the 
level of oxidative stress, up-regulation of key antioxidant enzymes and protection of key 
brain proteins from oxidative damage. Therefore, this dissertation provides possible 
mechanism for the improvement in learning and memory following a behavioral 
enrichment program and an antioxidant fortified diet in a canine model of human aging. 
This model is highly relevant to AD since Aβ (1-42) in both beagles and humans have the 
same amino acid sequence.     
One of the risk factors associated with developing age-related defects in learning 
and memory as observed in AD is traumatic brain injury (TBI) (Jellinger, 2004b). TBI is 
associated with a significant loss in mitochondrial bioenergetics, increased oxidative 
stress and neuronal cell death mediated by necrosis and apoptosis (Sullivan et al., 2002; 
Lifshitz et al., 2004a). Despite the well-established notion of increased oxidative stress 
and decline in mitochondrial function reported in TBI, the identities of specific proteins 
undergoing oxidative modification following TBI are yet to be established. As a result, 
one central goal of this dissertation research is to identify specific mitochondria-related 
proteins that have been oxidatively altered following TBI. 
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In Summary, this dissertation addresses the following questions: 
1. Which proteins are protected following the combined treatment of an antioxidant 
fortified diet and a program of behavioral enrichment in the brains of the canine 
(beagle) model of human aging? How do these proteins contribute to the 
improved learning and memory in the aging canine model?  
2. What proteins are differentially expressed in the brains of the canine model of 
human aging after treatment with an antioxidant-fortified diet and a program 
behavioral enrichment?  
3. Which brain mitochondrial-related proteins are oxidatively modified following 
experimental traumatic brain injury (TBI)? 
4. What brain proteins play a role in the mechanism of successful aging as seen the 
non-demented nonagenarians? 
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CHAPTER TWO 
 
 Background 
 
2.1 Neuronal structure and function  
 
The central nervous system (CNS) represents the largest part of the nervous 
system. The CNS is composed of the brain and the spinal cord, which is organized in a 
network of billions of interconnected components, with the major class of cells being 
neurons. In addition, this network is composed of glia and astrocytes that provide support 
to the neurons. Neurons in conjunction with other specialized cells like the astrocytes or 
microglia mediate the specialized function of the brain which involves the reception, 
processing and transmission of information as well as neuroprotection. 
The anatomy of nerve cells as shown in Fig 2.1 is composed of the cell body also 
known as the soma or perikaryon, cellular extension process known as dendrites, and a 
long tube-like projection known as the axon. Just like any other cellular structure, the 
neuron consists of a cell membrane and organelles that perform specialized functions. 
These include; the nucleus, mitochondria, Golgi apparatus, lysosomes, endoplasmic 
reticulum and ribosomes among others. Due to their specialization, neurons can be 
functionally classified as excitatory, inhibitory and modulatory. As already mentioned, 
the main function of the neuron is the reception and transmission of information in the 
form of nerve impulses. Nerve impulses are usually transmitted through electrochemical 
interactions. Briefly, at rest, the intracellular potassium ions and extracellular sodium ions 
generate and maintain a neuronal electrical potential of approximately -70 mV. This 
movement of potassium and sodium ions is facilitated by membrane bound sodium-
potassium pumps. At rest, the cell membrane is approximately 100 times more permeable 
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to potassium ions compared to sodium.  In the presence of a stimulus, voltage-gated 
sodium channels are opened, allowing sodium ions to diffuse into the cell hence making 
the cell more positive, i.e., depolarizing the cell to about 40+ mV. Once this has 
stabilized, the sodium channels close and the voltage -dependent potassium channels 
open, allowing potassium to influx into the cell. This large outward current of potassium 
ions hyperpolarizes the neuron. The voltage-sensitive potassium channels now close and 
the continual movement of potassium through potassium leak channels again dominates 
the membrane potential. Sodium-potassium pumps continue to pump sodium ions out and 
potassium ions in, preventing any long-term loss of the ion gradients. The resting 
potential of -70 mV is then re-established and the neuron is said to be repolarized. Fig 2.2 
provides a summary of the action potential process. 
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Figure 2.1 Schematic representation of the neuron and its various components.  
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                       Figure 2.2 Summary of the action potential.  
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2.2 Oxidative stress  
 
2.2.1 Overview 
 
Under normal physiological conditions, there exists a balance between the 
amounts of oxidants and antioxidant defenses present in the body. However, as a result of 
disease, trauma, or environmental factors, there is a shift towards an increase in the 
production of pro-oxidants or a decline in the levels of antioxidants. Consequently, the 
rate at which reactive species are generated exceeds the rate at which endogenous 
antioxidant defenses can scavenge oxidants. This resulting imbalance is what is defined 
as oxidative stress (Halliwell, 2006)  (Fig. 2.3). It has been established that ROS/RNS 
play a significant role in the normal aging process as well as in various age-related 
diseases neurodegenerative disorders (Ames et al., 1993a; Markesbery, 1997; Lewen et 
al., 2000; Poon et al., 2004a; Dalle-Donne et al., 2006). An increase in the levels of 
oxidative stress has been reported in a number of conditions like: Alzheimer’s disease 
(AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis 
(ALS) among many others (Butterfield and Kanski, 2001).  
 
 
 
 
 
 
 
 
 10
 
 
 
 
 
               Figure 2.3 A representation of normal vs. oxidative stress conditions. 
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2.2.2 Free radical production 
 
2.2.2.1 Overview 
 
Free radicals are defined as low molecular weight molecules that contain at least 
one unpaired electron and have previously been shown to mediate the pathophysiology of 
most neurodegenerative disorders (Nordberg and Arner, 2001; Droge, 2002). These 
radical species can be dived into primary radical species of which some examples are 
OH·, O2·- CO2·- NO· and non-radical species are H2O2, N2O2, O2, NO2, HO2, and HOCl 
among many others (Halliwell, 2006).  
 
2.2.2.2 Reactive oxygen species (ROS)  
 
ROS are defined as a group of highly reactive molecules usually derived from 
ground-state oxygen (O2) (Halliwell, 1996; Fridovich, 1999; Halliwell, 1999; Betteridge, 
2000). Some common examples include superoxide anion (O2· -), hydroxyl radical (OH·), 
and hydrogen peroxide H2O2 among many others.  This single most important source of 
ROS is the mitochondria. As a by-product of energy metabolism during normal cellular 
respiration, there is a 1-2% leakage of electrons from the mitochondria leading to the 
partial reduction of oxygen (reaction 1) to form a highly toxic free radical known as 
superoxide (Turrens, 2003). A detailed discussion on mitochondria’s role in oxidative 
stress is provided below (Section 2.4.5). Superoxide dismutase catalyzes the dismutation 
of superoxide to hydrogen peroxide and water. However, in the presence of transition 
metal ions in the reduced state, like Fe2+ or Cu+, H2O2 is further converted to hydroxyl 
radical OH· (reaction 2). Superoxide can also be produced from the activity of enzymes 
such as xanthine oxidase and NADPH oxidase. Fig 2.4 below provides a summary of the 
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pathways to the generation of the ROS mentioned above. A detail discussion of these 
pathways is provided below in Section (2.4 and 2.7.2).  
 
   Reaction 1: O2 + e-                    O2·-           
 
               Reaction 2: H2O2 + Fe2+                  HO· + OH- + Fe3+         
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Figure 2.4 Pathways leading to the production of ROS/RNS and antioxidant systems. 
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2.2.2.3 Reactive nitrogen species (RNS) 
RNS represent a group of reactive nitrogen containing compounds with the most 
common examples being NO, peroxynitrite (-OONO), and nitrogen dioxide (NO2). Nitric 
oxide radical is produced from the activation of the enzyme nitric oxide synthase (NOS). 
There are three isoforms of NOS, i.e., inducible NOS (iNOS), endothelial NOS (eNOS), 
and neuronal NOS (nNOS) (Calabrese et al., 2000). Nitric oxide (NO) in the presence of 
superoxide reacts to form peroxynitrite  reaction 3. Nitric oxide regulates various cellular 
processes that include vasodilatation, modulation of signaling cascades, and immune 
responses among many others. On the other hand, it has also been shown that nitric oxide 
is involved in tissue injury and the progression of various inflammatory pathways in 
neurodegenerative disorders as reviewed in (Halliwell, 2006). A detailed discussion on 
the reactions of OONO is provided in Section (2.2.1.3.2). 
                
                 Reaction 3: NO + O2·-                            -OONO 
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2.2.3 Targets of Reactive oxygen species 
 
2.2.3.1 Protein oxidation 
 
Protein oxidation is an important post-translational modification observed in a 
number of neurodegenerative disorders. Proteins are highly sensitive to oxidative 
modifications by ROS/RNS. Oxidative damage to proteins can have a wide range of 
downstream functional consequences. These can include inhibition of enzymatic activity, 
increased susceptibility to degradation among many others. In AD and other 
neurodegenerative disorders, there is a significant increase in the levels of protein 
oxidation (Aksenova et al., 1998; Levine and Stadtman, 2001; Butterfield and 
Lauderback, 2002; Halliwell, 2006). It should be noted, however, that the progressive 
accumulation of oxidative damage is a combination of multiple factors. These include; a) 
rate of formation of ROS/RNS; b) sensitivity of proteins to these ROS/RNS; c) 
availability of antioxidant defense mechanisms; and d) the effectiveness of the 
mechanism involve in the repair or elimination of damaged proteins (Stadtman and 
Berlett, 1997; Stadtman and Levine, 2003). Some examples of oxidative modifications 
are discussed here.  
 
2.2.3.1.1 Protein carbonyls 
The levels of protein carbonyls can index protein oxidation. The levels of protein 
carbonyls have been shown to be a good marker of oxidative stress (Levine et al., 1990). 
There is a significant increase in the levels of protein carbonyls in aging and in age-
related neurodegenerative disorders (Hensley et al., 1996). Protein carbonyl formation 
can be introduced into proteins through three major mechanisms (Levine et al., 1990; 
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Butterfield and Stadtman, 1997; Stadtman and Levine, 2003). These are I) Oxidation of 
specific amino acids present in protein residues (Fig 2.5) II);  β-scission of peptide 
backbone (Fig 2.6); and III); Covalent modification of amino acids by reactive aldehydes 
like HNE and acrolein (Fig 2.7). It can therefore be seen that protein carbonyl formation 
is orders of magnitude greater than other oxidative modifications making it a widely used 
marker for protein oxidation. The levels of protein carbonyls can be analyzed 
immunochemically. The details of this procedure will be discussed in Chapter 3. 
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Figure 2.5 Peptide bond cleavage and formation of protein carbonyls through the 
diamide and α-amidation pathways. 
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Figure 2.6 Mechanism of protein carbonyl formation from β-scission. 
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        Figure 2.7. Covalent modification of key amino acids by HNE. 
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2.2.3.1.2 3-Nitrotyrosine (3NT) 
Protein oxidation also can be indexed by the levels of 3-nitrotyrosine (3NT). As 
mentioned previously, the activity of nitric oxide synthase leads to the production of 
nitric oxide. This is usually through the catalytic conversion of L-arginine to citrulline 
(Calabrese et al., 2000). Nitric oxide in itself is not a strong oxidant, but the diffusion rate 
limited reaction with superoxide anion leads to the production of a highly reactive species 
known as peroxynitrite ONOO- (Reaction 3). This reaction leading to the formation of 
peroxynitrite is regulated by the enzymatic activities of NOS and SOD, since they are the 
two enzymes that produce the needed reactants. Peroxynitrite is highly reactive with a 
half-life of less than one second and it can exist in two forms; either as the peroxynitrite 
anion (ONOO-), or as the protonated peroxynitrous acid (ONOOH) (reaction 4). This 
protonated form can undergo hemolytic cleavage to form the toxic species hydroxyl and 
nitrite radicals (reaction 5). It should be noted however, that this reaction proceeds via 
carbon dioxide as shown in Fig 2.8a 
             Reaction 4: ONOO- + H+ HOONO   
             Reaction 5: HOONO                   .OH + NO2 . 
  
 Under physiological conditions it has been proposed that peroxynitrite reacts 
with carbon dioxide with the resulting reactive intermediates being responsible for the 
nitration of proteins (Fig 2.8a) (Denicola et al., 1996). The initial reaction of peroxynitrite 
and carbon dioxide produces an intermediate known as nitrosoperoxycarbonate (Lymar 
and Hurst, 1996; Lymar et al., 1996). This species then undergoes rearrangement, 
forming nitrocarbonate. The homolysis of nitrocarbonate can then generate a carbonate 
anion and a nitrite radical, which can then react with tyrosine residues on proteins leading 
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to the formation of 3-nitrotyrosine (3NT) Fig 2.8b). It should be noted however, that in 
certain cases (like the reaction of peroxynitrite with glutathione) the presence of carbon 
dioxide inhibits peroxynitrite reaction (Zhang et al., 1997). The levels of 3NT can be 
detected immunochemically, and it has been shown that in aging and age-related 
disorders, there is a relative increase in the levels of 3NT, further confirming the notion 
of increased oxidative stress in these neurodegenerative disorders (Schulz et al., 1997). 
Though not discussed, it should be noted that there are other possible nitration end 
products that can be produced from the reactions mentioned above. Some examples are 
dityrosine and tyrosine peroxide as shown in Fig 2.8b (Ducrocq et al., 1999). 
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Figure 2.8a: Formation of peroxynitrite and its reaction in the presence of carbon 
dioxide. 
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Figure 2.8b:  Mechanism of 3NT formation. 
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2.2.3.2 Lipid peroxidation 
 
There is accumulating evidence implicating lipid peroxidation in the aging 
process and also in age-related neurodegenerative disorders like AD among other 
diseases (Butterfield and Lauderback, 2002; Dei et al., 2002). Lipids are particularly 
vulnerable to oxidative attack due to the availability of unsaturated fatty acid β-chains 
and the solubility of paramagnetic oxygen in the bilayer. Lipid peroxidation proceeds via 
a free-radical mediated chain reaction that is initiated by the abstraction of labile 
hydrogen by the radical forming a carbon centered radical (reaction 6). The lipid radical 
then reacts rapidly with paramagnetic oxygen forming a peroxyl radical (reaction 7). This 
peroxyl radical reacts with nearby lipids, abstracting another nearby allylic hydrogen 
atom, forming lipid hydroperoxides and another carbon-centered radical. If not impeded 
the chain reaction propagates (reaction 8). Lipid peroxidation is terminated by the 
quenching reaction of two peroxyl radicals forming oxygen and a nonradical species 
(Reaction 9). The presence of vitamin E (α- tocopherol), an endogenous lipid soluble 
antioxidant can also terminate this chain reaction as a chain-breaking antioxidant. The 
lipid peroxyl radical can abstract a labile hydrogen from α- tocopherol (TOH) forming a 
tocopheroxyl radical TO·. This radical can be recycled back to TOH by ascorbic acid 
(vitamin C). Hence, the use of both vitamin E and C as supplements against oxidative 
stress-mediate disorders is often employed. This will be discussed in detail in Section 
(2.7.3). 
        Reaction 6: LH + X·                     L.  + XH 
     Reaction 7:  L. + O2                    LOO. 
     Reaction 8:  LOO. + LH                   LOOH + L. 
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     Reaction 9:  LOO. + LOO.                   Nonradical + O2 
 
2.2.3.2.1 Membrane composition 
 
Biological cellular membranes occur in several locations including the plasma 
membrane. Biological membranes are selectively permeable membranes composed of 
lipid bilayers, proteins, cholesterol and carbohydrates (Fig 2.9). The fluid mosaic model 
of lipid bilayer demonstrates that the cell membrane is composed of two “leaflets”. Each 
leaflet is composed of glycerol-derived phospholipids that contain a polar phosphate head 
and hydrophobic chains. The leaflets are oriented in such away that one polar phosphate 
head is towards the cytosol while the other is towards the extracellular milieu. The brain 
is particularly rich in peroxidizable polyunsaturated fatty acids (PUFA). Some common 
examples are arachidonic (AA, 20:4n-6) (Fig 2.10), and decosahexaenoic acid (DCH, 
22:6n-6) (Fig 2.11) among many others. In neurodegenerative disorders like AD, there is 
a decline in the levels of PUFA, possibly due to their release from the cell membrane by 
the actions of phospholipase A2 (Pratico et al., 1998). These free phospholipids in turn 
can undergo either enzymatic or non-enzymatic oxidation leading to the generation of 
reactive aldehydes, prostaglandin isomers and other key biomolecules that play a role in 
the oxidative stress pathology of neurodegenerative disorders. Figure 2.12 shows the free 
radical-mediated formation of 4-hydroxy-2-trans-nonenal (HNE) from arachidonic acid. 
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            Figure 2.9 Representation of the membrane bilayer. 
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                                  Figure 2.10 Arachidonic acid (AA, 20:4n-6) 
 
 
                                     
 
                                    Figure 2.11 Decosahexaenoic acid (DCH, 22:6n-6) 
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            Figure 2.12: Free radical formation of HNE from arachidonic acid. 
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2.2.3.2.2 Reactive aldehydes 
Reactive aldehydes are considered to be the end products of lipid peroxidation. 
Free radical attack on PUFA leads to the formation of reactive alkenals with varying 
carbon chain lengths. The most common α, β-unsaturated aldehydes observed in 
neurodegenerative disorders include: 4-hydroxy-2-nonenal (HNE), acrolein (2-propenal), 
and malondialdehyde (MDA). Relative to free radicals, these reactive aldehydes have 
longer half-lives that allow for their diffusion to distant sites from their site of formation. 
These alkenals can readily react via Michael addition with proteins, leading to the 
formation of stable covalent protein-bound adducts with cysteine, lysine, and histidine 
residues (Butterfield and Stadtman, 1997; Subramaniam et al., 1997). These 
modifications can lead to conformational and structural changes in proteins thereby 
leading to loss of function and cytopathologic effects observed during oxidative stress. 
These reactive aldehydes in themselves or as thiobabituric acid species have been used as 
excellent biomarkers of lipid peroxidation in various neurodegenerative disorders. There 
is an elevation in the concentrations of free HNE in the ventricular cerebral spinal fluid 
CSF of AD patient, while the levels of protein-bound HNE are also increased (Lovell et 
al., 1995; Markesbery and Lovell, 1998; Lauderback et al., 2001). HNE bound to proteins 
is also elevated in brain of subjects with mild cognitive impairments (Butterfield et al., 
2006b) usually the milder form of AD. Acrolein is the most reactive of this group of 
aldehydes. Acrolein adducts have been observed in the NFT of AD patients compared to 
control (Lovell et al., 2001). Acrolein has also been shown to bind to NADH-dependent 
mitochondrial enzymes, pyruvate dehydrogenase and α-ketoglutarate dehydrogenase 
leading to their inactivation (Pocernich and Butterfield, 2003). On the other hand, MDA 
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can also undergo similar reactions like HNE. There is an increase in the levels of MDA in 
the inferior temperal cortexes of aged human brain, (Palinski et al., 1990), and in 
cytoplasm of neurons and astrocytes (Dei et al., 2002). In the canine model of human 
aging, it was observed that lipid peroxidation as indexed by MDA was increased as a 
function of age (Head et al., 2002). As a result, these studies and others continue to 
provide support for the involvement of oxidative stress and lipid peroxidation in 
neurodegenerative disorders. 
 
2.2.3.2.3 Isoprostanes and Neuroprostanes 
In addition to reactive aldehydes, iso-and neuroprostanes present another index 
for lipid peroxidation and oxidative stress (Morrow and Roberts, 1999; Milne et al., 
2005). The free radical catalyzed non-enzymatic oxidation of the PUFA arachidonic acid 
and docosahexanoic acid, results in the generation of biologically active prostaglandin 
derivatives (Morrow, 2006). These prostaglandin isomers are referred to as isoprostanes 
(IsoPs) and neuroprostanes (NP), respectively, and they represent a reliable index for 
lipid peroxidation. The levels of isoprostanes and neuroprostanes have been reported to 
be increased in AD patients, providing additional evidence for lipid peroxidation in AD 
(Pratico et al., 1998; Montine et al., 2005). In addition, 8-isoprostaglandin F2 alpha has 
also been used as a marker for lipid peroxidation after experimental brain injury 
(Hoffman et al., 1996). 
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2.2.3.3 DNA oxidation 
 
Oxidative modification of DNA has been observed during normal brain aging and 
also in AD (Mecocci et al., 1993). There is increased damage to both nuclear and 
mitochondrial DNA. Mitochondrial DNA is particularly vulnerable to oxidative attack 
when compared to nuclear DNA because of their proximity to the source of production of 
ROS, the lack of protective histones and also their inability to perform repair mechanism 
(Wallace, 1992; Ames et al., 1993b). Also, there is recent evidence in AD brains that Aβ 
(1-42), which produces oxidative stress , resides in mitochondria (Beal, 2004). This 
damage could probably lead to deleterious effects to the mitochondria and it has been 
proposed that this is one of the mechanisms resulting to mitochondrial alterations in most 
neurodegenerative disorders (Beal, 2005; Schapira, 2006). DNA oxidation has been 
shown to be mediated through the oxidative attack of DNA by ROS particularly hydroxyl 
radical (OH·). Oxidative attack on DNA by hydroxyl radical yields a large number of 
possible base-adducts; for example, it could lead to modification of DNA bases, DNA 
strand breaks, DNA-DNA or DNA-protein crosses links among many others. The most 
common adduct is 8-hydroxy-2'-deoxyguanosine (8-OHdG), resulting from the 
hydroxylation of guanine at the C8 position. The quantified levels of 8-OHdG have since 
been used as the best biomarkers of DNA oxidative damage. During aging and age-
related disorders, there is a significant increase in the levels of 8-hydroxy-2'-
deoxyguanosine (8-OHdG) in AD patients compared to controls (Mecocci et al., 1993; 
Lovell et al., 1999). 
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2.3 Brain aging and oxidative stress 
 
2.3.1 Overview 
 
As noted above, aging is defined as the gradual alteration in structure and function 
that occurs over time, eventually leading to an increased probability of death not 
associated with disease or trauma. Aging can be considered to be a product of an 
interaction between genetic, environmental and lifestyle factors (Ashok and Ali, 1999; 
Gonos, 2000). Aging is usually characterized by impairments in physiological functions, 
such as impairments in the brain, mitochondrial dysfunction, increased susceptibility to 
dementia and neurodegenerative disorders, i.e., Alzheimer’s disease (AD) (Calabrese et 
al., 2001; Lenaz et al., 2006). As was mentioned previously, the aging process usually 
makes the brain susceptible to oxidative attack leading to neuronal cell death and loss of 
memory and cognitive functions. The brain is particularly susceptible to oxidative 
damage due to a number of factors. (a) The brain has one of the highest metabolic rates of 
any organ and is solely dependent of the supply of oxygen for its function. This 
characteristic therefore leads to the increased production of ROS through the 
mitochondria. (b) The brain lacks a relative capacity of antioxidant defense systems. (c) 
The brain has a high level of polyunsaturated fatty acids (PUFA) that can easily undergo 
peroxidation leading to the formation of reactive aldehydes among others as discussed 
previously and (d) There is a high level of redox metal ion (Fe2+), which can participate 
in lipid peroxidation reaction (Poon et al., 2004a). 
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2.3.2 Free radical theory of aging 
 
The aging process is an interaction of a wide range of factors leading to the 
proposition of various theories that try to define and elucidate the aging process. Among 
these theories is the free radical theory of aging. This was first proposed by Harman in 
1956 (Harman, 1956) and it postulates that the production of reactive free radicals leads 
to the progressive damage of biomolecules such as proteins, lipids or DNA resulting into 
a loss of cellular function leading to eventual cell death (Beckman and Ames, 1998; 
Droge, 2002; Harman, 2003, 2006).  This theory is supported not only by the 
involvement of oxidative stress in age-related disorders like AD, but also with the 
established notion that there is increased oxidative stress and altered antioxidant activity 
in the aging process (Beckman and Ames, 1998).    
 
2.3.3 Alzheimer’s disease   
 
 Alzheimer’s disease (AD), first reported by Alois Alzheimer in 1907, is one of the 
most common forms of dementia affecting the elderly population and accounting for 50-
60% of all dementia cases. In the western world, the prevalence of AD in people aged 85 
year and above is approximately 50% (Blennow et al., 2006). In 2001, it was estimated 
that approximately 24 million people were affected with AD, and it is believed that due to 
the increasing life expectancy, 81 million people will be affected by the year 2040 (Ferri 
et al., 2005). The costs involved with AD in the USA are estimated at least $100 billion 
annually and it has been suggested that AD has the potential to become an overwhelming 
public health concern. Consequently, these facts create an urgent need for the 
development of potential therapeutic interventions. The most common risk factors for 
developing AD is aging, other risk factors include; a decreased reserve capacity of the 
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brain, including reduced brain size, low educational and occupational attainment, low 
mental ability in early life, reduced mental and physical activity during late life, traumatic 
brain injury, and genetics among many others (Mayeux, 2003; Mortimer et al., 2003; 
Jellinger, 2004a, b). Clinically, AD is marked by loss in memory and cognitive functions, 
loss of language function and motor skills, altered behavior and ultimately death.  Its 
pathophysiological hallmarks include senile plaques (SP), neurofibrillary tangles (NFT), 
and synapse loss starting in the entorhinal cortex and progressing into the hippocampus 
and cortex (Markesbery, 1997). One underlying mechanism associated with AD is the 
involvement of oxidative stress as indexed by the increase in the levels of protein 
oxidation as indexed by protein carbonyls and 3-nitrotyrosine, and also by the levels of 
lipid peroxidation indexed by levels of free and protein bound HNE among many other 
indices.  
 
2.3.3.1 Amyloid-beta peptide (Aβ)  
 
Central to the mechanisms of increased oxidative stress in AD is amyloid-β-
peptide (Aβ). Senile plaques primarily are composed of Aβ protein, which is a 39-43 
amino acid peptide. Aβ is produced by the proteolytic cleavage of amyloid precursor 
protein (APP) by β-secretase and γ-secretase at the amino terminus by and at the carboxy 
terminus, respectively (Butterfield and Boyd-Kimball, 2005). The cleavage by γ -
secretase can occur at varying positions within the carboxy terminus, hence generating 
Aβ peptides of varying length. The two main Aβ peptides found in human brain are Aβ 
(1-40) and Aβ (1-42) with Aβ (1-42) being the main component of senile plaques and the 
more toxic form (Figure 2.13). 
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Our laboratory and others have established a role for Aβ-induced oxidative stress 
in AD. Support for this comes from the fact that Aβ (1-42) has been shown to induce 
protein oxidation and lipid peroxidation in vitro and in vivo (Hensley et al., 1995; 
Markesbery, 1997; Yatin et al., 1999; Butterfield and Lauderback, 2002; Drake et al., 
2003a). We have proposed that Aβ1-42 peptide, as a small oligomer, inserts itself in the 
lipid bilayer in an α-helix conformation. A one-electron oxidation of methionine forms 
the methionine sulfuranyl radical, which can then abstract a labile hydrogen atom from 
neighboring unsaturated lipids forming a carbon-centered lipid radical (L.), which can 
react with molecular oxygen to from a peroxyl radical (LOO.). This peroxyl radical can 
abstract hydrogen from a neighboring lipid to form the lipid hydroperoxide LOOH and a 
carbon centered radical L., which propagates the free radical chain reaction (Varadarajan 
et al., 2001; Butterfield et al., 2005) (See reactions 6-9 above). It is this mechanism of 
free radical generation that we believe is responsible for the increased levels of oxidative 
stress leading to neurodegeneration and a decline in memory and cognitive function in 
AD patients hence continuing to support the rationale of the free radical theory of aging 
(Markesbery, 1997; Beckman and Ames, 1998).  
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Figure 2.13 Proteolytic cleavage of APP by β-secretase and γ-secretase. 
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2.3.4 Successful aging 
 
 Successful aging or normal aging can be defined as the ability to achieve 
extreme old age while still maintaining intact cognitive function. Centenarians are the 
fastest growing age-group in the USA, and it is projected that there will be more that 
400,000 persons in the next 30 years over 100 years old (Silver et al., 2002). Studies have 
shown that there is an increase in the incidence of dementia among people aged 85 years 
and above (Silver et al., 2001; Perls, 2004b, a), and most people believe that dementia is 
inevitable to people in this age group (Blansjaar et al., 2000; Snowdon, 2003; Perls, 
2004a). However, various studies on nonagenarians and centenarians have shown that 
approximately 30% of centenarians are cognitively intact and that among those who are 
demented, 90% show a delay in the time they present signs of cognitive impairments well 
into their 90’s (Hagberg et al., 2001; Silver et al., 2001; Perls, 2004b, a). As a result, the 
increasing number of cognitively intact nonagenarians and centenarians disputes the 
notion that the older one becomes that dementia is inevitable (Green et al., 2000; Perls, 
2006). The mechanisms involved in the rising number of the dementia-free oldest-old 
appear to be the result of a complex combination of various factors. These include 
genetics, environment, and lifestyle among others. These factors, therefore, add to the 
complexity of understanding the mechanisms involved in the process of successful aging 
in the human population (Perls, 2005; Perls, 2006). In the current dissertation research, 
we have sought to gain a better understanding of biochemical mechanisms involved in 
successful aging.  
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2.3.5 Animal models of aging 
 
 Studies that try to elucidate the mechanisms of human aging and age-related 
disorders are usually hampered by the lack of a good animal model that can be easily 
translated to the human population. However, huge strides have been made in developing 
animal models, e.g. transgenic mice that have led to an increase in the understanding of 
the mechanisms of human aging. The differences between the genomes of the human and 
the animal species is one major setback in studying age-related neurodegenerative 
disorders; moreover, the use of primates which are closer species to humans is not always 
feasible for age-related studies, due to the length of time required to observe such age-
related effects. Recently, the use of the canine model of human aging has gained 
considerable interest (Cummings et al., 1996b; Cummings et al., 1996a; Cummings et al., 
1996c; Head and Torp, 2002). As will be seen in Chapters 4 and 5, the aging canine 
provides one of the best models for human aging due to a number of reasons. These are: 
a) Aged canines develop aspects of neuropathology similar to that observed in aged 
humans; (b) Canines exhibit a clinical syndrome of age-related cognitive dysfunction; (c) 
Aged canines are deficient on a variety of neuropsychological tests of cognitive function; 
and (d) Canines develop extensive β-amyloid deposition within neurons and their 
synaptic fields which appears to give rise to senile plaques. This level of β-amyloid 
deposition correlates with cognitive dysfunction, and the amino acid sequence of beagle 
Aβ is the same as that in humans.   
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2.4 Mitochondria  
 
2.4.1 Overview 
 
There is increasing evidence for mitochondrial involvement in the pathogenesis of 
neuronal cell death in most neurodegenerative disorders. This evidence applies to aging, 
age related-disorders like Alzheimer’s and Parkinson’s disease, amyotrophic lateral 
sclerosis (ALS) hereditary spastic paraplegia, and cerebellar degenerations, multiple 
sclerosis (MS) and also in various nervous system injuries like TBI. Oxidative stress and 
excitotoxicity seem to play a key role in the mechanisms leading towards the observed 
mitochondrial dysfunction (DiMauro et al., 1993; Melov, 2000; Calabrese et al., 2001; 
Dalakas et al., 2001; Lenaz et al., 2002; Fiskum et al., 2003; Lifshitz et al., 2004a; Beal, 
2005; Zeevalk et al., 2005).  
 
2.4.2 Mitochondria structure 
Mitochondria are organelles that evolved from a symbiotic relationship between 
aerobic bacteria and primordial eukaryotic cells. Mitochondria still carry a functional 
relic of their original genome (DiDonato et al., 1993; Wallace, 2005). They are 
intracellular tubular organelles delimited by two membranes. The outer mitochondrial 
membrane (OMM) is permeable to ions and small proteins of molecular weights < 10 
kDa, while the inner mitochondrial membrane houses the multimeric enzyme complexes 
of the electron transport chain (Schapira, 2002). Human mitochondrial DNA is a circular 
double stranded molecule of about 16.6 Kb long with the genome containing 37 genes. 
Of these, 13 genes encode protein subunits of respiratory chain complexes with a 
significant amount of mitochondrial proteins being encoded by the nuclear genome and 
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transported into the mitochondria. For example, complex II is solely composed of 
proteins encoded by nuclear genes (Orth and Schapira, 2001; Schapira, 2006). The 
varying mitochondrial density in various tissues is usually dictated by the need for 
oxidative phosphorylation and energy production (Orth and Schapira, 2001) . For 
example, it is considered that cardiac, skeletal muscles cells, and neurons have the 
highest density of mitochondria; hence, their sensitivity to energy dependent defects 
resulting from mitochondrial dysfunctions in aging, age-related disorders or injury are 
elevated (Schapira, 2006).  
2.4.3 Mitochondria and energy metabolism (Bioenergetics) 
 
 Central to the role of mitochondria is energy metabolism through the 
production of ATP. This energy production is usually carried out at the level of the inner 
mitochondrial membrane through oxidative phosphorylation involving the reduction of 
oxygen to water by multimeric enzyme complexes (Green and Reed, 1998; Stavrovskaya 
and Kristal, 2005). The electron transport chain (ETC) is composed of NADH-
ubiquinone oxidoreductase (complex I), succinate dehydrogenase-CoQ oxidoreductase 
(complex II), cytochrome reductase (complex III), cytochrome oxidase (complex IV), 
and ATP synthase, which is sometimes referred to as complex V (Dudkina et al., 2005; 
Schapira, 2006). These multimeric complexes are arranged in the inner mitochondrial 
membrane according to their reduction potentials (Sullivan et al., 2005) (Fig 2.14). 
During oxidative phosphorylation, ETC complexes are usually involved in reduction and 
oxidation reactions through reducing equivalents such as NADH or succinate, which are 
transported into the mitochondria from the cytosol. In the process, protons are pumped 
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from the matrix into the intermembrane space terminating with the reduction of O2 to 
H2O. The transfer of protons from the matrix to the inner mitochondrial membrane leads 
to the generation of a mitochondrial membrane potential ∆Ψm of 150-180 mV, which 
usually determines the energetic status of the mitochondria (Nicholls et al., 1999a). This 
reserve of potential energy through the electrochemical gradient is then coupled to the 
generation of ATP, from ADP and inorganic phosphate Pi through the ATP synthase 
complex (complex V) (Dubinsky et al., 2004). There is a significant compromise in the 
mitochondrial bioenergetics in aging and neurodegenerative disorders as mentioned 
above. Since neurons solely depend on the ATP from glycolysis and mitochondria 
metabolism, this loss in ATP production usually makes the neurons vulnerable to 
oxidative stress, which eventually results into neuronal cell loss through necrosis or 
apoptosis. 
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Figure 2.14 Representation of the inner mitochondrial membrane and the ETC 
complexes.  
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2.4.4 Excitotoxicity and Ca 2+ regulation.  
   
Mitochondria under normal conditions usually act as high capacity Ca2+ sinks 
through a highly complex system for the regulation and the transportation of Ca2+ 
(Gunter and Gunter, 1994; Bianchi et al., 2004; Campanella et al., 2004; Szabadkai et al., 
2006). Through these processes, mitochondria sense and respond to changes in cytosolic 
Ca2+ loads to maintain cellular Ca2+ homeostasis that is required for normal neuronal 
function (Ichas and Mazat, 1998; Rizzuto et al., 1998; Gunter et al., 2000). Disruption in 
Ca2+ homeostasis is one of the major factors that contribute to the neuropathology 
following most neurodegenerative disorders like AD and in some CNS injury like 
traumatic brain injury (Bianchi et al., 2004; Campanella et al., 2004). In 
neurodegenerative disorders, mitochondrial dysfunction is primarily involved in 
glutamate neurotoxicity (Globus et al., 1995; Azbill et al., 1997; Montal, 1998). In AD, 
glutamate excitotoxicity and calcium dysregulation have been shown to be examples of 
etiologies that follow in addition to oxidative stress. Glutamate excitotoxicity is usually 
triggered by the excessive influx of calcium following activation and over-stimulation of 
NMDA subtype of glutamate receptors (Lipton and Rosenberg, 1994; Nicholls and Budd, 
1998a; Liu et al., 1999; McAdoo et al., 1999). The resulting increase in intracellular 
calcium has been shown to lead to impaired function of the mitochondrial ETC, 
formation of ROS/RNS, and in particular superoxide anion and hydrogen peroxide 
(White and Reynolds, 1996; Brustovetsky et al., 2002; Brustovetsky et al., 2003; Sullivan 
et al., 2005). In addition, extreme loads of Ca2+, as will be discussed later, lead to the 
opening of the mitochondrial permeability transition pore (mPTP) and induction of  
apoptotic pathways eventually leading to neuronal cell death following most CNS trauma 
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(Kristal and Dubinsky, 1997; Hirsch et al., 1998; Brustovetsky et al., 2002; Halestrap et 
al., 2002; Sullivan et al., 2005). 
 
2.4.5 Mitochondria and oxidative stress  
 As mentioned earlier mitochondria are a key source of ROS. Through the 
generation of ATP via oxidative phosphorylation by the ETC components, there is 
always some leakage of electrons (1-2%) from the mitochondria resulting in the partial 
reduction of O2 to form superoxide anion O2. - , a majority of which is generated from 
complex I and complex III of the ETC (Kushnareva et al., 2002; Liu et al., 2002; Zeevalk 
et al., 2005; Halliwell, 2006). The production of superoxide anion can occur when the 
electron transport chain is impeded following mitochondrial injury or during 
neurodegenerative disorders as seen in the case of aging, AD and PD (DiMauro et al., 
1993; Lenaz et al., 2002; Lenaz et al., 2006). It should be noted that the production of 
ROS by mitochondria is tightly linked to the mitochondrial membrane potential, since 
hyperpolarization or high mitochondrial membrane potential promotes the production of 
ROS (Liu et al., 2002; Sullivan, 2005). With a high mitochondrial membrane potential, 
the ETC cannot transfer protons against the electrochemical proton gradient from the 
matrix. This, in essence, leads to a reduced state of electron carriers and an increase in the 
half life of semiquinone (Green and Kroemer, 2004). The intermediates thus remain in a 
prolonged reduced state therefore increasing the chances of electron leakage and partially 
reduction of O2 to superoxide anion O2.- (Liu et al., 2002).  
One major pathway predominantly involved in the production of ROS/RNS is the 
secondary activation of glutamate receptors and excitotoxicity following injury to the 
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nervous system (White and Reynolds, 1996; Nicholls and Budd, 1998b; Nicholls et al., 
1999b). As already mentioned, following elevated cytosolic levels of Ca2+ in 
neurodegenerative disorders or in CNS injury, excess Ca2+ is sequestered into the 
mitochondrial matrix through various transporters (Gunter et al., 1998; Bianchi et al., 
2004). However, excessive calcium loads result in the dysregulation of mitochondrial 
Ca2+ homeostasis leading to the activation of nitric oxide synthase (iNOS) and the 
production of nitric oxide radical (NO·). The presence of nitric oxide NO and superoxide 
anion O2.- as earlier discussed leads to the formation of peroxynitrite ONOO-, another 
significant RNS, which can lead to the oxidative modification of proteins through 
nitration (Beckman et al., 1990). Elevated intracellular Ca2+ levels also activate 
phospholipase A2 (PLA2). This enzyme liberates the unsaturated fatty acid arachidonic 
acid initiating the formation of free radicals via cyclooxygenase-2 (COX-2) and 
lipoxygenase pathways. Arachidonic acid can also be oxidized leading to the formation 
of lipid peroxidation products such as HNE, MDA, acrolein among others (Butterfield 
and Stadtman, 1997; Lipton, 1999; Mirjany et al., 2002). The activation of inflammatory 
response following CNS injury also leads to the production of substances such as 
cytokines, tumor necrosis factor α (TNFα), and interleukin 1 (IL-1β) that can damage 
neurons. In addition, activation of microglia and astrocytes can also lead to the generation 
of more ROS. For example, NADPH and xanthine oxidase significantly contribute to O2·- 
production upon activation of microglia (Gabryel and Trzeciak, 2001; Zeevalk et al., 
2005). If the significant increase in ROS and RNS following CNS injury is not 
controlled, damage to DNA, proteins or lipids would result, eventually leading to loss of 
function and possibly neuronal cell death as observed in neurodegenerative disorders. 
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2.4.6 Mitochondria permeability transition pore (mPTP) 
 The   mitochondrial permeability transition (mPT) is defined as an increase in 
the permeability of the inner mitochondrial membrane to solutes that have molecular 
masses lower than 1.5 KDa (Sullivan et al., 2005). The induction of this transition has 
since been demonstrated to involve the opening of a 2-3mm inner membrane mega 
channel now referred to as the mitochondria permeability transition pore (mPTP) (Jacotot 
et al., 1999; Halestrap et al., 2002). This pore is a voltage-dependent channel, which is 
activated by the elevation of Ca2+ levels, oxidative stress and low inner mitochondrial 
membrane potentials as observed in most nervous system injuries (Hunter and Haworth, 
1979). The exact identity of this mega -channel is still under investigation. However, 
recent progress has been made in trying to provide a logical model for its composition. 
The minimum configuration of the mPTP requires the adenine nucleotide translocator 
(ANT), which is located in the inner mitochondrial membrane, in association with outer 
mitochondrial membrane proteins such as the voltage-dependent anion channel (VDAC) 
and cyclophilin-D (CyP-D), a peptidyl–prolyl cis-trans isomerase whose activity is 
usually inhibited by immunosuppressant cyclosporine A (CsA) (Bernardi, 1996; 
Halestrap et al., 2002). In addition, other proteins such as Bcl-2 and Bax have been 
shown to interact with the ANT, as a result providing a regulatory role for the mPTP 
(Marzo et al., 1998b; Marzo et al., 1998a; Halestrap et al., 2002). The exact physiological 
function of the mPTP has not been established, however, there seems to be a clear 
consensus on its involvement in the induction of permeability transition in the 
neuropathology of various CNS injuries such as TBI and spinal cord injury (SCI) (Kristal 
and Dubinsky, 1997; Halestrap et al., 2004; Sullivan et al., 2005). This is particularly 
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evident, since, it has been established that CNS injury triggers the opening of the mPTP, 
resulting in a collapse of the electrochemical gradient, the swelling of mitochondria, the 
inhibition of ATP synthesis, the release of apoptotic factors and the eventual initiation of 
cell death pathways that are blocked by the use of cyclophilin-D binding 
immunosuppressant drug cyclosporine A (CsA) (Bernardi, 1996; Sullivan et al., 1999; 
Brustovetsky et al., 2002; Brustovetsky et al., 2003; Sullivan et al., 2005).  
 
2.4.7 Role of mitochondria in apoptosis and necrosis 
 
Mitochondria also play a central role in the regulation of both programmed cell 
death (also known as apoptosis) and of uncontrolled cell death, i.e., necrosis (Zamzami et 
al., 1996; Cai et al., 1998; Green and Reed, 1998; Springer, 2002). Evidence of apoptosis 
in neurodegenerative disorders like AD and CNS trauma have been well established 
(DiMauro et al., 1993; Budd and Nicholls, 1998; Hirsch et al., 1998; Lifshitz et al., 
2004a). CNS injury usually occur in a biphasic manner, i.e., through a primary necrotic 
process that results in rapid and significant decline in the levels of ATP and in the 
ensuing hours, days and weeks, a secondary injury that exacerbates the primary insult 
occurs through apoptosis (Rabchevsky and Smith, 2001; Springer, 2002; Sullivan et al., 
2005). These two mechanisms of neurodegeneration differ in their morphological 
features of general cell structure. Apoptosis is marked by cell shrinkage and DNA 
fragmentation, while necrosis is marked by cellular swelling and uncontrolled cell lysis 
(Hirsch et al., 1997; Green and Reed, 1998; Bras et al., 2005). Due to the duration in the 
manifestation of pathologies in neurodegenerative disorders, it is believed that apoptosis 
is the predominant cell death pathway in most neurodegenerative disorders. 
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As noted above, there is increase in oxidative stress and excitotoxicity leading to 
Ca2+ overload, which in turn triggers the induction of the permeability transition (Kruman 
and Mattson, 1999; Brustovetsky et al., 2002; Brustovetsky et al., 2003) in most 
neurodegenerative disorders and CNS injury. This usually leads to excessive 
mitochondrial swelling and depolarization of the mitochondria and uncoupling of the 
oxidative phosphorylation eventually leading to a rapid decline in ATP reserves which if 
not restrained as seen in sever CNS injuries, would more often that not lead to necrotic 
cell death (Halestrap et al., 2002). However, it has been shown that transient opening of 
the mPTP is associated with the induction of apoptosis through the release of cytochrome 
c and other pro-apoptotic proteins (Marchetti et al., 1996; Hirsch et al., 1998; Marzo et 
al., 1998a; Sullivan et al., 2002). Released cytochrome c usually complexes with 
apoptosis protease-activating factor 1 (Apaf-1), dATP, and procaspase-9 to form the high 
molecular weight complex, the apoptosome. The apoptosome then activates down-stream 
effector caspases, which then initiate the apoptotic cascade (Zamzami et al., 1996; Cai et 
al., 1998; Green and Reed, 1998; Springer et al., 1999; Eldadah and Faden, 2000). 
However, apoptotic events still can occur without the opening of the permeability 
transition pore. Pro-apoptotic proteins, such as Bax and Bad also have been thought to be 
capable of forming pores in the outer mitochondrial membrane, thereby influencing the 
release of other pro-apoptotic proteins such as cytochrome c, apoptosis inducing factor 
(AIF), endonuclease G and Smac/Diablo, thereby activating the apoptotic cascade (von 
Ahsen et al., 2000; Springer, 2002; Bras et al., 2005). These various pathways have been 
summarized in Fig 2.15.  
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Figure 2.15 Role of mitochondria in glutamate induced excitotoxicity a) represents cell 
death through necrosis b) depicts cell death through apoptosis. Adapted from                                             
Trends Neurosci. (2000) 23, 298–304 
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2.5 Traumatic brain injury and oxidative stress 
 
Traumatic brain injury (TBI) is a serious health care problem in the United States, 
with more than 400,000 individuals hospitalized each year and an estimated annual cost 
of $25 billion (Tibbs et al., 1998; McNair, 1999; Adekoya et al., 2002; Hall and Sullivan, 
2004). There is currently no therapeutic intervention for TBI. The pathophysiological 
events in TBI occur in a biphasic manner. Following TBI the primary insult results in a 
rapid and significant necrosis of cortical tissue at the site of injury and in the ensuring 
hours and days, a secondary injury occurs that exacerbates the primary damage (Sullivan 
et al., 1998b; Robertson, 2004; Sullivan et al., 2005). One underlying feature of this 
secondary injury in both experimental and clinical TBI is the loss in mitochondrial 
bioenergetics. This is usually characterized by mitochondrial dysfunction that include 
exposure of neurons to excitotoxic levels of excitatory neurotransmitters with excessive 
uptake of Ca2+ and eventual overload, generation of reactive oxygen species, induction of 
the opening of the mitochondrial permeability transition pore (mPTP), release of 
cytochrome C, inhibition of ATP production and ultimately neuronal cell death (Sullivan 
et al., 1998b; Nicholls and Budd, 2000; Harris et al., 2001; Xiong et al., 2001; Sullivan et 
al., 2002; Rego and Oliveira, 2003; Lifshitz et al., 2004b; Robertson, 2004; Sullivan et 
al., 2005).  
Oxidative stress has been shown to be one of the main mechanisms following 
TBI. Due to the proximity to the source of ROS, the mitochondria are believed to be 
extremely vulnerable to the effects of these ROS. In this dissertation we have proposed 
that mitochondrial-related proteins are undergoing significant oxidative modifications 
leading to their dysfunction hence the decline in mitochondrial related function.  
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2.6 HIV and AIDS 
 
2.6.1 Overview 
 
Infection with Human Immunodeficiency Virus (HIV) results in the severe 
compromise of the immune system and increased susceptibility to opportunistic 
infections (Wang et al., 2006). This leads to the development of acquired 
immunodeficiency syndrome (AIDS). The risk of developing AIDS after infection with 
HIV increases over time. It has been established that after HIV infects a cell, it uses the 
individual’s host cell machinery to replicate and produce toxic proteins that contribute to 
the mechanisms that lead to cell death (Nath and Geiger, 1998; Mattson et al., 2005; 
Wang et al., 2006). The rise in complications as a result of HIV infection has presented a 
tremendous challenge to both virologist and immunologists. In recent years, the use of 
highly active antiretroviral therapies (HAART) has revolutionized the treatment of AIDS, 
with a suppression of viral load and consequent reduction in complications observed in 
the late-stages of the disease (Gray et al., 2003). HAART can suppress the replication of 
the virus in the long term, but this is often accompanied by significant toxicities that can 
compromise treatment (Egger et al., 1997; Brinkman and Kakuda, 2000). One of the key 
challenges resulting from HIV infection is the development of neurological disorders 
resulting in the manifestation of HIV-related dementia (HIVD) (Nath and Geiger, 1998; 
McArthur et al., 2003; Mattson et al., 2005; Pocernich et al., 2005; Nath and Sacktor, 
2006).  A detailed discussion of HIVD is provided below. 
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2.6.2 Toxic HIV proteins and neurodegeneration 
 
 It had previously been thought that HIV encephalitis results from the direct 
infection of the nervous system with the virus (Nath and Geiger, 1998). However, 
neuronal cell loss occurs without the infection of the neurons  (Nath, 2002). It has been 
established that inflammatory mediators and toxic viral proteins known as “virotoxins” 
released form activated glial cells following infection with virus mediate this neuronal 
loss (Pocernich et al., 2005). This is through the release of a number of soluble factors 
that are either toxic to neurons or cause chemotaxis. Some examples of these virotoxins 
are gp120, gp41, tat, nef, and vpr among many others. When released, these virotoxins 
then initiate a cascade of positive feedback loop cascade that cause neuronal cell death 
(Nath, 2002). Moreover, antioxidants block the effect of tat (Pocernich et al., 2005). A 
summary of this cascade is provided in (Fig 2.16). 
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Figure 2.16 Mechanism of neuronal damage following HIV infection. 
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2.6.3 HIV-Dementia (HIVD) and oxidative stress 
 
 Human immunodeficiency virus type-1 (HIV-1) infection is the most common 
cause of dementia in adults less than 40 years of age. It is estimated that 20-30% of adults 
infected with (HIV-1) develop HIV dementia (Nath, 2002; Mattson et al., 2005). 
Currently in the United States, it is estimated that up to 500,000 individuals are affected 
with HIV-associated brain disease (Wang et al., 2006). The HIV virotoxins-mediated 
neuronal loss, leads to the development of a condition known as HIV dementia. HIV 
infection of the brain is characterized by among others, the presence of multinucleated 
giant cells which are infected macrophages that have fused together, and microglia 
nodules which are collections of lymphocytes and macrophages (Nath and Geiger, 1998).  
The cognitive effects are characterized mainly by psychomotor retardation while 
behavioral manifestations include apathy, social withdrawal, depression, psychosis and 
emotional incontinence. Motor manifestations include tremors, incoordination, 
Parkinsonism and impaired balance (Nath et al., 1987). There have been various 
hypothesis proposed for the entry of HIV into the CNS. One is as a free viral particle or 
most likely through the migration of infected across the blood-brain barrier, the "Trojan 
horse" hypothesis (Nath, 2002). The brain is particularly a good reservoir of HIV virus 
since it as been shown that the incident of HIVD increases with prolonged survival 
approaching 75% in patients with end-stage AIDS (McArthur et al., 2003; Wang et al., 
2006). As already noted, once in the brain, the virus then initiates a cascade of reactions 
through “virotoxins”. Recent reports have confirmed the clinical significance and 
involvement of free radicals and oxidative stress in HIV-dementia (Sacktor et al., 2004; 
Mattson et al., 2005; Pocernich et al., 2005; Wang et al., 2006). This is evident from the 
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increased oxidative stress as measured by protein oxidation in the brain and cerebrospinal 
fluid (CSF) of HIVD patients, there is increased expression of iNOS in individuals with 
server to moderate dementia compared to those with a milder impairments (Adamson et 
al., 1996). In addition, an increase in the levels of peroxynitrite has been observed in 
HIVD brains (Boven et al., 1999). It has also been showed that there is a significant 
decrease in the concentration of the antioxidant glutathione and catalase in HIV-infected 
patients, thus making them more vulnerable to free radical attack (Castagna et al., 1995; 
Yano et al., 1998). With the advent of HAART, the incidence of HIVD has fallen, while 
the cumulative prevalence of HIVD has risen (Neuenburg et al., 2002). Despite the 
decline of HIVD incidence, neurological complications still remain an important cause of 
disability and death associated with AIDS (Kandanearatchi et al., 2003; McArthur et al., 
2003). For example, in a recent study evaluating HIV-infected outpatients on HAART, it 
was demonstrated that 9% died with HIVD and, of those, 92% were diagnosed with 
HIVD within 12 months of death (Welch and Morse, 2002). As a result, from this 
dissertation and other studies it is proposed that some drugs used in the highly active 
antiretroviral therapy (HAART) could possibly be involved in the development of HIV 
dementia through oxidative stress mechanism (Schweinsburg et al., 2005; Nath and 
Sacktor, 2006). 
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2.7 Antioxidant defense systems 
 
2.7.1 Overview 
 
 
 As already mentioned increased levels of ROS/RNS can lead to oxidative 
damage to proteins or enzyme, DNA, and lipids leading to a loss in function and possibly 
cell death. As a result, cells are equipped with efficient strategies to control and maintain 
the intracellular levels of ROS/RNS through the use of various endogenous antioxidant 
systems. These antioxidants and antioxidant defense systems have been reported to be 
significantly decreased in aging and age-related neurodegenerative disorders (Mates et 
al., 1999). As a result, various strategies have been developed to modulate these levels of 
antioxidants and reduce oxidative damage using exogenous antioxidant compounds. The 
natural antioxidant defense system consists of endogenous antioxidant systems that 
include glutathione and its related enzymes, superoxide dismutase (SOD), catalase, 
among others. Other important non-enzymatic low-molecular-weight molecules including 
vitamin C, vitamin E, lipoic acid, compounds rich in flavonoids, and carotenoids among 
many others (Sen and Packer, 1996; Mates et al., 1999; Gutteridge and Halliwell, 2000; 
Martin, 2003; Kahl et al., 2004). These are discussed here in relation to 
neurodegenerative disorders.  
 
2.7.2 Superoxide dismutase 
 
 Superoxide dismutase (SOD) provides the first line of defense against ROS. 
There are two classes of SOD; manganese SOD (Mn-SOD) which is predominately 
located in the mitochondrial matrix and copper/zinc SOD (Cu/ZnSOD, SOD1) which is 
found in the cytosol, though recent studies have shown that Cu/Zn SOD can also be 
 57
located in the intermembrane space of the, nucleus, peroxisomes, and mitochondrial 
intermembrane space of human cells (Liochev and Fridovich, 2005; Selverstone 
Valentine et al., 2005). SOD acts as an antioxidant enzyme by lowering the steady-state 
concentration of superoxide. This enzyme catalyzes the disproportionation of O2.− to 
H2O2 and H2O thus eliminating the cytotoxic superoxide anion from the cell (Chan, 1996; 
Gutteridge and Halliwell, 2000; Kahl et al., 2004; Liochev and Fridovich, 2005).  
 It has been shown that there is a decline in the levels of SOD in neurodegenerative 
disorders like AD, HIVD and also in normal aging. This thus increases the vulnerability 
to attack by ROS/RNS. When mutated, SOD can also cause disease as in the case of  
familial amyotrophic lateral sclerosis (fALS), another neurodegenerative disorder 
(Selverstone Valentine et al., 2005). The toxic gain of function of mutant SOD (mSOD) 
leads to the generation of reactive oxygen/nitrogen species (Valentine, 2002; Perluigi et 
al., 2005a; Poon et al., 2005f). Some researchers believe that the elevated oxidative 
activity associated with mSOD occurs by enzymes acting as peroxidases (Valentine, 
2002)  or as superoxide reductases (Liochev and Fridovich, 2000) or by producing O2.− to 
form peroxynitrite (Rakhit et al., 2002).  
 
2.7.3 Vitamin E and C 
 
Vitamin E (α-tocopherol) and vitamin C (ascorbic acid) Fig 2.17a/b are key 
endogenous low molecular weight antioxidants that play a significant role in the 
protection against neurological disorders associated with oxidative stress. Vitamin E is 
lipid soluble, thus it predominately provides its antioxidant activity in the lipid-bilayer. 
On the other hand, vitamin C is predominantly found in the cystosol, where it is involved 
in the recycling of the tocopheroxyl radical thus maintaining the cellular levels of vitamin 
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E (Butterfield et al., 1999b; Butterfield et al., 2002c). The levels of vitamin E and C have 
been reported to be in low concentrations in the CSF of AD patients (Butterfield et al., 
2002c). However, there was a significant increase in the levels of both vitamins in the 
CSF of AD patients who were given both vitamin C and E. The beneficial effects of this 
supplementation was observed only in the group that had a combination of the vitamins 
compared to one that had only vitamin E (Morris et al., 1998; Morris et al., 2002b; 
Martin, 2003). This was thought to be as a result of the need to recycle the tocopheroxyl 
radical by a reducing agent, such as vitamin C. It has also been observed that dietary 
intake of antioxidants vitamins E and C, especially vitamin E, is associated with a lower 
risk of incident AD, though other studies have seen the contrary(Morris et al., 2002a; 
Petersen et al., 2005). There has also been a significant association found between 
vitamin E intake and cognitive decline and dementia (Engelhart et al., 2002). Vitamin E 
has been shown to block in vitro, the toxic effects of Aβ-induced toxicity (Koppal et al., 
1998; Butterfield et al., 1999b; Yatin et al., 2000). Also, other than its role as an 
antioxidant, vitamin E has been reported to be involved in the modulation of cellular 
signaling and transcriptional regulation that play a key role in reducing the risk of 
developing AD (Morris et al., 1998).  
On the other hand, vitamin C another antioxidant has been shown to participate in 
several enzymatic reactions essential to the synthesis of catecholamines (Launer, 2000). 
It has been established that medications or vitamins that increase the levels of brain 
catecholamines and protect against oxidative damage which may reduce the neuronal 
damage and slow the progression of neurodegenerative disorders like AD (Diliberto et 
al., 1982). As a result, these studies provided here establish that the use of antioxidants 
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vitamin C and E could be a potential source of therapeutic intervention against AD and 
other neurodegenerative disorders. Vitamin E and C were among the antioxidants 
included in the antioxidant fortified diet given to the aging canine in this dissertation. 
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Figure 2.17 a Structure of Vitamin E. 
 
 
 
                          
                                  
 
Figure 2.17 b Structure of Vitamin C. 
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2.7.4 Glutathione system 
 
2.7.4.1 Overview 
 
The glutathione antioxidant system is one of the most important antioxidant 
defense mechanisms available in living organisms. Glutathione (GSH) is a tripeptide 
composed of γ-glutamyl-cyteinyl-glycine present in milimolar concentrations in the brain 
Fig 2.18. It can exist in its oxidized GSSG or reduced for GSH, the ratio of which 
provides a good indicator of oxidative stress. It has been established that a decrease in 
GSH concentration is associated with aging and the pathogenesis of most 
neurodegenerative disorders (Pastore et al., 2003).  
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                       Figure 2.18 Structure of Glutathione. 
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2.7.4.2 GSH synthesis 
 
 GSH is not synthesized in mitochondria. GSH is synthesized in the cytosol from 
where it is then transported into the mitochondria (Dringen et al., 2000). GSH is 
synthesized from L-glutamate with L-cysteine forming L-γ-glutamyl-L-cysteine the rate 
limiting substrate Fig 2.18. This initial reaction is catalyzed by γ-glutamylcysteine 
synthetase in the presence of Mg 2+ and ATP. The addition of glycine to L-γ-glutamyl-L-
cysteine is catalyzed by GSH synthetase in the presence of Mg 2+ and ATP to yield GSH 
(Figure 2.19).  It should be noted that the L-cysteine concentration in the brain are in 
micomolar while the concentration of both L-glutamate and glycine are in millimolar, 
thus, L-cysteine is the limiting amino acid in the biosynthesis of GSH (Cooper, 1997). 
Our laboratory and others have successfully modulated the levels of GSH by using 
compounds that provide cysteine precursors such as N-acetyl-L-cysteine (NAC), 
glutathione monoethyl ester or through the use of γ-glutamylcysteine ethyl ester (GCEE) 
that provides the limiting substrate γ-glutamylcysteine of GSH synthesis in various 
models of neurodegeneration (Pocernich et al., 2001; Drake et al., 2003b; Anderson et al., 
2004; Boyd-Kimball et al., 2005a; Boyd-Kimball et al., 2005b). 
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 Figure 2.19 Glutathione synthesis. 
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2.7.4.3 Role of Glutathione 
 
The glutathione system in conjunction with glutathione peroxidase (GPx) and 
glutathione reductase (GR) are involved in a number of antioxidant defense reactions 
(Brigelius-Flohe, 1999). As mentioned earlier, the disproportionation of O2. - generates 
H2O2, another ROS. Though not toxic, H2O2 can also mediate oxidative damage through 
various mechanisms. In the presence of redox transition metal ions such as Fe2+ or Cu+, 
H2O2 can undergo a Fenton reaction resulting in the generation of hydroxyl radical OH·, a 
much more toxic ROS that can exact excessive damage at distant sites from where H2O2 
was generated (Butterfield and Stadtman, 1997). As a result, there is need for the cell to 
regulate the intracellular levels of H2O2. H2O2 can be converted to water by glutathione 
peroxidase GPx using GSH as the hydrogen donor. The oxidized glutathione (GSSG) is 
then recycled back to GSH by the enzyme glutathione reductase (GR) that uses NADPH 
as a cofactor. GSH through the enzyme glutathione-s-transferase (GST) can also form 
conjugated with reactive aldehydes such as HNE or MDA, which if not eliminated from 
the cell could lead to additional oxidative damage. With the aid of the multidrug resistant 
protein-1 (MRP1), the GSH-aldehdye conjugate is exported out of the cell getting rid of 
the toxic reactive aldehydes (Sultana and Butterfield, 2004). The activities of most of 
these enzymes have been shown to be decreased in AD. In particular, it has been shown 
that GST activity is significantly decreased in AD brain and ventricular fluid relative to 
control (Lovell et al., 1998). Summaries of the glutathione-related reactions described 
here are given in Fig 2.4 above. 
 
 
 
 
 66
2.7.5 Heme-oxygenase-1 (HO-1) 
 
 Heme oxygenase or heat shock protein 32 (HSP 32) is a member of the heat shock 
family of proteins. There are two key isoforms of heme oxygenase, i.e., the inducible 
form HO-1 and the constitutive form HO-2. Though recent studies have discovered a 
third isoforms, HO-3, its functions and role are still questionable and it is found only in 
rat brains. HO catalyzes the degradation of heme to iron (Fe), carbon monoxide, and 
biliverdin. Biliverdin is further converted to the potent antioxidant bilirubin by biliverdin 
reductase (Calabrese et al., 2003a; Maines, 2005). The levels of HO-1 are regulated by 
the activity of the antioxidant response element ARE, which is usually activated in events 
of increased oxidative stress or a decline in the levels of glutathione as seen in most aging 
and age-related neurodegenerative disorders. HO-1 levels in particular have been shown 
to be significantly decreased with age and in age-related neurodegenerative disorders. 
Interventions with antioxidant compounds that lead to its up-regulation have been found 
to have cytoprotective effects providing possible leads for the intervention against 
neurodegenerative disorders in which oxidative stress plays a key role (Calabrese et al., 
2003b; Calabrese et al., 2004b; Calabrese et al., 2004a).  
 
2.7.6 Lipoic acid 
 
Lipoic acid (LA) Fig 2.20a is an example of the low molecular antioxidants which 
can also be found in its reduced form, i.e., dihydrolipoic acid (DHLA) (Fig 2.20b). 
LA is a redox-active molecule capable of thiol-disulfide exchange, giving it its 
antioxidant activity. This antioxidant activity is derived from its ability to a) Scavenge 
ROS such as H2O2, HO·, NO and ONOO−  ; b) LA has the ability to chelate ions such as,  
Cu 2+ and Fe 2+ thereby inhibiting further Fenton reactions that could lead to the 
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generation of additional ROS; c) Lastly, LA antioxidant activity is derived from its ability 
to recycle endogenous antioxidants. It also protects membranes by interacting with 
vitamin C and glutathione, which may in turn recycle vitamin E (Packer et al., 1995). 
Lipoic acid is also known as an essential cofactor of key mitochondrial enzyme 
complexes particularly pyruvate dehydrogenase (PDH) and alpha ketoglutarate 
dehydrogenase complex (α-KDH) hence its involvement in energy metabolism (Bogaert 
et al., 1994; Gibson et al., 2005). The use of lipoic acid by itself or in combination with 
other antioxidants as a potential therapeutic, is gaining considerable interest. Studies of 
aging rat have suggested that the use of lipoic acid results in improved memory 
performance and delayed structural mitochondrial decay. In a study from our laboratory, 
we have shown that aged SAMP8 mice treated with alpha lipoic acid show improvements 
in cognitive function as a result of decreased oxidative stress (Farr et al., 2003). This thus 
suggests that lipoic acid could be a potential therapeutic for those at risk of developing 
age-related neurodegenerative disorders like AD. Lipoic acid was one of the antioxidants 
include in the antioxidant fortified diet given to the aging canine. 
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Figure 2.20 Structures of a) lipoic acid and b) dihydrolipoic acid. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
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2.8 Exercise 
 
It has been established that voluntary physical activity and exercise training can 
favorably influence brain plasticity by facilitating neurogenerative, neuroadaptive, and 
neuroprotective processes (Neeper et al., 1995; Cotman and Berchtold, 2002; Cotman and 
Engesser-Cesar, 2002; Adlard and Cotman, 2004; Adlard et al., 2005a). Physical activity 
in particular has been shown to be inversely related to cognitive decline as a function of 
age. The mechanism leading to these beneficial effects of physical activity and exercise 
on the central nervous system are still unknown, but it is believed that neurotrophic 
factors like brain derived neurotrophic factor (BDNF) play a key role (Cotman and 
Berchtold, 2002; Adlard et al., 2005a). BDNF is involved in neuronal survival, enhances 
learning, and protects against cognitive decline. It has also been established that 
voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease 
(Adlard et al., 2005b). Also, it has been shown that exercise benefits recovery of 
neuromuscular function from spinal cord injury (SCI) through the increase in the 
expression of key protective gene expression in the spinal cord in rats (Perreau et al., 
2005). These studies among others continue to provide evidence for the beneficial effects 
of exercise in delaying the deleterious effects associated with age-related 
neurodegenerative disorders. The biochemical mechanisms that ensue following exercise 
have been investigated in the current dissertation. 
 
 
 
 
 
 
 
 70
2.9 Learning and memory  
 
Learning can be defined as the acquisition of an altered behavioral response due 
to an environmental stimulus. Memory on the other hand, is defined as the process of 
storing and retrieving what has been learnt resulting from changes in synaptic structure 
and function (Sweatt, 2003). Memory can further be defined as either short-term or long-
term depending on how long it persists. There are various theories that have been put 
forth to try and define and understand the mechanisms of molecular learning and 
memory. The most current one being the Hebb’s theory that proposes that the 
simultaneous activation of pre and post synaptic neurons leads to an increase in synaptic 
efficacy leading to the formation of an associative link (Hebb, 1949).  
Age-related neurodegenerative disorders and in particular AD are usually 
manifested with significant loss in hippocampus-dependent cognitive function, marked 
by loss in memory and the inability to learn and remember new names, events and spatial 
information. The mechanisms underlying age-dependent loss in cognitive function are 
still not well understood. However, using a canine model of human aging among others 
its emerging that oxidative stress plays a key role since some of this loss in cognitive 
function can be reversed with the use of antioxidants. The possible mechanisms leading 
to improved learning and memory in the canine model of human aging will be discussed 
in detail in Chapters 4 and 5. 
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CHAPTER THREE 
                                                 
                                                           Methods 
 
3.1 Experimental Traumatic Brain injury 
3.1.1 Animal and surgical procedures  
 
The University of Kentucky Animal Use and Care Committee approved all 
procedures using animals. Male Sprague-Dawley rats (250–300 g), (Harlan Laboratories, 
IN) were used. All animals were housed in group cages on a 12-h light/dark cycle with 
free access to water and food. Animals were subjected to a moderate unilateral cortical 
contusion as previously described (Sullivan et al., 1999; Sullivan et al., 2000). This 
cortical contusion results in severe behavioral deficits, significant loss of cortical tissue, 
blood–brain barrier disruption and a loss of hippocampal neurons (Sullivan et al., 2002), 
mimicking some of the events that take place in human closed-head injury. Briefly, the 
subjects were anesthetized using isoflurane (2%) and placed in a stereotaxic frame (Kopf 
Instruments, Tujunga, CA). The head was positioned in the horizontal plane with the nose 
bar set at negative 5. Using sterile procedures, the skin was retracted and a craniotomy 
made with a hand-held trephine lateral to the sagittal suture and centered between 
Bregma and lambda. The skullcap was carefully removed without disrupting the 
underlying dura. The exposed brain was injured using a pneumatically controlled 
impacting device with a 5-mm beveled tip, which compressed the cortex at 3.5 m/s to a 
depth of 1.5 mm (Baldwin and Scheff, 1996; Sullivan et al., 1999). After injury, Surgicel 
(Johnson and Johnson, Arlington, TX) was laid on the dura and the skullcap replaced. A 
thin coat of dental acrylic was then spread over the craniotomy site and allowed to dry 
before the wound was stapled closed.  
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 3.2 Mitochondria isolation 
 
3.2.1 Overview 
 
As discussed in Chapter two, mitochondria play a significant role in the 
pathosphysiology of most neurodegenerative disorders. Despite being the “power house” 
of the cell through the production of ATP, they are also known to be involved in the 
production of ROS and regulation of cell death process through either apoptosis or 
necrosis. As a result they are among the best organelles for the study of mechanism 
involved in most neurodegenerative disorders. 
 
3.2.2 Mitochondria isolation procedure 
 
 Total brain mitochondria were isolated by the method of Sullivan (Sullivan et al., 
2003; Sullivan et al., 2004b; Sullivan et al., 2004a). Desired tissues were dissected using 
a cork punch (d=8 mm). The tissue minced, and then homogenized separately in a glass 
dounce homogenizer containing approximately five times the volume of isolation buffer 
with 1 mM EGTA (215 mM mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, 1 
mM EGTA, pH 7.2). The homogenate was spun twice at 1300 × g for 3 min in an 
eppendorf microcentrifuge at 4◦C. The supernatant were then transferred to new tubes, 
topped off with isolation buffer with EGTA and spun at 13,000 × g for 10 min. The 
resulting supernatant was discarded and the pellet resuspended in 500 µL of isolation 
buffer with EGTA; The resulting pellet was then resuspended in 0.5 ml of mitochondrial 
isolation buffer (215 mM mannitol, 75 mM sucrose, 0.1% bovine serum albumin, 1 mM 
EGTA, 20 mM HEPES, pH 7.2), and the plasma membranes were ruptured by nitrogen 
decompression (Parr Cell Disruption Bomb) at 1000 p.s.i. for 5 min (Brown et al., 2004). 
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The homogenized tissue and an equal volume of 30 % Percoll in isolation buffer was 
added (~4 ml). The resultant homogenate was layered on a discontinuous Percoll gradient 
with the bottom layer containing 40 % Percoll solution in isolation buffer, followed by a 
24 % Percoll solution, and finally the sample in a 15 % Percoll solution. The density 
gradients were spun in a Sorvall RC-5C plus super speed refrigerated centrifuge 
(Asheville, NC) in a fixed angle SE-12 rotor at 30,400 x g for 10 minutes.  Following 
centrifugation, band 3 (Sims, 1990) were separately removed from the density gradient. 
The samples were washed by centrifugation at 16,700 x g for 15 minutes. The 
supernatant was discarded and the loose pellet was resuspended in the 1 ml of isolation 
buffer. The mitochondrial fractions were then placed in separate 15 ml conical tubes and 
an equal volume of 30 % Percoll was added to each sample and discontinuous Percoll 
density gradient centrifugation was performed again as described above. Band 3 was 
obtained from the gradients and 10 ml of isolation buffer without EGTA (215 mM 
mannitol, 75 mM sucrose, 0.1 % BSA, 20 mM HEPES, pH is adjusted to 7.2 with KOH) 
was added. The fractions were centrifuged at 16,700 x g for 15 minutes and subsequently 
at 11,000 x g for 10 minutes. The resultant pellet was resuspended in 1 ml of isolation 
buffer without EGTA and centrifuged at 10,000 x g for 10 minutes. The final 
mitochondrial pellet was resuspended in isolation buffer without EGTA to yield a protein 
concentration of ~10mg/ml and stored on ice for respiration assays or resuspended in 
lysis buffer (10 mM HEPES, 137 mM NaCl, 4.6 mM KCl, 1.1 mM KH2PO4, 0.6 mM 
MgSO4 and 0.5 mg/mL leupeptin, 0.7 µg/mL pepstatin, 0.5 µg/mL trypsin inhibitor, and 
40 µg/mL PMSF) for subsequent assays.  
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3.3 Mitochondria respiration 
3.3.1 Overview 
 
Isolated mitochondria are a very useful model used for the in vivo analysis of 
oxygen consumption in various paradigms. Isolated mitochondria are always depleted of 
substrates needed for energy metabolism. As a result, to successfully study respiratory 
control, mitochondria need to establish and maintain a chemiosmotic gradient unless they 
are deliberately poisoned. This is usually accomplished by the addition an excess of 
substrate depending on the state of respiration one is studying. Using an oxygen 
electrode, the amount of oxygen the isolated mitochondria consumes can then be 
analyzed. Thus, one can be able to determine how well isolated mitochondria can 
consume oxygen and hence determine the state of mitochondria in various conditions. 
 
3.3.2 Mitochondria respiration assay 
Mitochondrial oxygen consumption was measured by using a Clark-type electrode in 
a continuously stirred, thermostated sealed chamber (Oxytherm System; Hansatech 
Instruments Ltd.) at 37°C as previously described (Brown et al., 2004; Jin et al., 2004; 
Sullivan et al., 2004b). Isolated mitochondrial protein (~30 µg) was suspended in 
respiration buffer (215 mM mannitol, 75 mM sucrose, 20 mM HEPES, 2 mM MgCl2, 2.5 
mM inorganic phosphate, 0.1% BSA, Ph 7.2) in a final volume of 0.25 ml. The 
respiratory control ratio (RCR) was calculated as the ratio of oxygen consumption in the 
presence of 10 mM pyruvate and 5 mM malate or 10 mM succinate in the presence of 
ADP (state III) and in the absence of ADP (State IV).  
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3.4 Synaptosomes  
 
3.4.1 Overview 
 Synaptosomes are used as models of functional synapse for the study of neuronal 
terminal processes. They are usually cleaved from homogenized neurons through the use 
of ultracentrifugation and a discontinuous sucrose gradient. Synaptosomes are composed 
of a continuous plasma membrane that have functional pumps and channels capable of 
ion exchange, and respond to depolarization. They also contain some mitochondria hence 
are able to carry out respiratory activities. It has also recently been shown that 
synaptosomes are capable of carrying out protein synthesis; hence they provide a 
complete model of a functional synapse. 
 
3.4.2 Synaptosomes preparation  
 
 The University of Kentucky Animal Care and Use Committee approved animal 
protocols.  Animals were housed in the University of Kentucky Central Animal Facility 
in 12 hour light/dark conditions and fed standard Purina rodent laboratory chow.  
During light phase Synaptosomes were isolated from three-month old male Mongolian 
gerbils (100g) as previously described (Whittaker, 1993).  Briefly, the gerbils sacrificed 
by decapitation and the brain immediately isolated and dissected. The cortex was placed 
in 0.32 M sucrose isolation buffer containing 4 µg/ml leupeptin, 4 µg /ml pepstatin, 5 µg 
/ml aprotinin, 2 mM ethylene di-amine tetra-acetic acid (EDTA), 2 mM ethylene glycol-
bis-tetraacetic acid (EGTA), 20 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid 
(HEPES), 20 µg/ml trypsin inhibitor, and 0.2 mM phenylmethanesulfonyl fluoride 
(PMSF), pH 7.4.  The tissue was homogenized by 20 passes with a Wheaton tissue 
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homogenizer.  The homogenate was centrifuged at 1500 g for 10 minutes.  The 
supernatant was retained and centrifuged at 20,000 g for 10 minutes.  The resulting pellet 
was resuspended in ~1 ml of 0.32 M sucrose isolation buffer and layered over 
discontinuous sucrose gradients (0.85 M pH 8.0, 1.0 M pH 8.0, 1.18 M pH 8.5 sucrose 
solutions each containing 2 mM EDTA, 2 mM EGTA, and 10 mM HEPES) and spun at 
82,500 g for 1 hr at 4oC.  Synaptosomes were collected from the 1.0/1.18M sucrose 
interfaces, and washed in Locke’s buffer (154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2, 
1.0 mM MgCl2, 3.6 mM NaHCO3, 5 mM glucose, 5 mM HEPES) twice for 10 minutes at 
32,000 g.  The synaptosomal preparation was relatively free of non-synaptic moieties 
(Whittaker, 1993). 
 
3.5 Protein concentration 
 
The protein concentrations of all samples in this dissertation were performed using 
the Bicinchoninic acid (BCA) protein assay. This method is based on the protein-
mediated reduction of Cu2+ to Cu+ by the electron-rich peptide bond and amino acids (the 
biuret reaction). Cu+ can then be complex with BCA to from a soluble purple complex 
exhibits a strong absorbance at 562 nm (Figure 3.1). In this dissertation, bovine serum 
albumin (BSA) was used as a standard and Beer’s law was used to calculate the 
concentration of protein in sample solution. 
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Figure 3.1 Reaction of Cu+ with BCA.  
  
 
 
 
 
 
 
 
 
 
 
 
 78
3.6 Cytochrome c release 
  
3.6.1 Overview 
 
Cytochrome c usually resides in the inner mitochondrial membrane as a member 
of the electron transport chain complexes. However, as mentioned in chapter two, its 
release from the inner mitochondrial membrane to the cytosol marks a key event in the 
initiation of the apoptotic cascade leading to cell death. As a result, analysis of the levels 
of Cytochrome c usually serves as a good indicator of cell death processes as seen in 
neurodegenerative disorders. 
 
 
3.6.2 Cytochrome c release assay  
  
Cytochrome c release was detected as previously described with slight 
modifications (Yang et al., 1997). Briefly, after centrifugation of mitochondrial samples, 
the cytosolic fraction which is the supernatant was used for Western blot analysis for 
cytochrome c release. The membrane was blocked in blocking buffer (3% bovine serum 
albumin) in PBS/Tween for 2 h and incubated with a 1:2000 dilution of anti-cytochrome 
c polyclonal antibody (C-5723; anti-sheep; Sigma) in PBS/Tween for 2 h. The membrane 
then was washed in PBS/Tween for 5 min three times after incubation. The membrane 
was incubated for 1 h, after washing, with an anti-sheep IgG alkaline phosphatase 
secondary antibody diluted in PBS/Tween in a 1:8000 ratio. The membrane then was 
washed three times in PBS/Tween for 5 min and developed in Sigma Fast tablets. Blots 
were dried, scanned with Adobe PhotoShop, and quantified using Scion Image software. 
 
 
 
 79
3.7 Bcl-2 protein levels 
 
Bcl-2 family of proteins provides a link between apoptosis and mitochondrial 
physiology. Bcl-2 and Bcl-xL are anti-apoptotic proteins that suppress release of 
sequestered matrix Ca2+ induced by uncouplers of respiration (Vander Heiden et al., 
1999). In isolated mitochondria, Bcl-2 or Bcl-xL enhances proton extrusion from 
mitochondria and increases mitochondrial Ca2+ buffering capacity.  Bcl-2 is also thought 
to regulate the opening of the mPTP hence regulating the possible induction of apoptosis 
and eventual cell death.  The levels of anti-apoptotic protein Bcl-2 were detected as 
previously described (Yang et al., 1997) with slight modification as described above, 
except a 1:2000 dilution of anti-Bcl-2 monoclonal antibody (AAM-072; anti- mouse; 
stressgen) in PBS/Tween for 2 h was used.  
 
3.8 Oxidative stress parameters 
 
3.8.1 Protein carbonyls 
 
As mentioned in Chapter 2, increased oxidative stress usually results in the 
oxidative modification of proteins. The introduction of the carbonyl moiety in proteins 
makes protein carbonyls to be a significant index of protein oxidation. The levels of 
protein carbonyls in this dissertation were analyzed using the OxyBlot Protein Oxidation 
Kit (Chemicon International, Temecula, CA, USA). Briefly, samples (5 µg of protein) 
were derivatized with 10 mM 2, 4-dinitrophenylhydrazine (DNPH) in the presence of 5 
µL of 12% sodium dodecyl sulfate for 20 min at room temperature (23°C) forming a 
Protein-DNP adduct (Fig 3.2). The samples were then neutralized with 7.5 µL of the 
neutralization solution (2 M Tris in 30% glycerol). Derivatized protein samples were then 
blotted onto a nitrocellulose membrane with a slot-blot apparatus (250 ng per lane). The 
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membrane was then washed with wash buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
0.05% Tween 20) and blocked by incubation in the presence of 5% bovine serum 
albumin, followed by incubation with rabbit polyclonal anti-DNPH antibody (1: 100 
dilution) as the primary antibody for 1 h. The membranes were washed with wash buffer 
and further incubated with alkaline phosphatase-conjugated goat anti-rabbit antibody as 
the secondary antibody for 1 h. Blots were developed using fast tablet (BCIP/NBT; 
Sigma-Aldrich) and densitometric levels quantified using Scion Image (PC version of 
Macintosh-compatible NIH Image) software. 
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Figure 3.2 Protein carbonyl reactions with DNP forming the protein –DNP adduct.  
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3.8.2 3-Nitrotyrosine (3NT) 
Protein nitration is another form of protein oxidation and can be indexed 
immunochemically by the levels of 3NT (Castegna et al., 2003). Briefly, samples were 
incubated with Laemmli sample buffer in a 1:2 ratio (0.125 M Trizma base, pH 6.8, 4% 
sodium dodecyl sulfate, 20% glycerol) for 20 min. Protein (250 ng) was then blotted onto 
the nitrocellulose paper using the slot-blot apparatus and immunochemical methods as 
described above for protein carbonyls. The mouse anti-nitrotyrosine antibody (5: 1000 
dilutions) was used as the primary antibody and alkaline phosphatase-conjugated anti-
mouse secondary antibody was used for detection. Blots were then scanned using scion 
imaging and densitometric analysis of bands in images of the blots was used to calculate 
levels of 3-NT. 
3.8.3 4-Hydroxy-2-nonenal (HNE) 
The level of lipid peroxidation in this dissertation was determined by the analysis 
of protein–bound HNE (Figure 2.7). Briefly, 10 µl of sample were incubated with 10 µl 
of Laemmli buffer containing 0.125 M Tris base pH 6.8, 4 % (v/v) SDS, and 20% (v/v) 
Glycerol.  The resulting sample (250 ng) was loaded per well in the slot blot apparatus 
containing a nitrocellulose membrane under vacuum pressure.  The membrane was 
blocked with 3% (w/v) bovine serum albumin (BSA) in phosphate buffered saline 
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST) for 1 h and 
incubated with a 1:5000 dilution of anti-4-hydroxynonenal (HNE) polyclonal antibody in 
PBST for 90 min.  Following completion of the primary antibody incubation, the 
membranes were washed three times in PBST.  An anti-rabbit IgG alkaline phosphatase 
secondary antibody was diluted 1:8000 in PBST and added to the membrane.  The 
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membrane was washed in PBST three times and developed using Sigma fast Tablets 
(BCIP/NBT substrate).  Blots were dried, scanned with Adobe Photoshop, and quantified 
with Scion Image.   
 
3.8.4 Isoprostanes and Neuroprostanes 
 
Another indicator of the levels lipid peroxidation used in this dissertation was 
determined through the analysis of Isoprostanes and Neuroprostanes. F2-IsoPs and F4-
NPs were quantified in brain specimens using highly precise and accurate mass 
spectrometric assays applying stable isotope dilution techniques, as described previously 
(Morrow and Roberts, 1999; Musiek et al., 2004).  Briefly, lipids were extracted from 
specimens by the method of Folch and colleagues (Folch et al., 1957).  F2-IsoP and F4-
NPs were esterified in tissue and hydrolyzed by chemical saponification, extracted using 
C18 and silica Sep-Pak cartridges (Waters Corporation, Milford, MA), purified by thin-
layer chromatography, converted to pentafluorobenzyl ester trimethylsilyl ether 
derivatives, and quantified using gas chromatography/negative ion chemical 
ionization/mass spectrometry.  The stable isotope dilution techniques used [2H4]-8-iso-
PGF2a as an internal standard for F2-IsoPs and [18O2]17-F4c-NP as an internal standard for 
F4-NPs. 
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3.9 Enzyme assays 
 
3.9.1Overview 
 
One underlying hypothesis being fronted by our laboratory and others is that 
oxidative stress leads to the oxidative modification of key proteins and enzymes. In 
addition, supplementation with antioxidant and antioxidant related compounds has been 
shown to result in an increase in expression and in some conditions, activity of various 
protective enzymes. However, it is believed that oxidative modification of critical amino 
especially those found in the active sites of enzymes it leads to their inactivation and 
alteration in function. As a result, enzyme activity has particularly been used in this 
dissertation to try and confirm the hypothesis that oxidative modification of 
proteins/enzymes leads to their possible inactivation 
 
3.9.2 Glutathione-S-transferase (GST) 
The clearance of toxic reactive aldehydes is carried out through their conjugation 
to GSH catalyzed by GST. In particular, it has been shown that GSTs catalyze the 
conjugation of GSH to HNE 300 to 600 times faster than the uncatalyzed reaction. In this 
dissertation, the activity of Glutathione-S-transferase was measured as previously 
described using 1-chloro-2, 4-dinitrobenzene (CDNB) as substrate (Habig and Jakoby, 
1981). Briefly, the standard assay mixture contained CDNB (1 mM), reduced glutathione 
(1 mM), and potassium phosphate buffer (100 mM; pH = 6.5) in a volume of 100 µL. 
The thioether formed was determined by reading the absorbance at 340 nm, and 
quantification was performed by using a molar absorptivity of 9.6 M−1.  
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3.9.3 Superoxide dismutase (SOD) 
 
As mentioned earlier, the first line of defense against ROS is through the enzyme 
SOD that catalyzes the disproportionation of superoxide anion to H2O2. In this 
dissertation the activity of total superoxide dismutase (SOD) was measured. Briefly, the 
reaction mixture of total volume 184 µL contained 160 µL of 50 mmol/l glycine buffers, 
pH 10.4, and 20.0 µL sample. The reaction was initiated by the addition of 4.0 µL of a 20 
mg/ml solution of (–)-epinephrine. Due to its poor solubility, (–)-epinephrine (40 mg) 
was suspended in 2 ml water and was solubilized by adding 2–3 drops of 2N HCl. The 
auto-oxidation of (–)-epinephrine was monitored at 480nm and the millimolar 
absorptivity (4.02 mmol · l–1 · cm–1) was used for calculations. 
 
3.9.4 Pyruvate dehydrogenase (PDH) 
 
 Pyruvate dehydrogenase (PDH) is a mitochondrial enzyme complex that catalyzes 
the conversion of pyruvate to acetyl CoA, NADH and CO2, making this protein the 
central link between glycolysis and the TCA cycle. In this dissertation, the activity of 
PDHC was measured using increment in fluorescence measurement of NADH with 
BioTek Synergy HT plate reader (Winooski, VT, USA). Briefly, mitochondria were 
freeze thawed and sonicated for 3 cycles. About 8 µg of double ficoll gradient purified 
mitochondrial protein were added into the buffer containing final concentration of 50mM 
KCl, 10mM HEPES pH 7.4, 0.3mM thiamine pyrophosphate (TPP), 10µM CaCl2, 0.2mM 
MgCl2, 5mM pyruvate, 1 µM rotenone and 0.2mM NAD+. Reactions were started by 
addition of 0.14mM CoASH and assay was performed at Ex λ 340 nm/ Em λ 460nm and 
increases in fluorescence were observed at 1 min intervals at 300C. The PDHC activity 
was calculated and expressed as nmol/mg protein 
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3.9.5 Complex I assay 
 
 Complex I activity was measured in isolated mitochondria as the rotenone-
sensitive decrease in NADH absorption at 340 nm with ubiquinone-1 as the final 
acceptor, as previously described (Sriram et al., 1998) with some slight modifications 
(Sullivan et al., 2004b). Briefly, mitochondria were freeze-thawed and sonicated three 
times and diluted 1 µg/µl in 10 mM K3PO4 buffer. The assay was performed in 25 mM 
K3PO4 buffer (pH 7.2) containing mitochondrial protein (6 µg), 5 mM MgCl2, 1 mM 
KCN, 1 mg/ml BSA, and 150 µM NADH. The reaction was preincubated for 2 minutes 
at 30°C, the baseline established, and the reaction initiated by addition of coenzyme Q-1 
(50 µM). The activity was measured by monitoring NADH fluorescence (340 nm 
excitation, >450 nm emission) over time under the same conditions as described above. 
The assay was also performed in the presence of rotenone (10 µM) to determine the 
rotenone-insensitive activity and the rotenone-sensitive complex I enzyme activity 
calculated by subtracting the rotenone-insensitive activity from the total activity. All the 
assay protocol for a 96-well plate performed with BioTek Synergy HT plate reader 
(Winooski, VT, USA) 
 
3.9.6 Complex IV activity assay  
Cytochrome C Oxidase (Complex IV) of mitochondrial electron transport chain 
component activity measured with method previously described (Wharton and Tzagoloff, 
1967) with slight modification using  BioTek Synergy HT plate reader (Winooski, VT, 
USA). Briefly, mitochondria were freeze thawed and sonicated for 3 cycles. About 8 µg 
of double ficoll gradient purified mitochondrial protein were added into the 10mM K3PO4 
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buffer pH 8.0, 50µM reduced cytochrome c and the decrease in absorbance was observed 
with difference with and without addition of Cytochrome c at 1 min interval at 370C at 
550nm. First the rate constant k was calculated for oxidation reaction of ferricytochrome 
c calculated and the specific activity A were expressed as (k/mg protein) for cytochrome 
c oxidase.  
 
3.10 Proteomics 
 
3.10.1 Overview 
 
Proteomics is defined as the study of the entire protein complement of the 
genome. The proteomic technique encompasses the analysis of complex protein mixtures 
leading to their identification and detection of possible quantitative changes. This 
separation of proteins is usually carried out in two dimensions. 
In the first dimension, proteins are separated according to their isoelectric point. 
This is the pH, at which the protein carries no net charge and is therefore immobilized in 
the electric field (Fig 3.3a).  This is carried out through isoelectric focusing (IEF) using 
immobilized pH gradients (IPG). IPGs are formed by the copolymerization of buffering 
and titrant groups of acrylamido derivatives into a polyacrylamide gel matrix hence 
permitting the steady state focusing with high reproducibility of spot positions.  
In the second dimension, proteins are separated according to the rate of migration, 
which in most cases is similar to their molecular weight (Fig 3.3b). Here the low 
molecular weigh proteins travel faster through the gel and are found on the lower end of 
the gel. On the other hand, high molecular weight proteins will travel slowly through the 
polyacrylamide matrix and will be found on the upper end of the gel slab.  
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With the development of novel mass spectrometry techniques such as MALDI 
and ESI mass analyzers have been able to better resolve the molecular ion to their mass 
and charge ratio leading to the proper identification of proteins through various 
databases. The proteomic techniques in our laboratory and that of others has revolved 
around the identification of differentially expressed proteins in diseased verse control 
states and also the identification of the redox status of a protein, specifically oxidatively 
modified proteins. We have come to refer to the latter as redox proteomics. 
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Figure 3.3a First dimension isoelectric focusing (IEF). 
 
 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3b Second dimension polyacrylamide gel electrophoresis (PAGE). 
 
 
 
 
 
 
 
+
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3.10.2 Sample preparation 
Samples (200 µg) were incubated with 4 volumes of 2N HCl for electrophoresis 
or 20mM DNPH for western blotting at room temperature for 20 min at room 
temperature. Proteins were then precipitated by the addition of ice-cold 100% 
trichloroacetic acid (TCA) to obtain a final concentration of 15% TCA. Samples were 
then placed on ice for 10 min and precipitate centrifuged at 16,000 g for 3min. The 
resulting pellet was then washed three times with a 1:1(v/v) ethanol/ethyl acetate 
solution. The samples were then suspended in 200 µl of rehydration buffer composed of a 
1:1 ratio (v/v) of the Zwittergent solubilization buffer (7M urea, 2M thiourea, 2% Chaps, 
65 mM DTT, 1% Zwittergent 0.8% 3-10 ampholytes and bromophenol blue) and ASB-14 
solubilization buffer (7M urea, 2M thiourea 5Mn TCEP, 1% (w/v) ASB-14, 1% (v/v) 
Triton X-100, 0.5% Chaps, 0.5% 3-10 ampholytes) for 1 h. 
3.10.3 First dimension electrophoresis 
For the first-dimension electrophoresis, 200 µL of sample solution was applied to 
a 110-mm pH 3–10 ReadyStrip™ IPG strips (Bio-Rad, Hercules CA). The strips were 
then actively rehydrated in the protean IEF cell (Bio-Rad) at 50 V for 18 h. The 
isoelectric focusing was performed in increasing voltages as follows; 300 V for 1 h, then 
linear gradient to 8000 V for 5 h and finally 20 000 V/h. Strips were then stored at –80 
°C until the 2nd dimension electrophoresis was to be performed. 
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3.10.4 Second dimension (2D) electrophoresis 
For the second dimension, the IPG® Strips, pH 3–10, were equilibrated for 10 min 
in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium dodecyl sulfate 
(SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15 min in 
the same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient 
precast criterion Tris–HCl gels (8–16%) (Bio-Rad) were used to perform second 
dimension electrophoresis. Precision Protein™ Standards (Bio-Rad, CA) were run along 
with the sample at 200 V for 65 min. 
3.10.5 Western blotting and immunochemical detection 
The identification of oxidatively modified proteins was carried out through redox 
proteomics through the analysis of protein carbonyls levels. Here, the 200 µg proteins 
incubated with 20mN DNPH described above were used. The strips and gels were run as 
described above. After the second dimension, the proteins from the gels were transferred 
onto nitrocellulose papers (Bio-Rad) using the Transblot-Blot® SD semi-Dry Transfer 
Cell (Bio-Rad), at 15 V for 4 h. The 2,4-dinitrophenyl hydrazone (DNP) adduct of the 
carbonyls of the proteins was detected on the nitrocellulose paper using a primary rabbit 
antibody (Chemicon, CA) specific for DNP-protein adducts (1:100), and then a 
secondary goat anti-rabbit IgG (Sigma, MO) antibody was applied. The resulting stain 
was developed by application of Sigma-Fast (BCIP/NBT) tablets. In this dissertation 
these blots have been referred to as 2D-Oxyblots. 
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3.10.6 Image and statistical analysis 
 
The spots on 2D gels were visualized using SYPRO™ Ruby stain, which is a 
fluorescent dye with sensitive (1-2ng) detection limits and linear dynamic range over 
three orders of magnitude (Molloy and Witzmann, 2002). Images from SYPRO Ruby 
stained gels, were obtained using a UV transilluminator (λex=470 nm, λem=618 nm, 
Molecular Dynamics, Sunnyvale, CA, USA). On the other hand, 2D Oxyblots were 
scanned on a Microtek Scanmaker 4900 and saved in TIFF format for further analysis. 
With the use of PD-Quest (Bio-Rad) imaging software, gel-gel, blot-blot, and gel-blot 
analysis were performed, generating a large pool of data. After the completion of spot 
matching, the normalized intensities of each protein spot from individual gels/blots are 
compared between groups using statistical analysis. Those spots showing significant 
differential expression or oxidation are then excised from the gel and   processed for in-
gel digestion. 
 
3.10.7 In-gel trypsin digestion 
 
After the identification of the protein of interest and its excision from the gel, the 
spot is then subjected to digestion using proteolytic enzymes. In this dissertation, the 
digestive enzyme trypsin was used in all in gel digestion studies. Trypsin specifically 
cleaves peptide bonds after positively charged residues amino acids. In-gel-digestion 
reduces the mass of a protein into small peptides and also forms a collection of 
proteolytically sequence-specific peptides that enable the identification of the protein. 
These digested proteins are easily eluted from the gel and are ready for mass 
spectrometry analysis. In this dissertation excised spots were washed with 0.1 M 
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ammonium bicarbonate (NH4HCO3) at room temperature for 15 min. Acetonitrile was 
then added to the gel pieces and incubated at room temperature for 15 min. This solvent 
mixture was then removed and gel pieces dried. The protein spots were then incubated 
with 20 µL of 20 mM DTT in 0.1 M NH4HCO3 at 56 °C for 45 min. The DTT solution 
was removed and replaced with 20 µL of 55 mM iodoacetamide in 0.1 M NH4HCO3. The 
solution was then incubated at room temperature for 30 min. The iodoacetamide was 
removed and replaced with 0.2 mL of 50 mM NH4HCO3 and incubated at room 
temperature for 15 min. Acetonitrile (200 µL) was added. After 15 min incubation, the 
solvent was removed, and the gel spots were dried in a flow hood for 30 min. The gel 
pieces were rehydrated with 20 ng/µL-modified trypsin (Promega, Madison, WI) in 
50 mM NH4HCO3 with the minimal volume enough to cover the gel pieces. The gel 
pieces were incubated overnight at 37 °C in a shaking incubator. 
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Figure 3.4 Schematic representation of the parallel analysis of 2D-PAGE and oxyblot for 
the identification of specifically carbonylated or differentially expressed proteins.   
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3.11 Mass Spectrometry 
 
3.11.1 Overview 
 
Mass spectrometry technique has recently emerged as very invaluable tool in the 
rapid identification and characterization of proteins. This is particularly evident from the 
presentation of the 2005 chemistry Nobel Prize for the development of two novel 
ionization techniques i.e., matrix assisted laser desorption/ionization (MALDI) and 
electrospray ionization (ESI). These softer ionization techniques have enabled the 
identification of large biomolecules with fewer fragmentations. 
 
3.11.2 Matrix Assisted Laser Desorption/Ionization (MALDI) 
 
MALDI is a pulsed ionization technique; generally coupled with TOF (time-of-
flight) mass analyzer. In MALDI, the peptide sample is mixed with a matrix (commonly 
α-cyano-4-hydroxycinnamic acid) and condensed on a plate that is subjected to laser 
radiation. On application of a high-energy laser to the matrix, the peptides along with the 
matrix particles are vaporized. This usually occurs in a vacuum to ensure the sublimation 
of the matrix-peptides solid. Due to the acidic nature of the matrix, the positive ions of 
the peptides are formed in the gas phase the mechanisms of these are however not well 
described. 
3.11.2.1 The MALDI method 
 
All mass spectrometry data reported in this dissertation were acquired from the 
Core Proteomic Laboratory, University of Louisville, Louisville, Kentucky headed by 
Drs Jon. B. Klein and William Pierce. Briefly, MALDI-TOF mass spectrometer in the 
reflectron mode was used to generate peptide mass fingerprints. Peptides resulting from 
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in-gel digestion with trypsin were analyzed on a 384 position, 600 µm AnchorChipTM 
Target (Bruker Daltonics, Bremen, Germany) and prepared according to AnchorChip 
recommendations (AnchorChip Technology, Rev. 2, Bruker Daltonics, Bremen, 
Germany).  Briefly, 1 µL of digestate was mixed with 1 µL of alpha-cyano-4-
hydoxycinnamic acid (0.3 mg/mL in ethanol: acetone, 2:1 ratio) directly on the target and 
allowed to dry at room temperature. The sample spot was washed with 1 µL of a 1% TFA 
solution for approximately 60 seconds.  The TFA droplet was gently blown off the 
sample spot with compressed air.  The resulting diffuse sample spot was recrystallized 
(refocused) using 1 µL of a solution of ethanol: acetone: 0. 1 % TFA (6:3:1 ratio).  
Reported spectra are a summation of 100 laser shots.  External calibration of the mass 
axis was used for acquisition and internal calibration using either trypsin autolysis ions or 
matrix clusters was applied post acquisition for accurate mass determination.  
 
3.11.3 Electrospray Ionization (ESI) 
 
In ESI the peptide in the solution is sprayed through a narrow capillary tube 
maintained at ~4000 volts and atmospheric pressure. The potential difference between the 
outlet and the mass spectrometer leads to the generation of a repulsive columbic force 
between the like charges on the droplets to extend the solution to form a cone (Taylor 
cone) from the outlet, causing the solution to disperse into fine droplets (Taylor, 1964). 
ESI can be coupled to other separation techniques such as HPLC making it more 
versatile. However the high flow rates and short analysis time presents a drawback when 
performing multiple analyses.  
 
 97
3.11.4 Data base searching and bioinformatics 
Mass spectrometry analysis usually results in a mass spectrum that consists of 
peaks, which correlate to the mass of peptides obtained following protein digestion. 
Using various software programs and performing data base searches through different 
search algorithms, the identity of specific proteins can be obtained. This process is 
referred to as peptide mass finger printing. The search engines (Table 3.1) provide a 
theoretical digest of all known proteins, which can be compared with the experimental 
masses obtained. These comparisons can also be done taking it account several other 
factors, such as; molecular weight, pI, the probability of a single peptide to occur in the 
whole database, knowledge of peptide modifications, among many others. For each entry, 
a probability score is provided based on a mathematical algorithm specific to each search 
engine. This score, represents the probability that the experimental peptides match those 
of the theoretical digest. A hit with a probability score corresponding to p< 0.05 has a 
legitimate chance of being the protein cut from a particular spot. 
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Name Address 
Mass Search http://cbrg.inf.ethz.ch 
Peptide Search http://www.mann.emblheidelberg.de 
Mascot http://www.matrixscience.com 
MOWSE http://www.hgmp.ac.uk/Bioinformatics/Webapp/mowse 
SEQUEST http://thompson.mbt.washington.edu/sequest 
Table 3.1 Table of search engines. 
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3.11.5 Analysis of peptide sequences 
 In the current dissertation the MASCOT search engine based on the entire NCBI 
and SwissProt protein databases. Database searches were conducted allowing for up to 
one missed trypsin cleavage and using the assumption that the peptides were 
monoisotopic, oxidized at methionine residues, and carbamidomethylated at cysteine 
residues. Mass tolerance of 150 ppm, 0.1 Da peptide tolerance and 0.2 Da fragmentation 
tolerance was the window of error allowed for matching the peptide mass values 
(Butterfield and Castegna, 2003b). Probability-based MOWSE scores were estimated by 
comparison of search results against estimated random match population and were 
reported as -10*log10 (p), where p is the probability that the identification of the protein 
is a random event. MOWSE scores greater than 63 were considered to be significant (p < 
0.05). 
3.11.6 Protein Interacteome 
  The proteins identified through proteomics have been found to be involved in a 
wide range of functions, and are also believed to interact with a plethora of molecules and 
other proteins. To enable us obtain a consequential possibility that will result from their 
alterations and how these affect various cellular process, the Interaction Explorer TM 
Software Pathway Assist software package (Stratagene, La Jolla, CA) was used in the 
current dissertation. Pathway Assist is software for functional interaction analysis. It 
allows for the identification and visualization of pathways, gene regulation networks and 
protein interaction maps (Donninger et al., 2004). The proteins are first imported as the 
gene symbols as a set of data. This data set is then searched against ResNet, a database 
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containing over 500,000 biological interactions built by applying the MedScan text-
mining algorithms to all PubMed abstracts. These interactions are then visualized by 
building interaction networks with shortest-path algorithms. This process can graphically 
identify all known interaction among the proteins. The information of the function of 
these proteins and their relevance to diseases are then obtained by using the BIOBASE's 
Proteome BioKnowledge Library form Incyte Corporation (Incyte, Wilmington, DE) 
(Hodges et al., 2002). 
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CHAPTER FOUR 
 
Redox Proteomic Identification of Less Oxidized Brain Proteins Following a Long-
Term Treatment with Antioxidants and a Program of Behavioral Enrichment in the 
Canine Model of Human Aging 
 
4.1 Overview 
 
Oxidative stress may be one of the main mechanisms contributing to neurodegeneration 
and cognitive decline observed in a number of age-related neurodegenerative disorders such as 
Alzheimer’s disease (AD). The use of antioxidants results in reductions in oxidative damage and 
in improvements in cognitive function in many animal models. In the present study, the effect of 
a long-term treatment with an antioxidant fortified diet and a program of behavioral enrichment 
on oxidative damage was studied in aged canines. The parietal cortex from 21 beagle dogs was 
obtained from animals placed in one of four treatment groups: i.e., control food- control 
behavioral enrichment (CC); control food - behavioral enrichment (CE); antioxidant food-control 
behavioral enrichment (CA); and enriched environment - antioxidant fortified food (EA). We 
analyzed the levels of the oxidative stress biomarkers, i.e., protein carbonyls, 3-nitrotyroine 
(3NT), and the lipid peroxidation product, 4-hydroxynonenal (HNE), and observed a decrease in 
their levels on all treatments paradigms compared to control. The most significant effects were 
found in the combined treatment, EA. We also used a parallel redox proteomics approach to 
identify proteins that were less oxidized from the parietal cortex of the beagle dog brain. The 
specific protein carbonyl levels of glutamate dehydrogenase [NAD (P)], glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), α-enolase, neurofilament triplet L protein, glutathione S-
transferase (GST) and fascin actin bundling protein were significantly reduced in EA treated 
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dogs compared to control. In addition, we observed a significant increase in the activities of 
glutathione-S-transferase (GST) and total superoxide dismutase (SOD), and significant increase 
in the protein levels of heme oxygenase (HO-1) in EA treated dogs compared to control. In 
addition, a subset of proteins and antioxidant enzymes were found to correlate with an 
improvement in cognitive function. These results suggest that the combined treatment reduces 
the levels of oxidative damage and improves the antioxidant reserve systems in the aging canine 
brain, and may contribute to improvements in learning and memory, hence providing a possible 
neurobiological mechanism underlying the effects of the combined treatment.  These results 
support combination treatments as a possible therapeutic approach that could be translated to the 
aging human population who are at risk for age-related neurodegenerative disorders, including 
Alzheimer’s disease. 
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4.2 Introduction 
Aged dogs naturally develop cognitive deficits and accumulate brain pathology 
similar to aging humans, providing a useful model for studying the neurobiological 
mechanisms underlying age- related cognitive dysfunction (Head et al., 2000; Head and 
Torp, 2002). Aged canine show reduced cerebral volume, cortical atrophy, ventricular 
widening by in vivo magnetic resonance imaging (Su et al., 1998; Tapp et al., 2004; Tapp 
et al., 2006). The aging canine also shows impairment on visuospatial working memory 
and executive function (Chan et al., 2002; Tapp et al., 2003c; Studzinski et al., 2006). 
Aged beagle brain deposits amyloid-β-peptide (Aβ) that is of the same sequence as 
humans (Selkoe et al., 1987; Johnstone et al., 1991) and is correlated with decline in 
cognitive function with age (Cummings et al., 1996b; Head et al., 1998). Beagle dogs are 
accessible, easy to handle, capable of learning a broad repertoire of cognitive tasks, do 
not need food deprivation to be motivated and absorb dietary nutrients in similar ways as 
humans, hence making them a good model for studying human aging (Cummings et al., 
1996a). The deposition of Aβ could play a significant role in molecular pathways 
involving free radical generation and oxidative stress as previously shown in AD-related 
studies from our laboratory (Butterfield and Lauderback, 2002; Butterfield and Boyd-
Kimball, 2004a).  
The aging process is associated with a progressive accumulation of oxidative 
damage that could play a role in the development or accumulation of neuropathology 
typically observed in age-related neurodegenerative disorders like AD (Hensley et al., 
1996; Markesbery, 1997; Lovell et al., 1999; Butterfield and Kanski, 2001). When 
compared to age-matched controls, the AD brain shows a higher levels of protein and 
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DNA oxidation, and lipid peroxidation leading to loss of function of key enzymes (Smith 
et al., 1991; Hensley et al., 1995; Lovell et al., 1999). In various AD studies from our 
laboratory, we have shown that Aβ 1-42 plays a central role in the oxidative stress 
observed and that the key to this link is a key amino acid residue methionine 35 
(Butterfield and Lauderback, 2002; Butterfield and Boyd-Kimball, 2004a). Similar events 
may also occur in the canine model of aging as deposits of Aβ1-42 may account for 
increased oxidative damage, a decline in glutathione content and decreased glutamine 
synthetase (GS) activity reported previously (Head et al., 2002).  
The use of antioxidants and/or related compounds reduces the level of oxidative 
damage and delays or reduces age-related cognitive decline in both animal models and in 
humans (Joseph et al., 1998a; Bickford et al., 2000; Milgram et al., 2002c).  Previous 
studies in aged canines show that oxidative damage may be critically involved in the 
maintenance of cognitive function and long-term treatment with antioxidants and a 
program of behavioral enrichment reduces cognitive decline (Cotman et al., 2002; Head 
et al., 2002; Milgram et al., 2004; Milgram et al., 2005). Further, an antioxidant enriched 
diet alone leads to rapid improvements in complex learning ability in aging dogs 
(Cotman et al., 2002; Milgram et al., 2002c). However, the neurobiological changes 
elicited by these two interventions alone or in combination have yet to be established. 
We show here that there is a significant reduction in the levels of oxidative damage as 
measured by levels of protein carbonyls, 3NT and HNE, following a combination of the 
treatments (EA). Using redox proteomics, we identified six proteins that were 
significantly less oxidized in animal receiving the combined treatment relative to control 
animals and these included: glutamate dehydrogenase (GDH), glyceraldehyde-3-
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phosphate dehydrogenase (GAPDH), α-enolase, neurofilament triplet L protein, 
glutathione-S-transferase (GST) and fascin actin bundling protein. This improvement 
was also associated with increased activity of the antioxidant enzymes glutathione-S-
transferase (GST) and superoxide dismutase (SOD) and an increase in the protein levels 
of inducible heme oxygenase (HO-1), a well known neuroprotective chaperone of the 
family of heat shock proteins (Poon et al., 2004b). A subset of proteins and antioxidant 
enzymes analyzed were also found to correlate with an improvement in cognitive 
function. As a result, the use of antioxidants composed of mitochondrial cofactors and 
cellular antioxidants and a program of behavioral enrichment in the present study could 
potentially protect proteins from oxidative damage and enhance mitochondrial function 
leading to the observed improved memory and cognitive function in this model.  
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4.3 Experimental procedures 
The breeding and maintenance of the animals used in the studies described here 
and in chapter 5 were done by our collaborators at the Lovelace Respiratory Research 
Institute Albuquerque NM. In addition, behavioral and cognitive tasks and correlational 
analysis were carried out by Dr Head and group. 
4.3.1 Subjects 
Twenty-four beagle dogs ranging in from 8.05-12.35 yrs at the start of the study 
(Mean = 10.69 yrs SE=0.25) were obtained from the colony at the Lovelace Respiratory 
Research Institute (Table 4.1).  These study animals were bred and maintained in the 
same environment and all had documented dates of birth and comprehensive medical 
histories.  At the time of euthanasia, 23 dogs had received the intervention and ranged in 
age from 10.72-15.01 yrs (Mean=13.31 yrs, SE=0.26) with one animal not completing 
the baseline phase of the study. All research was conducted in accordance with approved 
IACUC protocols. 
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4.3.2 Group Assignments and study timeline 
  All study dogs underwent extensive baseline cognitive testing as described 
previously (Milgram et al., 2002a).  Animals were subsequently ranked based on 
cognitive test scores and placed into 4 groups.  These four groups were randomly 
assigned as one of the treatment conditions as follows:  C/C – control enrichment/control 
diet, E/C – behavioral enrichment /control diet, C/A – control enrichment/antioxidant 
diet, E/A – behavioral enrichment /antioxidant diet.   
 
4.3.3 Behavioral enrichment treatment 
             The behavioral enrichment protocol consisted of social enrichment, by housing 
animals in pairs, environmental enrichment, by providing play toys, physical enrichment, 
by providing two 20-minute outdoor walks per week, and cognitive enrichment, through 
continuous cognitive testing. The cognitive enrichment consisted of a landmark 
discrimination task, an oddity discrimination task (Milgram et al., 2002b), and size 
concept learning (Tapp et al., 2003a).  In addition, all animals, regardless of treatment 
condition were evaluated annually on a test of visuospatial memory (Chan et al., 2002), 
object recognition memory (Callahan, 2000) and either size discrimination and reversal 
learning (Tapp et al., 2003b), or black/white discrimination and reversal on consecutive 
years. 
4.3.4 Diet treatment 
The two foods were formulated to meet the adult maintenance nutrient profile for 
the American Association of Feed Control Officials recommendations for adult dogs 
(AAFCO 1999). Control and test foods were identical in composition, other than 
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inclusion of a broad-based antioxidant and mitochondrial co-factor supplementation to 
the test food. The control and enriched foods had the following differences on an as-fed 
basis, respectively: dl-alpha-tocopherol acetate (vitamin E, approximately 100 vs. 1000 
ppm), -carnitine (<20 ppm vs. approximately 250 ppm), dl-alpha-lipoic acid (<20 ppm 
vs. approximately 120 ppm), ascorbic acid or vitamin C as Stay-C (<30 ppm vs. 
approximately 80 ppm), and 1% inclusions of each of the following (1 to 1 exchange for 
corn): spinach flakes, tomato pomace, grape pomace, carrot granules and citrus pulp. The 
rationale for these inclusions were as follows: Vitamin E is lipid soluble and acts to 
protect cell membranes from oxidative damage; vitamin C is essential in maintaining 
oxidative protection for the soluble phase of cells as well as preventing vitamin E from 
propagating free radical production (Butterfield et al., 2002c); alpha-lipoic acid is a 
cofactor for the mitochondrial respiratory chain enzymes, pyruvate and alpha-
ketoglutarate dehydrogenase, as well as an antioxidant capable of redox recycling other 
antioxidants and raising intracellular glutathione levels (Pocernich and Butterfield, 2003); 
L-carnitine is a precursor to acetyl-L-carnitine and is involved in mitochondrial lipid 
metabolism and maintaining efficient function (Calabrese et al., 2006). Fruits and 
vegetables are rich in flavonoids and carotenoids and other antioxidants (Joseph et al., 
1998b; Bickford et al., 2000). To define this further, added inclusions were measured for 
oxygen radical absorbing capacity (ORAC) as well as carotenoid and flavonoid profiles 
(Cao et al., 1995). Fruit and vegetables selected for inclusion were based on ORAC 
content and general commercial availability. Results of this analysis revealed that ORAC 
content of the individual fruit and vegetable inclusions were higher than the corn for 
which they were substituted. In addition, inclusion of these ingredients, in combination 
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with the vitamins, resulted in increased ORAC content of the finished product. The food 
was produced by an extrusion process and a production batch was fed for no more than 6 
months before a new lot was manufactured.  
 
4.3.5 Cognitive testing 
All animals were given annual tests of cognition to detect changes in response to 
the different treatments.  Within 8 months of euthanasia, animals were given an 
black/white discrimination and reversal problem that is impaired in aged animals and is 
significantly improved in both antioxidant treated and/or behaviorally enriched animals 
(Milgram et al., 2005).  Also within a year of the end of the study, spatial memory was 
tested using a nonmatching to position paradigm described previously to be sensitive to 
age in dogs (Chan et al., 2002).  All of the testing procedures were described in previous 
publications (Chan et al., 2002; Milgram et al., 2005). 
 
4.3.6 Animal euthanasia 
Twenty minutes before induction of general anesthesia, animals were sedated by 
subcutaneous injection with 0.2 mg/kg acepromazine.  General anesthesia was induced 
by inhalation with 5% isoflurane.  While being maintained under anesthesia, dogs were 
exsanguinated by cardiac puncture and blood samples were collected to obtain plasma 
and serum for future studies.  Within 15 minutes, the brain was removed from the skull 
and a cerebrospinal fluid sample was obtained from the lateral ventricles.  The brain was 
sectioned midsagitally, with the entire left hemisphere being immediately placed in 4% 
paraformaldehyde for 48-72 hours at 4°C prior to long term storage in phosphate buffered 
 111
saline with 0.05% sodium azide at 4°C.  The remaining hemispheres were sectioned 
coronally and flash frozen at -80°C and the parietal cortex was dissected for use in the 
current studies.  The dissection procedure was completed within 20 minutes.  Thus, the 
post mortem interval for all animals was 35-45 minutes. 
4.3.7 Measurement of protein carbonyls 
 
 
Protein carbonyls are an index of protein oxidation and were determined as 
described (Butterfield and Stadtman, 1997). Briefly, samples (5 µg of protein) were 
derivatized with 10 mM 2, 4-dinitrophenylhydrazine (DNPH) in the presence of 5 µL of 
12% sodium dodecyl sulfate for 20 min at room temperature (23°C). The samples were 
then neutralized with 7.5 µL of the neutralization solution (2 M Tris in 30% glycerol). 
Derivatized protein samples were then blotted onto a nitrocellulose membrane with a 
slot-blot apparatus (250 ng per lane). The membrane was then washed with wash buffer 
(10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20) and blocked by incubation 
in the presence of 5% bovine serum albumin, followed by incubation with rabbit 
polyclonal anti-DNPH antibody (1: 100 dilution) as the primary antibody for 1 h. The 
membranes were washed with wash buffer and further incubated with alkaline 
phosphatase-conjugated goat anti-rabbit antibody as the secondary antibody for 1 h. Blots 
were developed using fast tablet (BCIP/NBT; Sigma-Aldrich) and quantified using Scion 
Image (PC version of Macintosh-compatible NIH Image) software. No non-specific 
background binding of the primary or secondary antibodies was found. 
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4.3.8 Measurement of 3-nitrotyrosine (3-NT) 
Nitration of proteins is another form of protein oxidation (Castegna et al., 2003; 
Sultana et al., 2006b). The nitrotyrosine content was determined immunochemically as 
previously described (Drake et al., 2003b). Briefly, samples were incubated with 
Laemmli sample buffer in a 1:2 ratio (0.125 M Trizma base, pH 6.8, 4% sodium dodecyl 
sulfate, 20% glycerol) for 20 min. Protein (250 ng) was then blotted onto the 
nitrocellulose paper using the slot-blot apparatus and immunochemical methods as 
described above for protein carbonyls. The mouse anti-nitrotyrosine antibody (5: 1000 
dilutions) was used as the primary antibody and alkaline phosphatase-conjugated anti-
mouse secondary antibody was used for detection. Blots were then scanned using scion 
imaging and densitometric analysis of bands in images of the blots was used to calculate 
levels of 3-NT. No non-specific binding of the primary or secondary antibodies was 
found. 
4.3.9 Measurement of 4-hydoxynonenal (HNE) 
HNE is a marker of lipid oxidation and the assay was performed as previously 
described (Lauderback et al., 2001). Briefly, 10 µl of sample were incubated with 10 µl 
of Laemmli buffer containing 0.125 M Tris base pH 6.8, 4 % (v/v) SDS, and 20% (v/v) 
Glycerol. The resulting sample (250 ng) was loaded per well in the slot blot apparatus 
containing a nitrocellulose membrane under vacuum pressure. The membrane was 
blocked with 3% (w/v) bovine serum albumin (BSA) in phosphate buffered saline 
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST) for 1 h and 
incubated with a 1:5000 dilution of anti-4-hydroxynonenal (HNE) polyclonal antibody in 
 113
PBST for 90 min. Following completion of the primary antibody incubation, the 
membranes were washed three times in PBST. An anti-rabbit IgG alkaline phosphatase 
secondary antibody was diluted 1:8000 in PBST and added to the membrane. The 
membrane was washed in PBST three times and developed using Sigmafast Tablets 
(BCIP/NBT substrate).  Blots were dried, scanned with Adobe Photoshop, and quantified 
by Scion Image. A small background of the primary antibody binding to the membrane 
was found, but this was scattered from both control and subject blots. 
4.3.10 Two-dimensional electrophoresis 
Brain samples (200 µg) were incubated with 4 volumes of 2N HCl at room for 
electrophoresis or 20mM 2, 4-dinitrophenyl hydrazine (DNPH) for western blotting at 
room temperature for 20 min.  Proteins were then precipitated by the addition of ice-cold 
100% trichloroacetic acid (TCA) to obtain a final concentration of 15% TCA. Samples 
were then placed on ice for 10 min and precipitate centrifuged at 16,000 g for 3min. The 
resulting pellet was then washed three times with a 1:1(v/v) ethanol/ethyl acetate 
solution. The samples were then suspended in 200 µl of rehydration buffer composed of a 
1:1 ratio (v/v) of the Zwittergent solubilization buffer (7M urea, 2M thiourea, 2% Chaps, 
65 mM DTT, 1% Zwittergent 0.8% 3-10 ampholytes and bromophenol blue) for 1 h. 
4.3.11 First dimension electrophoresis 
For the first-dimension electrophoresis, 200 µL of sample solution was applied to 
a 110-mm pH 3–10 ReadyStrip™ IPG strips (Bio-Rad, Hercules CA). The strips were 
then actively rehydrated in the protean IEF cell (Bio-Rad) at 50 V for 18 h. The 
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isoelectric focusing was performed in increasing voltages as follows; 300 V for 1 h, then 
linear gradient to 8000 V for 5 h and finally 20 000 V/h. Strips were then stored at –80 
°C until the second dimension electrophoresis was to be performed. 
4.3.12 Second dimension electrophoresis 
For the second dimension, the IPG® Strips, pH 3–10, were equilibrated for 10 min 
in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium dodecyl sulfate 
(SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15 min in 
the same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient 
precast criterion Tris–HCl gels (8–16%) (Bio-Rad) were used to perform second 
dimension electrophoresis. Precision Protein™ Standards (Bio-Rad, CA) were run along 
with the sample at 200 V for 65 min. 
4.3.13 SYPRO ruby staining 
After the second dimension electrophoresis, the gels were incubated in fixing 
solution (7% acetic acid, 10% methanol) for 20 min and stained overnight at room 
temperature with 50ml SYPRO Ruby gel stain (Bio-Rad). The SYPRO ruby gel stain was 
then removed and gels stored in DI water. 
4.3.14 Western Blotting 
Brain samples (200 µg) incubated with 20mM DNPH were used for western 
blotting. The strips and gels were run as described above. After the second dimension, the 
proteins from the gels were transferred onto nitrocellulose papers (Bio-Rad) using the 
Transblot-Blot® SD semi-Dry Transfer Cell (Bio-Rad), at 15 V for 4 h. The 2,4-
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dinitrophenyl hydrazone (DNP) adduct of the carbonyls of the proteins was detected on 
the nitrocellulose paper using a primary rabbit antibody (Chemicon, CA) specific for 
DNP-protein adducts (1:100), and then a secondary goat anti-rabbit IgG (Sigma, MO) 
antibody was applied. The resulting stain was developed by application of Sigma-Fast 
(BCIP/NBT) tablets. 
4.3.15 Image analysis 
The nitrocellulose blots (oxyblots) were scanned and saved in TIFF format using 
Scan jet 3300C (Hewlett Packard, CA). SYPRO ruby-stained gel images were obtained 
using a STORM phosphoimager (Ex. 470 nm, Em. 618 nm, Molecular Dynamics, 
Sunnyvale, CA, USA) and also saved in TIFF format. PD-Quest (Bio-Rad) imaging 
software was then used to match and analyze visualized protein spots among differential 
2D gels and 2D oxyblots, with one blot and one gel for each individual sample. 
 
4.3.16 In-gel trypsin digestion 
In those brain proteins less oxidized from EA dogs compared to CC dogs as 
judged by PDQuest analysis, protein spots were digested by trypsin using protocols 
previously described (Thongboonkerd et al., 2002). Briefly, spots of interest were excised 
using a clean blade and placed in Eppendorf tubes, which were then washed with 0.1 M 
ammonium bicarbonate (NH4HCO3) at room temperature for 15 min. Acetonitrile was 
then added to the gel pieces and incubated at room temperature for 15 min. This solvent 
mixture was then removed and gel pieces dried. The protein spots were then incubated 
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with 20 µL of 20 mM DTT in 0.1 M NH4HCO3 at 56 °C for 45 min. The DTT solution 
was removed and replaced with 20 µL of 55 mM iodoacetamide in 0.1 M NH4HCO3. The 
solution was then incubated at room temperature for 30 min. The iodoacetamide was 
removed and replaced with 0.2 mL of 50 mM NH4HCO3 and incubated at room 
temperature for 15 min. Acetonitrile (200 µL) was added. After 15 min incubation, the 
solvent was removed, and the gel spots were dried in a flow hood for 30 min. The gel 
pieces were rehydrated with 20 ng/µL-modified trypsin (Promega, Madison, WI) in 
50 mM NH4HCO3, with the minimal volume enough to cover the gel pieces. The gel 
pieces were incubated overnight at 37 °C in a shaking incubator. 
4.3.17 Mass spectrometry 
A MALDI-TOF mass spectrometer in the reflectron mode was used to generate 
peptide mass fingerprints. Peptides resulting from in-gel digestion with trypsin were 
analyzed on a 384 position, 600 µm AnchorChipTM Target (Bruker Daltonics, Bremen, 
Germany) and prepared according to AnchorChip recommendations (AnchorChip 
Technology, Rev. 2, Bruker Daltonics, Bremen, Germany). Briefly, 1 µL of digestate was 
mixed with 1 µL of alpha-cyano-4-hydroxycinnamic acid (0.3 mg/mL in ethanol: 
acetone, 2:1 ratio) directly on the target and allowed to dry at room temperature. The 
sample spot was washed with 1 µL of a 1% TFA solution for approximately 60 seconds.  
The TFA droplet was gently blown off the sample spot with compressed air. The 
resulting diffuse sample spot was recrystallized (refocused) using 1 µL of a solution of 
ethanol: acetone: 0. 1 % TFA (6:3:1 ratio). Reported spectra are a summation of 100 laser 
shots. External calibration of the mass axis was used for acquisition and internal 
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calibration using either trypsin autolysis ions or matrix clusters and was applied post 
acquisition for accurate mass determination.  
4.3.18 Analysis of peptide sequences 
 
Peptide mass fingerprinting was used to identify proteins from tryptic peptide 
fragments by utilizing the MASCOT search engine based on the entire NCBI and 
SwissProt protein databases. Database searches were conducted allowing for up to one 
missed trypsin cleavage and using the assumption that the peptides were monoisotopic, 
oxidized at methionine residues, and carbamidomethylated at cysteine residues. Mass 
tolerance of 150 ppm, 0.1 Da peptide tolerances and 0.2 Da fragmentation tolerances was 
the window of error allowed for matching the peptide mass values. Probability-based 
MOWSE scores were estimated by comparison of search results against estimated 
random match population and were reported as -10*log10 (p), where p is the probability 
that the identification of the protein is a random event. MOWSE scores greater than 63 
were considered to be significant (P < 0.05). All protein identifications were in the 
expected size and isoelectric point (pI) range based on the position in the gel. 
4.3.19 Immunoprecipitation  
Immunoprecipitation of specific proteins was performed as previously described 
(Sultana and Butterfield, 2004). Brain samples (200 µg) from control or treated animals 
were incubated overnight with anti-GAPDH antibody. This was followed by three 
washing steps with buffer B (50Mm Tris HCl (pH-8.0), 150 Mm NaCl, and 1% NP40). 
The proteins were resolved by SDS-PAGE followed by immunoblotting on a 
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nitrocellulose membrane (BioRad). The proteins were then detected with alkaline 
phosphate labeled secondary antibody (Sigma).  
4.3.20 Protein Interacteome 
  The functional protein interacteome was obtained by using Interaction Explorer 
TM Software Pathway Assist software package (Stratagene, La Jolla, CA). Pathway Assist 
is software for functional interaction analysis. It allows for the identification and 
visualization of pathways, gene regulation networks and protein interaction maps. The 
proteins are first imported as the gene symbols as a set of data. This data set is then 
searched against ResNet, a database containing over 500,000 biological interactions built 
by applying the MedScan text-mining algorithms to all PubMed abstracts. These 
interactions are then visualized by building interaction networks with shortest-path 
algorithms. This process can graphically identify all known interaction among the 
proteins. The information of the function of these proteins and their relevance to diseases 
are then obtained by using the BIOBASE's Proteome BioKnowledge Library form Incyte 
Corporation (Incyte, Wilmington, DE) (Hodges et al., 2002). 
4.3.21 Determination of glutathione-S-transferase (GST) activity  
Glutathione-S-transferase activity was measured as previously described using 1-
chloro-2, 4-dinitrobenzene (CDNB) as substrate (Habig and Jakoby, 1981). Briefly, the 
standard assay mixture contained CDNB (1 mM), reduced glutathione (1 mM), and 
potassium phosphate buffer (100 mM; pH = 6.5) in a volume of 100 µL. The changes in 
absorbance were monitored at 340 nm. The thioether formed was determined by reading 
 119
the absorbance at 340 nm, and quantification was performed by using a molar 
absorptivity of 9.6 M−1.  
4.3.22 Determination of superoxide dismutase (SOD) activity  
 
Superoxide dismutase (SOD) activity was measured as previously described 
(Stevens et al., 2000). Briefly, the reaction mixture of total volume 184 µL contained 160 
µL of 50 mmol/l glycine buffers, pH 10.4, and 20.0 µL sample. The reaction was initiated 
by the addition of 4.0 µL of a 20 mg/ml solution of (–)-epinephrine. Due to its poor 
solubility, (–)-epinephrine (40 mg) was suspended in 2 ml water and was solubilized by 
adding 2–3 drops of 2N HCl. The auto-oxidation of (–)-epinephrine was monitored at 
480nm and the millimolar absorptivity (4.02 mmol · l–1 · cm–1) was used for calculations. 
4.3.23 Measurement of HO-1 Protein levels 
Mixtures of loading buffer and brain samples (50 µg) were denatured and 
electrophoresed on a 10% SDS-polyacrylamide gel. Proteins were transferred to 
nitrocellulose at 90 mA/gel for 2 h. The blots were blocked for 1h in fresh wash buffer 
and incubated with HO-1 primary antibody for 2 h. The membrane was then washed for 
three times in PBS for 5 min and the incubated with a secondary alkaline phosphatase-
conjugated antibody. Proteins were visualized by developing with Sigma fast tablets 
(BCIP/NBT substrate). Blots were dried, scanned with Adobe Photoshop, and quantified 
using Scion Image (PC version of Macintosh-compatible NIH Image) software. 
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4.3.34 Statistics 
An analysis of variance was used to compare the 4 treatment groups on measures 
of oxidative damage (protein carbonyls, 3-NT, HNE).  Post hoc comparisons were made 
using both the Bonferroni correction and Dunnett’s post-hoc test. For measures of 
antioxidant enzymes and HO-1 protein levels, independent t-tests were used. In all of 
these analyses, raw data were used but percent changes are presented in the plots. Pearson 
product moment correlations were used to test the linear association between oxidative 
damage, antioxidant enzymes and cognition.  A linear stepwise multiple regression was 
used to determine which of the measures of oxidative damage best predicted cognition. 
SPSS for Windows was used and a p value of < 0.05 were used to establish statistical 
significance. Statistical analysis of specific protein carbonyl levels matched with anti-
DNP-positive spots on 2D-oxyblots from brain samples from animals on an enriched 
environment and antioxidant fortified diet (EA) and age matched control of dogs that 
were on control food- control environment.(CC) was carried out using Student's t-tests. A 
value of p < 0.05 was considered statistically significant. Only proteins that are 
considered significantly different by Student's t-test were subjected to in-gel trypsin 
digestion and subsequent proteomic analyses. This is the normal procedure for 
proteomics studies, as sophisticated statistical analysis used for micro array studies are 
not applicable for proteomics studies (Maurer et al., 2005). 
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4.4 Results 
4.4.1 Combined treatment (EA), decreases in the levels of protein oxidation 
 
As shown in Fig.4.1A and 4.1B, total protein oxidation measured by the 
accumulation of protein carbonyls (F (3, 22) =4.93 p=0.011) and 3-nitrotyrosine (3NT) (F 
(3, 22) =3.82 p=0.027) respectively, were reduced in all treatment conditions. Post hoc 
comparisons show that the extent of neuroprotection was greater for the combined 
treatment of the enriched environment and antioxidant-fortified food (EA) (p=0.013 and 
p=0.031 for protein carbonyls and 3NT, respectively). The levels of lipid peroxidation, 
detected as protein-bound 4-hydoxynonenal (HNE), (Fig.4.1C), showed a tendency 
towards reduction when the groups were compared, but was not significantly different 
than controls (F (3, 22) =1.34 p=0.29). 
4.4.2 Combined treatment (EA), results in a decrease in specific protein carbonyl 
levels 
 
An estimate of the carbonyl levels of specific proteins were obtained by dividing 
the carbonyl level of a protein spot on the nitrocellulose membrane by the protein level of 
its corresponding protein spot on the gel. This ratio gives the carbonyl level per unit of 
protein. We used a parallel approach to quantify the carbonyl protein levels by SYPRO 
Ruby staining and the extent of DNP-bound proteins by immunoblotting (Fig. 4.2 and Fig 
4.3). When we analyzed brain samples from canines that were on the control diet and 
control environment (CC) and compared them to brain samples from animals that were 
on an antioxidant fortified diet and in an enriched environment (EA), six proteins were 
identified that were significantly less oxidized. As shown in (Table 4.2), these proteins 
were: glutamate dehydrogenase [NAD (P)], glyceraldehyde-3-phosphate dehydrogenase 
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(GAPDH), α-enolase, neurofilament triplet L protein, glutathione S-transferase (GST), 
and fascin actin bundling protein. The summary of specific carbonyl levels of the six 
identified proteins is shown in Table 4.3. The probability of an incorrect identification 
was established to be minimal (Table 4.2). Nevertheless, to confirm the proteomics 
identification of GAPDH, we used immunoprecipitation of GAPDH with an anti-
GAPDH antibody and Western blot analysis as shown in Fig. 4.4. 
4.4.3 Enzyme activities 
We next hypothesized that in addition to reduced protein oxidation that 
antioxidant enzyme activity would be increased in response to treatment.  We directly 
compared the CC animals with the EA animals for these experiments as they showed the 
largest difference in protein oxidation treatment effects. Thus, the activity and expression 
of key enzyme systems that contribute to tissue defense against oxidative stress and that 
are vulnerable to oxidative modification were analyzed following the treatment with an 
antioxidant fortified diet and a program of behavioral enrichment in the aging canine 
brain. 
The activity of GST in aged canine brain isolated from dogs that had been treated 
long-term with antioxidants and a program of behavioral enrichment (EA) was found to 
be significantly (t (8) =3.3 p=0.011) increased by approximately 25% in aged EA animals 
compared to controls (Fig 4.5). The activity of a second antioxidant enzyme, superoxide 
dismutase (SOD) was also increased by approximately a 50% (Fig 4.5) in the aging 
canines after the combined treatment (EA) compared to controls (CC) (t (8) =2.29 
p=0.05). This is consistent with the hypothesis that oxidative modification of an enzyme 
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leads to a loss or decrease in function and the reversal of this oxidative damage can 
restore the function of an enzyme (Poon et al., 2005e).  
4.4.4 Correlation among Cognition, Oxidative Damage and Antioxidant Status 
 
 
 To determine if error scores on individual cognitive tasks were associated with 
reduced oxidative damage or increased antioxidant enzyme/protein levels, a correlational 
analysis was used.  Table 4.4 shows that generally, higher error scores (i.e. poorer 
cognition) on tests of black/white discrimination, black/white reversal and spatial 
memory were associated with higher levels of oxidative damage. Correlations were 
significant for black/white reversal and 3-NT (Fig 4.7A) and for 3-NT and spatial 
memory (Fig. 4.7B). Overall, higher levels of antioxidant enzyme activity (SOD, GST) or 
higher protein levels of HO-1 were generally associated with lower error scores on all the 
tasks.  These were statistically significant for GST and HO-1 (Fig 4.7 C, D) but not SOD, 
although all showed the same inverse relationship.  Because age at death may also be a 
contributor to both increased error scores and increased oxidative damage, correlations 
were computed that corrected for age.  The correlation between GST activity and 
black/white discrimination was significant (r=-0.81 p=0.05) and between black/white 
reversal learning and HO-1 protein levels was significant (r=-0.81 p=0.05). 
A multiple stepwise regression was used to determine which measures of 
oxidative damage or antioxidant status best predicted cognitive dysfunction.  Age at 
death was also included in the analysis. The best predictor of error scores on black/white 
discrimination learning was GST activity (F (1, 6) =14.31 p=0.013 r2=0.74), on 
black/white reversal learning was HO-1 (F (1, 6) =11.54 p=0.019 r2=0.70) and on spatial 
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memory was age at death (F (1, 6)-7.22 p=0.044 r2=0.59).  Thus, at least one significant 
explanatory variable for error scores on tasks administered within 1 year of euthanasia 
was antioxidant enzyme function.  
4.4.5 Protein Interacteome  
Fig 4.8 shows the protein interacteome of proteomics-identified proteins with 
decreased oxidation in response to the various intervention paradigms are illustrated by 
using Interaction Explorer Software Pathway Assist (Stratagene) software. The proteins 
identified in this study are related to hormone activities, transcription and regulation of 
signal transduction among others. As a result, the present findings continue to confirm 
and support previous findings (Poon et al., 2004c; Poon et al., 2005e) that antioxidants 
and a programme of behavioral enrichment provide beneficial effect of protection and 
improvement in cognitive functions and memory through the deceased oxidation and 
increased activity of key proteins 
 
 
 
 
 
 
 125
Figure 4.1 
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Figure 4.1 Changes in protein carbonyls (A), 3NT (B) and HNE (C) levels in canine 
brain homogenate samples following treatment. There was a decrease in the levels of 
protein carbonyls, 3NT and HNE measured from the various treatments i.e. EC, CA and 
EA compared to the control group CC. Data are represented as % control ± SEM for 
animals in each treatment group. Measured values are normalized to the CC values (n=6) 
* p < 0.05 for canines on EA treatment. 
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Figure 4.2 
 
 
 
 
 
 
 
 
 
Figure 4.2 Two-dimensional SYPRO Ruby-stained gels from the parietal cortex of 
canines provided with a combined treatment with an antioxidant fortified diet and 
behavioral enrichment EA) (B) and compared to control (CC) (A). Positions of the 
proteins identified by mass spectrometry to be less oxidized are shown as the boxed 
spots. 
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Figure 4.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Combined treatment of aged dogs with an antioxidant enriched diet and 
behavioral enrichment leads to reduced protein oxidation. Carbonyl immunoblots 
showing proteins with less oxidation in the parietal cortex of canines given a combined 
treatment with an antioxidant fortified diet and an exposure to a behavioral enrichment 
programme EA) (B) as compared to control (CC) (A) 
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Figure 4.4  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Validation of protein identified by proteomics, (A) shows blots probed with 
anti GADPH antibody and, (B) shows position of GAPDH on the gel. 
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Figure 4.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 SOD and GST activity are significant increased in response to treatment in 
aged dogs. Dogs provided with the combination of an antioxidant-fortified diet and 
behavioral enrichment show significantly increased GST and total SOD enzyme activity 
relative to controls. Activities of GST and SOD are expressed as units per milligram of 
protein and data are presented as % control ± SEM for animals in each treatment group, 
(n=5) * p <0.05. 
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Figure 4.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6 HO-1 protein levels increase in response to treatment in aged canines. 
Western immunoblot analysis and quantification of canine brain homogenates samples 
containing 50µg of protein loaded onto 10% SDS-PAGE gels were completed using an 
anti-HO-1 antibody.  A representative immunoblot (A) with Lanes (1-6) representing the 
treatment group EA, and 7-12 represent control group CC is shown and GAPDH was 
used as a control for equal loading of protein. Densitometric values are plotted as a 
function of treatment group (B) showing a significant increase in HO-1 expression 
following the combined treatment of enriched environment and antioxidant-fortified food 
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(EA) compared to control (CC). GAPDH densitometric data are represented as % control; 
± SEM for each group. (n=6), * p <0.05. 
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Figure 4.7 
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Figure 4.7 Association between cognitive test scores and measures of oxidative damage 
in treated animals. Shows error scores on individual cognitive tasks associated with 
reduced oxidative damage or increased antioxidant enzyme/protein levels. Higher error 
scores on tests of black/white discrimination, black/white reversal and spatial memory 
were associated with higher levels of oxidative damage. Higher error scores on a reversal 
learning task (A) and on a visuospatial memory task (B) were correlated with 3-NT. 
Discrimination learning ability was inversely associated with GST activity (C).  Reversal 
learning error scores were also negatively associated with HO-1, with higher levels of 
HO-1 associated with better cognition (D).  
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Figure 4.8 
 
 
 
 
 
 
 
Figure 4.8 Schematic diagram of a functional interacteome of all parietal cortex proteins 
identified to be significantly less oxidatively modified following the combined treatment 
of the enriched environment and antioxidant-fortified food (EA). This diagram was 
generated by the interaction explorer ™ Pathway Module (Stratagene), indicating that all 
the proteins are directly or indirectly associated with cellular process shown 
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4.5 Discussion 
 
Oxidative stress may be involved in the development of pathology leading to 
decline in memory and cognitive functions observed in AD and in other age-related 
neurodegenerative disorders (Hensley et al., 1995; Butterfield and Kanski, 2001; 
Butterfield and Lauderback, 2002). However, interventions with antioxidants delays age-
related cognitive decline and improves performance in animal models of AD and other 
age-related neurodegenerative disorders (Joseph et al., 1998b; Bickford et al., 2000; Farr 
et al., 2003). The present study investigated the effect of a antioxidant-fortified diet and a 
program of behavioral enrichment on the levels of oxidative damage and in restoring 
antioxidant reserve systems in the aging canine brain. Four different treatments were 
compared (CC, CE, CA and EA) in 23 age-matched beagle dogs for a period of 2.8yrs 
and markers of oxidative stress in the parietal cortex were analyzed. There was a 
reduction in the levels of brain 3NT and protein carbonyls assayed with all treatments, 
but only those in the combined treatment EA showed a significant reduction when 
compared to control. The levels of brain lipid peroxidation as measured by HNE were 
marginally reduced in all treatments, but none was significantly reduced compared to 
control. We also used redox proteomics to show that following the combined treatment 
EA; the aging canine shows less oxidation to key brain proteins involved in energy 
metabolism, antioxidant systems, and in maintenance and stabilization of cell structure. 
In addition, there is a significant increase in the activity of antioxidant enzymes GST and 
SOD in the combined treatment EA when compared to control, and a significant increase 
in the expression of HO-1 protein, an important defense system in neurons under 
oxidative stress (Calabrese et al., 2003a). The significant decrease in oxidation of some of 
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these key brain proteins was also shown to correlate with improved cognitive function in 
the aged canines undergoing these interventions. These results suggest possible 
mechanisms for the improved memory and cognitive function previous reported in the 
(Cotman et al., 2002; Milgram et al., 2004) and are discussed herein with relevance to 
AD. 
In AD, the Aβ peptide plays a central role in the generation of free radicals and 
oxidative stress (Hensley et al., 1994; Butterfield et al., 2001). In the aging canine, no 
significant correlation between the levels of Aβ deposition in brain and oxidative damage 
is observed (Head et al., 2002), however, since the aging canine deposits the more toxic 
form of Aβ 1-42 as that seen in human aging (Markesbery, 1997; Butterfield et al., 
2002b) and since Aβ load and decline in cognitive function events develop in parallel, Aβ 
could still play a significant role in the mechanism of oxidative stress observed in the 
aging canine (Cummings et al., 1993; Cummings et al., 1996b; Head et al., 2000). In the 
peptide sequence of Aβ (1-42), there is a methionine-35 residue that our laboratory has 
shown to play a critical role in Aβ induced oxidative stress and neurotoxicity observed in 
AD (Butterfield et al., 2005). We have proposed that the Aβ1-42 peptide, as a small 
oligomer, inserts itself in the lipid bilayer in an alpha helix conformation. A one-electron 
oxidation of methionine forms the methionine sulfuranyl radical, which can then abstract 
a labile hydrogen atom from neighboring unsaturated lipids forming a carbon-centered 
lipid radical (L.), which can react with molecular oxygen to from a peroxyl radical 
(LOO.). This peroxyl radical can abstract hydrogen from a neighboring lipid to form the 
lipid hydroperoxide LOOH and a carbon centered radical L., which propagates the free 
radical chain reaction (Varadarajan et al., 2001; Butterfield et al., 2005). It is with this 
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mechanism of free radical generation that we believe is similarly taking place in the aging 
canine and is responsible for the increased levels of oxidative stress leading to 
neurodegeneration and a decline in memory and cognitive function.  
The use of dietary intervention with anti-oxidants or free radical quenchers and a 
regular program of behavioral enrichment (social, cognitive, environmental and physical 
exercise) is protective against oxidative damage, reduces oxidative stress, protects neurons 
and consequently improves cognitive function in human aging and in animal models (Joseph 
et al., 1998b; Bickford et al., 2000; Eckles-Smith et al., 2000; Milgram et al., 2002b; 
Calabrese et al., 2003a; Adlard et al., 2005b). In the present study, the fortified antioxidant 
diet included vitamin E and vitamin C, both well-known free radical quenchers. Vitamin E is 
lipid soluble, hence protects cell membranes from oxidative insults while vitamin C protects 
the soluble phase of the cell and also regenerates the vitamin E from the vitamin E free 
radical (Butterfield et al., 2002c), but recent studies in which vitamin C was not included, 
reported vitamin E did not inhibit the conversion of patients with mild cognitive impairment 
to AD (Petersen et al., 2005). As a result, the ability of vitamin E in protecting cell 
membranes provides one possible mechanism through which the fortified diet given to the 
aging canines provides protection from oxidative damage as seen by the decreased levels of 
lipid peroxidation assayed by HNE and previously seen to have been elevated as measured 
by malondialdehyde (Head et al., 2002). In addition, the inclusion of fruits and vegetables 
rich in flavonoids and carotenoids, could help in quenching the possible free radicals 
generated by Aβ, which as noted here is deposited in the aging canine brain (Cummings et 
al., 1996b; Head and Torp, 2002), leading to the low levels of protein oxidation as measured 
by protein carbonyls and 3NT observed in the present study. Further, there was a significant 
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correlation between 3NT and spatial memory and black/white reversal learning indicating 
that there is a correlation between improved cognition and reduction in oxidative damage in 
the aging canine brain following the combined treatment with a diet fortified with 
antioxidants and a program of behavioral enrichment. 
The behavioral enrichment program used in this study involved a regimen of extra 
physical exercise, enhanced environmental and social stimulation and cognitive training 
leading to cognitive improvement (Milgram et al., 2005). Exercise is reported to improve 
cognitive function, reduce the risk of developing cognitive impairment and reduce 
neuropathology in humans or in animal models (Hultsch et al., 1999; van Praag et al., 
1999; Laurin et al., 2001; Adlard et al., 2005b). In aging dogs, behavioral enrichment 
leads to significant improvements in visual discrimination learning and frontal-dependent 
reversal learning (Milgram et al., 2005). The mechanism by which behavioral enrichment 
provides protection against oxidative damage is still unknown, but the current study 
provides new insights. Aging usually lowers the expression of antioxidant enzymes and 
stress protein expression. This loss can be modulated through interventions with diet or 
exercise (Heydari et al., 1993; Wu et al., 1993; Ji, 2002). One effect of the combined 
treatment EA was a significant increase in the expression of inducible heme oxygenase 
(HO-1) also known as HSP32. The heme oxygenase pathway is an important neuronal 
defense system in conditions of oxidative stress (Chen et al., 2000) and has been reported 
to be involved in oxidative stress-related neurodegenerative disorders, including AD, 
(Takahashi et al., 2000). In AD, for example, the expression of HO-1 is significantly 
altered and is up-regulated during oxidative stress, as well as by GSH depletion (Tyrrell, 
1999; Calabrese et al., 2004a). The induction of HO-1 catabolizes heme forming carbon 
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monoxide (CO) and biliverdin and subsequently bilirubin, a potent antioxidant and anti-
inflammatory agent (Calabrese et al., 2004a). In the aging canine increased oxidative 
stress and depletion of GSH is observed (Head et al., 2002) and with interventions with 
an antioxidant diet and a program of behavioral enrichment, a perfect environment is 
created for the induction of HO-1. This in effect could provide an additional antioxidant 
i.e. bilirubin, contributing to the decreased levels of oxidative damage and improvement 
in memory and cognitive function in the aging canine. The higher protein levels of HO-1 
were also associated with lower error scores on individual cognitive tasks. This 
correlation was statistically significant even after correction for age at death. As a result 
HO-1 was one of the best predictors of error scores on black/white reversal learning, i.e., 
higher HO-1 protein levels were associated with improved cognitive function. 
A by-product of mitochondrial respiration is the generation of superoxide, which 
leaks from the mitochondria inducing more oxidative stress and damage. 
Supplementation of the diet in the present study with mitochondrial co-factors, could lead 
to more efficiently functioning mitochondria. We have also shown in the present study 
that there is increased activity of total SOD, which would then provide protection against 
an increase in the production of superoxide, leading to a reduction in oxidative damage. 
On looking at the correlation between increased enzymatic activity and cognition, we 
found that though high levels of antioxidant activity were associated with lower error 
scores, though this correlation was not significant for SOD.  
We also hypothesized that of the use of mitochondrial co-factors in the canine 
enriched diet would result in improved mitochondrial function and may increase ATP 
production, consequently improving cognition (Milgram et al., 2004). Using redox 
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proteomics in the current study, we were able to identify key brain proteins not only 
related to energy metabolism but also those related to antioxidant systems, and those 
involved in the maintenance and stabilization of cell structure to be less oxidized. These 
proteins may be playing a role in the improved cognitive function observed in these 
animals.  
Energy metabolism 
Alpha enolase (ENO1) is a glycolytic enzyme that interconverts 2-
phosphoglycerate to phosphoenolpyruvate and is one of the proteins recently identified to 
be significantly oxidatively modified in individuals with mild cognitive impairment 
(MCI) (Butterfield et al., 2006d), which to some extent, the aged canine models 
(Cummings et al., 1996a; Cotman et al., 2002). We have also shown that α-enolase is 
oxidatively modified in AD and in various models of neurodegenerative disorders 
(Butterfield et al., 2002a; Perluigi et al., 2005a; Perluigi et al., 2005b; Poon et al., 2005c), 
indicating that this key protein is involved in several age-related neurodegenerative 
disorders. In addition, we have also shown that following caloric restriction in aging rats 
(Poon et al., 2005g) and after treatment with lipoic acid in the SAMP8 mice (Poon et al., 
2005e), the specific carbonyl levels of α-enolase are significantly decreased leading us to 
believe that this protein may play a key  role in the restoration of cognitive function. 
Consistent with this idea, our present findings show that following treatment with 
antioxidants and mitochondrial co-factors (including lipoic acid) and a program of 
behavioral enrichment in the aging canine, the specific carbonyl levels of α-enolase are 
significantly reduced.  
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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is another glycolytic enzyme that 
catalyzes the oxidation of glyceraldehyde-3-phosphate to 1, 3-bisphosphoglycerate and 
NADH (Chuang et al., 2005). GAPDH can also act as a sensor for nitrosative stress (Hara 
et al., 2006). Our laboratory has shown that GAPDH undergoes significant nitration, 
another form of oxidative modification, in the hippocampus of AD patients (Sultana et 
al., 2006b) and also in rats after intracerebral injection with Aβ (1-42) (Boyd-Kimball et 
al., 2005c). Interestingly, we have also shown that the use of gamma-glutamylcysteine 
ethyl ester (GCEE), a compound that leads to increased synthesis of glutathione in 
neuronal cell culture treated with Aβ (1-42), protects GAPDH against Aβ (1-42)-
mediated protein oxidation (Boyd-Kimball et al., 2005b). In the present study we have 
also identified GAPDH as one of the proteins that is protected from oxidative damage 
following the combined treatment with antioxidants and behavioral enrichment. As a 
result, the decreased oxidation of GAPDH and α-enolase could lead to improved 
glycolytic function and increased ATP production and possible neuronal recovery and 
improved cognitive function as seen in the canine model of human aging.  
Maintenance and stabilization of the integrity of the cell structure 
Neurofilament triplet L protein also known as NF68/NF-L is a subunit of 
neurofilaments (NFs), which give axons their structure and diameter (Hoffman et al., 
1987). In addition NFs are involved in cytoskeleton organization, neurogenesis and 
supports the neuronal architecture in the brain (Poon et al., 2006a). The protein levels of 
NF-L in brains of AD, Down syndrome, and ALS patients is significantly decreased 
(Bergeron et al., 1994; Bajo et al., 2001), suggesting that normal NF-L expression could 
be critical to central nervous system (CNS) function. Oxidation or nitration of 
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neurofilament (NF) proteins transform the α-helix secondary structure to β-sheet and 
random coil conformations, destabilizing the interactions between the NF proteins and 
resulting in axonal damage (Crow et al., 1997) and CNS dysfunction. We have previously 
shown that NF68 was significantly oxidized in the brain of the gracile axonal dystrophy 
(gad) mouse (Castegna et al., 2004). NF-66 (α-internexin) another family of the NF’s is 
also significantly oxidized in the brains of old versus young mice (Poon et al., 2005b). In 
the SAMP 8 mice, following treatment with alpha lipoic acid, we have observed a 
significant increase in the expression of NF-68 and since alpha lipoic acid treated 
SAMP8 aged mice have improved learning and memory, this protein could be important 
for brain function (Poon et al., 2005e). In the present study we established that the levels 
of protein oxidation for neurofilament triplet L protein were decreased following 
interventions with antioxidants and a program of behavioral enrichment in aging dogs.     
Another cytoskeleton related protein identified to be less oxidized in this study is 
Fascin. Fascin, a 55kD globular protein, is an actin bundling protein responsible for 
organizing F-actin into well-ordered, tightly packed parallel bundles in vitro and in cells 
(Adams, 2004b). It is also known to be one of the core actin bundling protein of dendrites 
among other structures (Adams, 2004a). Fascins function in the organization of two 
major forms of actin-based structures: dynamic, cortical cell protrusions and cytoplasmic 
microfilament bundles (Kureishy et al., 2002). Cell protrusions in the plasma membrane 
sense the cellular environment, provide cell adhesion in the extracellular matrix and act in 
cellular migration (Adams, 2004b). These cell protrusions usually require a rigid 
cytoskeleton to support the localized extension of the plasma membrane. Formation of 
these structures is highly regulated by extracellular and intracellular signals, with a key 
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point of regulation being the binding of fascin to filamentous actin (F-actin) (Adams, 
2004b). Alterations in the expression of fascin are associated with disorders such as 
cardiovascular diseases and in various carcinomas among others, (Kureishy et al., 2002; 
Adams, 2004b, a). Fascin was one of the brain proteins identified in the aged canine 
undergoing treatment with an antioxidant diet and a program of behavioral to be less 
oxidized. As a result, the identification of NFL and fascin as less oxidized following the 
combined treatment would possibly lead to a decrease in axonal dystrophy (Poon et al., 
2004d), increased cellular migration, cell adhesion and communication, leading to 
improved neuronal communication and survival and particularly possibly leading to 
improved memory and cognitive function previously seen in the aging canine. However 
since the role of fascin in aging or neurodegenerative disorders is not known, the 
beneficial role of its reduced oxidation and the role it plays in cognitive function remain 
speculative. 
Cellular detoxification 
Glutathione-S-transferase (GST) catalyzes the conjugation of a number of 
exogenous and endogenous compounds such as 4-hydroxynonenal (HNE) or 
malondialdehyde (MDA) with glutathione inactivating the toxic products of oxygen 
metabolism (Singh et al., 2002). Hence, GST plays a critical role in cellular protection 
against oxidative stress. There is a significant decline in the activity of GST in the 
amygdala, hippocampus and inferior parietal lobule of patients with AD (Lovell et al., 
1998), contributing to the accumulation of toxic effects of HNE and related compounds. 
Our laboratory has previously shown that in the AD brain, GST and multidrug resistant 
protein MRP1 are oxidatively modified leading to an impairment of detoxification 
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mechanisms causing increased oxidative stress consistent with elevated HNE in AD 
(Sultana and Butterfield, 2004). In the aged canine, there is a overall decrease in GSH 
content and a significant increase in the lipid peroxidation product, MDA (Head et al., 
2002). In the present study we show that following the combined treatments of an 
antioxidant fortified diet and a program of behavioral enrichment, GST was less oxidized. 
In addition, we also show that the activity of GST is significantly increased. This would 
potentially enhance the clearance of toxic aldehydes leading to improved memory and 
cognitive function in aging dogs. The higher activity of GST was also associated with 
lower error scores on individual cognitive tasks. This correlation was statistically 
significant even after correction for age at death. Further, increased GST activity was the 
best predictor of error scores on black/white discrimination learning, thus providing a 
possible mechanism underlying improved cognitive function following treatment in the 
aging canine with a diet fortified with antioxidants and a program of behavioral 
enrichment. 
Glutamate dehydrogenase (GDH) is an enzyme located in the mitochondrial 
matrix that acts in both catabolic and metabolic pathways. GDH can catalyze the 
reductive amination of α-ketoglutarate with NADPH to yield glutamate in the metabolic 
pathway and can also catalyze the formation of α-ketoglutarate from glutamate with 
NAD+ and ammonium ion in the catabolic pathway (Boyd-Kimball et al., 2005d). The 
latter pathway is particularly important in eliminating the excitotoxin glutamate. Excess 
glutamate can stimulate NMDA receptors leading to an increase in Ca2+ influx and 
altered calcium homeostasis, which would lead to alteration in long-term potentiation 
(LTP) and consequently, learning and memory deficits as seen in AD (Boyd-Kimball et 
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al., 2005d). We have shown in the present study that following treatment with 
antioxidants and a program of behavioral enrichment in the canine model of human 
aging, there is a decrease in the specific carbonyl levels of GDH. This would possibly 
lead to an increase in its activity, and more importantly its metabolic activity thereby 
helping to clear excess glutamate in the synaptic cleft. Consequently, this may lead to 
controlled Ca2+ homeostasis, improved LTP, and eventually improvement in cognitive 
function as observed in the canine model of human aging following interventions with 
antioxidants and a program of behavioral enrichment. 
Using the Interaction Explorer Software PathwayAssist (Stratagene) to analyze 
our current results as shown in Fig 5, the proteins identified in this study can be divided 
into three functional categories: those related to energy metabolism, antioxidant systems 
and maintenance, and stabilization of cell structure. These results therefore continue to 
support a role for oxidative damage in the development of age-associated cognitive 
dysfunction and indicate that the use of foods enriched with antioxidants and 
mitochondrial cofactors can reduce the levels of oxidative damage and result in reducing 
the effects of aging on memory and cognitive function. In addition, the increased activity 
of GST continues to confirm our previous notion that oxidation of particular proteins lead 
to loss of function, and that reduced oxidation of proteins can lead to an improvement in 
function (Castegna et al., 2004; Perluigi et al., 2005a; Perluigi et al., 2005b; Poon et al., 
2005f). This study suggests that cognitive decline can be reversed or cognitive function 
can be maintained following use of antioxidants and a program of behavioral enrichment 
and this approach conceivably can be beneficial to the aging human population and in 
age-related neurodegenerative disorders. 
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The present study continues to provide additional evidence that oxidative stress 
may be a key mechanisms contributing to decline in memory and cognitive function with 
age. We have shown that a diet fortified with antioxidants in combination with a program 
of behavioral enrichment is capable of reducing the levels of oxidative damage, and 
increasing the activity and expression of key endogenous antioxidant enzymes in the 
aging canine brain. As a result of the reduction in the levels of oxidative stress/damage 
following this intervention, we have also established that key brain proteins associated 
with energy metabolism, antioxidant systems, and with the maintenance and stabilization 
of cell structure are protected from oxidative damage. This we believe would lead to 
improved activity or function consequently leading to the improved memory and 
cognitive function observed in the aging canine. Further we have also shown that there is 
a strong correlation between the increased in expression/activity of some of the identified 
proteins and improved cognitive function. Therefore the present study provides possible 
mechanisms through which the aging canine, provided with the combined intervention of 
an antioxidant fortified diet and a program of behavioral enrichment, shows 
improvements in cognitive function (Milgram et al., 2002b; Milgram et al., 2005) . 
Further, the increased expression of HO-1, increased activity of GST and SOD together 
could all have synergistic effects in the reduction of oxidative damage and protection of 
key proteins from oxidative damage observed in this study. Results from the current 
study in aging canines may be translatable to humans, providing a possible intervention 
for Aβ induced cognitive decline observed in AD. 
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CHAPTER FIVE 
 
Long-Term Treatment with Antioxidants and a Program of Behavioral Enrichment 
Leads to Increased Expression of Key Brain Proteins in the Canine Model of 
Human Aging 
5.1 Overview 
Aging and age-related disorders such as Alzheimer’s disease (AD) are usually 
accompanied by increased oxidative stress and eventually a decline in memory and 
cognitive function. Aging canines develop cognitive dysfunction and neuropathology 
similar to those seen in humans, such as, beta-amyloid deposition, oxidative stress and 
learning and memory impairments. In the canine model of human aging, interventions 
with an antioxidant fortified diet and a program of behavioral enrichment improves 
learning ability of the aging dog. To identify the neurobiological mechanisms underlying 
these treatment effects, we carried out a comparative proteomics study to identify specific 
brain proteins that were differentially expressed from the parietal cortex in treated aged 
dogs. Twenty-one beagle dogs (8.1-12.4 years) were treated for 2.8 years after grouping 
into 4 treatments: control food with either a control environment (CC) or with behavioral 
enrichment (CE); antioxidant fortified food with a control environment (CA); and 
behavioral enrichment and antioxidant fortified food (EA). Analysis of the parietal cortex 
revealed significant increases in expression of, Cu/Zn superoxide dismutase, fructose-
bisphosphate aldolase C, creatine kinase, glutamate dehydrogenase and glyceraldehyde-
3-phosphate dehydrogenase. In addition, we also observed a significant increase in the 
enzymatic activity of superoxide dismutase (SOD) following the combined treatment EA. 
The increased expression of these proteins in particular Cu/Zn SOD correlated with 
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improved cognitive function. These findings provide insights into possible mechanisms 
through which long-term treatment with antioxidants and a program of behavioral 
enrichment improve and maintain learning ability in aged beagle dogs. In addition it 
provides possible mechanisms through which this program can be beneficial when 
translated to the aging human population at risk for age-related neurodegenerative 
disorders such as AD. 
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5.2 Introduction 
Elucidating mechanisms and developing therapeutic intervention strategies for 
age-related neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s 
disease (PD) and amyotrophic lateral sclerosis (ALS), among others, requires animal 
models that can be translated to the human population. We have been using a canine 
model of cognitive and brain aging that develops similar features of normal and 
pathological aging in humans (Cummings et al., 1996a). Canines show cognitive decline 
with increased age, (Milgram et al., 1994; Milgram et al., 2002c) , impairments in 
visuospatial learning and memory (Chan et al., 2002), and age-dependent neuropathology 
similar to that observed in elderly humans, i.e., accumulation of human-type amyloid β-
peptide (Aβ) of the same sequence as humans (Johnstone et al., 1991), which correlates 
with age-dependent cognitive dysfunction (Cummings et al., 1996b; Head et al., 1998) . 
In addition, the aging canine brain accumulates oxidative damage and a decline in 
antioxidant reserves (Kiatipattanasakul et al., 1996; Head et al., 2002) , events similar to 
those seen in the AD brain (Markesbery, 1997), providing a possible common 
neurobiological mechanism leading to cognitive dysfunction. 
The use of antioxidants and regular exercise has beneficial effects in various 
models of age-related neurodegenerative disorders, resulting in maintenance, 
improvement or restoration of memory and cognitive function (Joseph et al., 1998b; 
Laurin et al., 2001). In the canine model of human aging, short term and long term 
treatment with a diet rich in a broad spectrum of antioxidants leads to rapid and sustained 
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learning ability and improved spatial attention; these effects were further enhanced with 
the addition of behavioral enrichment (Cotman et al., 2002; Milgram et al., 2004). 
Improved cognition in response to an antioxidant diet suggests that oxidative 
stress plays a significant role in the decline of cognitive function observed in this model. 
In addition, there is a significant decline in antioxidant reserves, making the aging canine 
more vulnerable to oxidative attack. Consistent with this hypothesis, we previously 
reported (Chapter 4) that following a program of behavioral enrichment and an 
antioxidant fortified diet in the aging canine, there is a significant reduction in the levels 
of protein oxidation as indexed by protein carbonyls and 3-nitrotyrosine (3NT) and also a 
significant increase in enzymatic activity of key antioxidant proteins. The reduction in 
oxidative stress and increased activity of antioxidant enzymes provides a possible 
mechanism for the improvement in memory and cognition following these treatments. 
Since the aging canine brain is under significant oxidative stress, we believe that this in 
itself could trigger a stress response leading to the altered transcription of key proteins or 
enzymes involved in mechanisms for protection against oxidative damage (Calabrese et 
al., 2003a). Moreover, the use of an antioxidant fortified diet and a program of behavioral 
enrichment could also trigger this response thereby providing an additive effect. To better 
understand the mechanisms for protection at the molecular level, we have used 
proteomics to identify key brain proteins that have been differentially expressed 
following the treatments provided in this program.  
Proteomics is the study of the proteome. Proteome analysis is “the analysis of the 
entire PROTEin complement expressed by a genOME”. The analysis involves the 
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systematic separation, identification, and quantification of many proteins simultaneously 
from a single sample (Butterfield and Castegna, 2003b). Proteomic analysis encompasses 
the qualitative, quantitative and functional characterization of the entire protein profile of 
a given cell, tissue and/or organism. Proteomics has become an important and efficient 
tool in the analyses of protein changes in various disease states (Butterfield, 2004). Our 
laboratory has been successful in using proteomics to identify key brain proteins that are 
oxidatively modified and proteins that have shown differential expression in AD and mild 
cognitive impairment (Butterfield et al., 2002a; Castegna et al., 2002b; Castegna et al., 
2003; Butterfield, 2004; Butterfield et al., 2006c; Sultana et al., 2006a), the senescence 
accelerated prone mouse strain 8 (SAMP8) (Butterfield and Poon, 2005), and mouse 
models of Huntington’s disease (Perluigi et al., 2005b), PD (Poon et al., 2005c) , ALS 
(Perluigi et al., 2005a; Poon et al., 2005f), among many others.  
In the present study, we identified five proteins from the parietal cortex of the 
aging canine showing a significant increase in expression following treatment with 
antioxidants, exposure to a program of behavioral enrichment or a combination of both 
treatments. The proteins identified were, fructose-bisphosphate aldolase C, creatine 
kinase, glutamate dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase and Cu/Zn 
superoxide dismutase, whose activity was also shown to be significantly increased 
following the combined treatment (EA) relative to control. In addition, the increased 
expression of Cu/Zn SOD correlates with improvements in cognition as shown by an 
improvement in the black/white reversal and spatial learning. These results suggest that a 
program of behavioral enrichment and treatment with a diet of antioxidants is capable of 
improving age-related cognitive function by increasing the activity of a key antioxidant 
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enzyme and by increasing the expression of key proteins involved in energy metabolism 
and antioxidant activity.  
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5.3 Experimental procedures 
5.3.1 Subjects  
Subjects same as 4.3.1 
5.3.2 Group assignments and study timeline  
Group assignment and study timeline same as 4.3. 
5.3.3 Behavioral enrichment treatment 
Behavioral enrichment treatment same as 4.3.3 
5.3.4 Diet treatment 
 Diet treatment same as 4.3.4 
5.3.5 Cognitive Testing 
Cognitive testing same as 4.3.5 
5.3.6 Animal Euthanasia 
Animal euthanasia same as 4.3.6 
5.3.7 Two-dimensional electrophoresis 
Brain samples (200 µg parietal cortex) were incubated with 4 volumes of 2N HCl 
at room for electrophoresis. Proteins were then precipitated by the addition of ice-cold 
100% trichloroacetic acid (TCA) to obtain a final concentration of 15% TCA. Samples 
were then placed on ice for 10 min and precipitate centrifuged at 16,000 g for 3min. The 
resulting pellet was then washed three times with a 1:1(v/v) ethanol/ethyl acetate 
solution. The samples were then suspended in 200 µl of rehydration buffer composed of a 
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1:1 ratio (v/v) of the Zwittergent solubilization buffer (7M urea, 2M thiourea, 2% Chaps, 
65 mM DTT, 1% Zwittergent 0.8% 3-10 ampholytes and bromophenol blue for 1 h. 
5.3.8 First dimension electrophoresis 
For the first-dimension electrophoresis, 200 µL of sample solution was applied to 
a 110-mm pH 3–10 ReadyStrip™ IPG strips (Bio-Rad, Hercules CA). The strips were 
then actively rehydrated in the protean IEF cell (Bio-Rad) at 50 V for 18 h. The 
isoelectric focusing was performed in increasing voltages as follows; 300 V for 1 h, then 
linear gradient to 8000 V for 5 h and finally 20 000 V/h. Strips were then stored at –80 
°C until the 2nd dimension electrophoresis was to be performed. 
5.3.9 Second dimension electrophoresis 
For the second dimension, the IPG® Strips, pH 3–10, were equilibrated for 10 min 
in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium dodecyl sulfate 
(SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15 min in 
the same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient 
precast criterion Tris–HCl gels (8–16%) (Bio-Rad) were used to perform second 
dimension electrophoresis. Precision Protein™ Standards (Bio-Rad, CA) were run along 
with the sample at 200 V for 65 min. 
5.3.10 SYPRO ruby staining 
After the second dimension electrophoresis, the gels were incubated in fixing 
solution (7% acetic acid, 10% methanol) for 20 min and stained overnight at room 
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temperature with 50ml SYPRO Ruby gel stain (Bio-Rad). The SYPRO ruby gel stain was 
then removed and gels stored in DI water. 
5.3.11 Image analysis 
SYPRO ruby-stained gel images were obtained using a STORM phosphoimager 
(Ex. 470 nm, Em. 618 nm, Molecular Dynamics, Sunnyvale, CA, USA) and also saved in 
TIFF format. PD-Quest (Bio-Rad) imaging software was then used to match and analyze 
visualized protein spots among differential 2D gels with one gel for each individual 
sample. 
5.3.12 In-gel trypsin digestion 
Protein spots statistically different that controls were digested in-gel by trypsin 
using protocols previously described and modified by (Thongboonkerd et al., 2002). 
Briefly, spots of interest were excised using a clean blade and placed in Eppendorf tubes, 
which were then washed with 0.1 M ammonium bicarbonate (NH4HCO3) at room 
temperature for 15 min. Acetonitrile was then added to the gel pieces and incubated at 
room temperature for 15 min. This solvent mixture was then removed and gel pieces 
dried. The protein spots were then incubated with 20 µL of 20 mM DTT in 0.1 M 
NH4HCO3 at 56 °C for 45 min. The DTT solution was removed and replaced with 20 µL 
of 55 mM iodoacetamide in 0.1 M NH4HCO3. The solution was then incubated at room 
temperature for 30 min. The iodoacetamide was removed and replaced with 0.2 mL of 
50 mM NH4HCO3 and incubated at room temperature for 15 min. Acetonitrile (200 µL) 
was added. After 15 min incubation, the solvent was removed, and the gel spots were 
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dried in a flow hood for 30 min. The gel pieces were rehydrated with 20 ng/µL-modified 
trypsin (Promega, Madison, WI) in 50 mM NH4HCO3 with the minimal volume enough 
to cover the gel pieces. The gel pieces were incubated overnight at 37 °C in a shaking 
incubator. 
5.3.13 Mass spectrometry 
A MALDI-TOF mass spectrometer in the reflectron mode was used to generate 
peptide mass fingerprints. Peptides resulting from in-gel digestion with trypsin were 
analyzed on a 384 position, 600 µm AnchorChipTM Target (Bruker Daltonics, Bremen, 
Germany) and prepared according to AnchorChip recommendations (AnchorChip 
Technology, Rev. 2, Bruker Daltonics, Bremen, Germany).  Briefly, 1 µL of digestate 
was mixed with 1 µL of alpha-cyano-4-hydroxycinnamic acid (0.3 mg/mL in ethanol: 
acetone, 2:1 ratio) directly on the target and allowed to dry at room temperature. The 
sample spot was washed with 1 µL of a 1% TFA solution for approximately 60 seconds.  
The TFA droplet was gently blown off the sample spot with compressed air.  The 
resulting diffuse sample spot was recrystallized (refocused) using 1 µL of a solution of 
ethanol: acetone: 0. 1 % TFA (6:3:1 ratio).  Reported spectra are a summation of 100 
laser shots.  External calibration of the mass axis was used for acquisition and internal 
calibration using either trypsin autolysis ions or matrix clusters and was applied post 
acquisition for accurate mass determination.  
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5.3.14 Analysis of peptide sequences 
Peptide mass fingerprinting was used to identify proteins from tryptic peptide 
fragments by utilizing the MASCOT search engine based on the entire NCBI and 
SwissProt protein databases. Database searches were conducted allowing for up to one 
missed trypsin cleavage and using the assumption that the peptides were monoisotopic, 
oxidized at methionine residues, and carbamidomethylated at cysteine residues. Mass 
tolerance of 150 ppm, 0.1 Da peptide tolerance and 0.2 Da fragmentation tolerance was 
the window of error allowed for matching the peptide mass values (Butterfield and 
Castegna, 2003b). Probability-based MOWSE scores were estimated by comparison of 
search results against estimated random match population and were reported as -
10*log10 (p), where p is the probability that the identification of the protein is a random 
event. MOWSE scores greater than 63 were considered to be significant (p < 0.05). All 
protein identifications were in the expected size and isoelectric point (pI) range based on 
the position in the gel. 
5.3.15 Immunoprecipitation  
Immunoprecipitation of specific proteins was performed as previously described 
(Sultana and Butterfield, 2004). Brain samples (200 µg) from control or treated animals 
were incubated overnight with anti-GAPDH antibody. This was followed by three 
washing steps with buffer B (50Mm Tris Hcl (pH-8.0), 150 Mm NaCl, and 1% NP40). 
The proteins were resolved by SDS-PAGE followed by immunoblotting on a 
nitrocellulose membrane (BioRad). The proteins were then detected with alkaline 
phosphate labeled secondary antibody (Sigma). 
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5.3.16 Protein Interacteome 
  The functional protein interacteome was obtained by using Interaction Explorer 
TM Software Pathway Assist software package (Stratagene, La Jolla, CA). Pathway Assist 
is software for functional interaction analysis. It allows for the identification and 
visualization of pathways, gene regulation networks and protein interaction maps 
(Donninger et al., 2004). The proteins are first imported as the gene symbols as a set of 
data. This data set is then searched against ResNet, a database containing over 500,000 
biological interactions built by applying the MedScan text-mining algorithms to all 
PubMed abstracts. These interactions are then visualized by building interaction networks 
with shortest-path algorithms. This process can graphically identify all known interaction 
among the proteins. The information of the function of these proteins and their relevance 
to diseases are then obtained by using the BIOBASE's Proteome BioKnowledge Library 
form Incyte Corporation (Incyte, Wilmington, DE) (Hodges et al., 2002). 
5.3.17 Statistical analysis 
Statistical analysis of differentially expressed protein levels matched with spots 
on 2D-gels from parietal cortex brain samples from the various treatment groups control 
food- control environment (CC), control food - enriched environment (CE), control food-
antioxidant fortified food (CA) and enriched environment - antioxidant fortified food 
(EA) were used and carried out using Student's t-tests. Here we report a comparative 
proteomics analysis of CC vs. CE, CA, and EA .A value of p < 0.05 was considered 
statistically significant. Only proteins that are considered significantly different by 
Student's t-test were subjected to in-gel trypsin digestion and subsequent proteomic 
analysis. This is the normal procedure for proteomics studies, since sophisticated 
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statistical analysis used for micro array studies are not applicable for proteomics studies 
(Maurer et al., 2005).  To test for associations between cognitive test scores and 
differentially expressed proteins identified in the study, we computed correlation co-
efficients both with and without age at death as a covariate.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 164
5.4 Results 
5.4.1 Antioxidant diet and behavioral enrichment program induces increased 
protein expression 
Two-dimensional electrophoresis offers an excellent tool for the screening of 
abundant protein changes in various disease states (Butterfield et al., 2003; Butterfield, 
2004; Perluigi et al., 2005b; Poon et al., 2005a). In the present study, we investigated the 
pattern of protein expression in the parietal cortex of aged canines following a 2.8 year 
treatment with an antioxidant fortified diet and/or a program of behavioral enrichment 
and compared this with age-matched controls in four different groups. We had a four-way 
analysis consisting of 23 beagle dogs divided into the following groups: CC, CE, CA and 
EA. The final comparison was made as follows 1) CC vs. CE; 2) CC vs. CA, and 3) CC 
vs. EA. Fig 5.1 shows SYPRO ruby stained 2D gels of the groups mentioned above with 
identified protein boxed and labeled. Compared to control, all treatment groups showed a 
significant increase in the expression of specific proteins. Some proteins showed an 
increase in expression in all treatment groups while others were specific for a particular 
treatment. The proteins identified were: Cu/Zn superoxide dismutase, fructose-
bisphosphate aldolase C, creatine kinase, glutamate dehydrogenase and glyceraldehyde-
3-phosphate dehydrogenase, showing that the antioxidant and behavioral enrichment 
programme was successful in increasing the expression of proteins associated with 
energy metabolism and also a protein associated with antioxidant reserve. These proteins 
were identified by mass spectrometry and are shown in Table 5.1. Table 5.2 provides the 
changes in protein levels expressed as % control ± S.E.M across the treatment conditions. 
As a representative protein to validate these proteomic identifications, we used 
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immunoprecipitation of GAPDH with anti-GAPDH as shown (Fig 5.2), confirming our 
previous identification by mass spectrometry. 
5.4.2 Combined treatment (EA), increases superoxide dismutase (SOD) activity 
We have previously shown that the oxidative modification of specific enzymes 
generally decreases their activity (Perluigi et al., 2005b; Poon et al., 2006a).  Therefore, 
in the present study we hypothesized that since increased oxidation leads to loss of 
enzymatic activity, then protection from oxidative damage could restore or maintain the 
activity of enzymes with up-regulated expression levels. To test this hypothesis, we 
measured the activities of total SOD, which was significantly increased following the 
combined treatment of an antioxidant fortified diet and exposure to a behavioral 
enrichment program in the aging canine. There was a about a 50% increase in the activity 
of SOD  (Fig 5.3) in canine brain after the combined treatment (EA), and this activity was 
found to be significantly increased when compared to control (CC). These results suggest 
that oxidative damage plays a key role in the loss of function of key enzymes and that use 
of antioxidants not only increases their expression but also likely protects them from 
oxidative damage and significantly increases their enzymatic activities.  
 
5.4.3 Correlation between protein expression levels and cognitive function 
To determine if error scores on individual cognitive tasks were associated with 
increased protein expression of CuZnSOD, FBP, CK, GLUD or GAPDH a correlational 
analysis was used. CuZnSOD protein level was negatively correlated with error scores on 
a black/white reversal task and on a spatial memory task with higher SOD levels, i.e. 
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higher antioxidant protein level, being associated with lower error scores (improved 
cognition).  Figure 5.4 shows the linear association between CuZnSOD protein and 
cognitive ability.  Because age at death may also be a contributor to either increased error 
scores or increased protein expression, correlations were also computed and corrected for 
age.  The significant association between CuZnSOD and cognition remained. Other 
protein measures (FBP, CK, GLUD, and GAPDH) did not correlate with cognitive 
scores.   
5.4.4 Protein Interacteome 
Fig 5.5 shows the protein interacteome of proteomics-identified proteins of 
increase expression following various intervention paradigms. The Interaction Explorer 
Software PathwayAssist (Stratagene) software results are shown in (Fig 5). The proteins 
identified in this study are related to hormone activities, transcription and regulation of 
signal transduction among others. As a result the present findings continue to confirm and 
support previous findings (Poon et al., 2004c; Poon et al., 2005e) that antioxidants and a 
program of regular exercise provide beneficial effect of protection and improvement in 
cognitive functions and memory through the increase in expression and activity of key 
proteins.  
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Figure 5.1 
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Figure 5.1 SYPRO Ruby-stained 2D-gels maps, a) CC vs. EA b) CC vs. CA, and c) CC 
vs. CE of canine parietal cortex homogenates samples from the CC, CA, CE and EA 
treated animals are presented. Proteins identified by mass spectrometry are presented as 
the boxed spots. 
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Figure 5.2 Validation of protein identified by proteomics 
Same as figure 4.4 
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Figure 5.3 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Comparison of the specific activity of SOD enzyme measured in canine brains 
obtained from animals on a control food- control environment treatment (CC) and canine 
on an enriched environment - antioxidant fortified food programme EA. There is a 
significant increase in SOD activity in EA compared to CC and is expressed as units per 
milligram of protein. Data are represented as % control ± SEM for animals in each 
treatment group, (n=6) * p <0.05. 
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Figure 5.4 
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Figure 5.4 Correlation between measures of protein levels and cognitive function. 
Individual error scores are plotted as a function of CuZnSOD protein levels in the parietal 
cortex.  (A). Black/white reversal learning was poorer in animals with lower levels of 
SOD. (B). Spatial learning was also impaired in animals with lower SOD protein levels.  
Line represents the results of a linear regression analysis 
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Figure 5.5 
 
Figure 5.5 Schematic diagram of a functional interacteome of all parietal cortex proteins 
identified whose expression levels are significantly increased following treatment with 
and antioxidant-fortified food and a program of behavioral enrichment. This diagram was 
generated by the interaction explorer ™ Pathway Module (Stratagene), indicating that all 
of the proteins are directly or indirectly associated with cellular process shown. 
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5.5 Discussion 
 Long-term treatment with antioxidants and a program of behavioral enrichment in 
the canine model of human aging improves cognition (Milgram et al., 2002c; Milgram et 
al., 2004; Milgram et al., 2005). Age-related disorders are often accompanied by an 
increase in oxidative stress, reduction in antioxidant reserves and loss in energy 
metabolism among other pathological features (Hensley et al., 1996; Markesbery, 1997; 
Butterfield and Lauderback, 2002). In many animal models of aging, interventions with 
antioxidants are beneficial and result in a reduction of oxidative stress and improvements 
in cognitive function, however, the mechanisms that underlie these improvements are still 
not well understood (Joseph et al., 1998a; Joseph et al., 1998b; Farr et al., 2003). In the 
present study, we used brain tissue from a higher mammalian species provided with a 
long treatment protocol (2.8 years), typically not possible in aged rodent models, to 
elucidate biochemical pathways and mechanisms for the improvement of cognitive 
function observed. Using proteomics, we were able to identify key proteins from the 
canine parietal cortex whose expressions were significantly increased following a 
program of behavioral enrichment and treatment with a diet fortified with antioxidants. 
Four proteins related to energy metabolism, i.e., fructose-bisphosphate, creatine kinase, 
glutamate dehydrogenase and glyceraldehyde-3-phosphate dehydrogenase were increased 
in expression as was the protein level and activity of a key antioxidant protein, Cu/Zn 
superoxide dismutase that also showed a significant association with cognition. 
Fructose bisphosphate aldolase C (FBP) is a glycolytic enzyme that catalyses the 
reversible aldol cleavage or condensation of fructose-1, 6-bisphosphate into dihydroxyacetone-
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phosphate and glyceraldehyde 3-phosphate (Perham, 1990). In vertebrates, three forms of this 
enzyme are found: aldolase A is expressed in muscle, aldolase B in liver, kidney, stomach and 
intestine, and aldolase C in brain, heart and ovary. The different isozymes have different 
catalytic functions: aldolases A and C are mainly involved in glycolysis, while aldolase B is 
involved in both glycolysis and gluconeogenesis (Perham, 1990). On the other hand, 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) catalyzes the oxidation of 
glyceraldehyde-3-phosphate to 1, 3-bisphosphoglycerate and NADH (Boyd-Kimball et al., 
2005c). In addition to glycolysis GAPDH plays a role in membrane fusion and transport, 
accumulation of glutamate into presynaptic vesicles, and acting as a cellular sensor of oxidative 
stress (Chuang et al., 2005). Recent studies suggest GAPDH acts as a NO sensor (Hara et al., 
2006). In AD, there is a reduced activity of glyceraldehyde-3-phosphate dehydrogenase 
(Mazzola and Sirover, 2001), and our laboratory has shown that GAPDH is significantly 
oxidized in AD and in animal models of AD (Boyd-Kimball et al., 2005a; Boyd-Kimball et al., 
2005c; Sultana et al., 2006b). In the present study the expression of these glycolytic proteins 
was significantly increased following a program of enriched environment and a diet of 
antioxidants. This increased expression of FBP and GAPDH, proteins that are decreased in 
patients with AD (Bigl et al., 1999), may lead to increased glycolytic activity and function and 
when coupled to other bioenergetics pathways would further lead to an increase and 
maintenance of ATP production.  Increased ATP production may be important for neuron 
survival and thus may serve as one mechanism underlying observed improvements in cognitive 
functions in the canine model of human aging. 
The creatine kinase (CK) system is the most important immediate energy 
buffering and transport system especially in muscle and neuronal tissue (Wallimann et al., 
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1998). CK consists of a cytosolic and a mitochondrial isoform (MtCK) with their substrates 
creatine and phosphocreatine. Creatine is typically phosphorylated to phosphocreatine in 
the intermembrane space of mitochondria where mitochondrial CK is located and is then 
transported into the cytosol (Schlattner et al., 1998). In the cytosol, the energy pool can be 
regenerated by transphosphorylation of phosphocreatine to ATP, which is catalyzed by 
cytosolic CK in close proximity to cellular ATPases. Moreover, the mitochondrial 
synthesis of creatine phosphate is restricted to uMiCK expressing neurons, suggesting 
uMiCK protects neurons under situations of compromised cellular energy state, which are 
often linked to oxidative stress and calcium overload through compensatory up-regulation 
of gene expression (Boero et al., 2003). CKs are prime targets of oxidative damage, MtCK 
in particular is a principal target of such damage, not only because if its sensitivity 
(Stachowiak et al., 1998; Koufen and Stark, 2000), but also due to its mitochondrial 
localization. Our laboratory has shown that though there is increased expression of CK in 
AD, it is significantly oxidized and its activity significantly reduced (Aksenov et al., 2000; 
Castegna et al., 2002b). In the brain of old brown Norway rats, CK is oxidatively modified 
and its activity significantly decreased (Aksenova et al., 1998). Also in aging neuronal 
cultures, there is a gradual increase in CK content but decreased activity of the enzyme. 
These changes in CK expression have been considered to be an early indicator of oxidative 
stress in aging neurons (Aksenova et al., 1999). In the present study, following exposure of 
the aging beagle dogs to a program of environmental enrichment and a diet fortified with 
anti-oxidants, we observed a significant increase in the expression of CK. This is in 
agreement with a previous study from our laboratory that showed a significant increase in 
the expression of CK in the senescence accelerated prone mouse strain 8 (SAMP8) mice 
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after intervention with alpha-lipoic acid, a mitochondrial co-factor and antioxidant included 
in the diet used in the present study (Poon et al., 2005e). This increased expression we posit 
is a compensatory mechanism for restoration of ATP production in the aging canine, thus 
leading to maintenance of energy reserves and possibly cognitive function 
Glutamate dehydrogenase (GDH) is an enzyme located in the mitochondrial 
matrix that acts in either a metabolic or a catabolic pathway. In the biosynthetic pathway, 
GDH catalyzes the reductive amination of α-ketoglutarate with NADPH to yield glutamate. 
Alternatively, GDH can catalyze the formation of α-ketoglutarate from glutamate with 
NAD+ and ammonium ion (Boyd-Kimball et al., 2005d). The catabolic activity of GDH is 
particularly important for the elimination of excitotoxic glutamate. We have previously 
shown using proteomics that when synaptosomes are treated with Aβ (1-42) (Boyd-
Kimball et al., 2005d), GDH is oxidized and loses its function, a phenomenon observed in 
aging. In the present study, we observed that after treatment with antioxidants and exposure 
to a program of behavioral enrichment, the canine brain showed an increased expression of 
GDH. Increased expression of GDH could lead to increased elimination of excitotoxic 
glutamate by increasing the conversion of glutamate to α-ketoglutarate. The conversion of 
excess glutamate to α-ketoglutarate would desensitize NMDA receptors leading to a 
reduction in Ca2+ influx. Improved calcium homeostasis would in turn lead to maintenance 
of the long-term potentiation (LTP) and consequently, improved learning and memory 
(Michaelis, 1997), as observed in the canine study. 
Cu/Zn Superoxide dismutase (CuZnSOD, SOD1 protein) is an abundant copper- 
and zinc-containing protein that is present in the cytosol, nucleus, peroxisomes, and 
mitochondrial intermembrane space of human cells and acts as an antioxidant enzyme by 
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lowering the steady-state concentration of superoxide (Selverstone Valentine et al., 2005). 
When mutated, SOD can also cause disease as in the case of the neurodegenerative 
disorder, familial amyotrophic lateral sclerosis (fALS) (Selverstone Valentine et al., 2005). 
The toxic gain of function of mutant SOD (mSOD) leads to the generation of reactive 
oxygen/nitrogen species (Valentine, 2002; Perluigi et al., 2005a; Poon et al., 2005f). Some 
researchers believe that the elevated oxidative activity associated with mSOD occurs by 
enzymes acting as peroxidases (Valentine, 2002)  or as superoxide reductases (Liochev and 
Fridovich, 2000) or by producing O2.− to form peroxynitrite (Rakhit et al., 2002). In the 
wild type form, SOD dismutates superoxide to oxygen and water, hence reducing the levels 
of oxidative stress and protecting proteins, lipid and DNA from the toxic superoxide 
molecule (Gutteridge and Halliwell, 2000). In the present study a significant increase in the 
expression of SOD1 and significant increase in SOD enzymatic activity in the brain from 
canines that had undergone a combination of both treatment with antioxidant diet and a 
program of behavioral enrichment compared to age matched controls were found. This 
finding shows that a diet of antioxidants and a program of behavioral enrichment provided 
to the aging canine are able to increase the expression and activity of a key antioxidant 
protein, in turn protecting the cells form oxidative stress and improving memory and 
cognitive function. Consistent with this hypothesis is that of the measures of protein 
expression that distinguished the treatment groups in the current study. SOD1 protein level 
was the best predictor of a frontal-cortex dependent learning task and a measure of spatial 
memory.  Animals that were showing improved error scores on these two tasks also had 
higher SOD1 protein.   
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In the current study, we demonstrated that following a long-term treatment with a 
diet fortified with antioxidants and a program of behavioral enrichment in the aging 
canine, there is a significant increase in the expression of key proteins related to energy 
metabolism and antioxidant activity. Increased protein expression does not necessarily 
directly translate to increased enzyme activity as reported for creatine kinase in AD 
(Aksenov et al., 1998a); however, we have shown here both an increase in expression and 
activity of Cu/Zn SOD in response to treatment. In addition, this increase in protein levels 
was found to be a good predictor of frontal-cortex dependent learning and a measure of 
spatial memory. The present findings therefore provide a neurobiological basis for 
improved neuronal function and cognition in canines treated with either or both an 
antioxidant enriched diet and behavioral enrichment. The inclusion of vitamin E, alpha-
lipoic acid L-carnitine flavanoids in the diet not only provide improvements in 
antioxidant reserves but also plays a role in increasing the expression of key energy 
metabolism proteins that help in the maintenance of ATP levels, maintenance of cellular 
pathways and functions dependent on ATP eventually leading to an improvement in 
cognitive function and memory. Fig 5.6 provides a summary of the functional 
consequence of increased expression and reduced oxidation of proteins identified in the 
aging canine following treatment with an antioxidants fortified diet and a program of 
behavioral enrichment. 
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Figure 5.6 A summary of the functional consequence of increased expression and 
reduced oxidation of proteins identified in the aging canine following treatment with an 
antioxidants fortified diet and a program of behavioral enrichment. 
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CHAPTER SIX 
Proteomic Expression Analysis of Brain Proteins from Dementia-free 
Nonagenarians: Relevance to Successful Aging and Alzheimer’s disease 
6.1 Overview  
Aging is a unique phenomenon that affects all animal species. In humans, aging is 
usually accompanied by impairments in the functional capacity of the brain leading to its 
susceptibility to neurodegenerative disorders such as Alzheimer’s disease (AD) among 
others. In spite of functional declines in aging, recently, there has been a rise in the 
number of nonagenarian and centenarians who are cognitively intact and who 
demonstrate no evidence of neurodegenerative diseases despite their advanced ages; this 
phenomenon is usually referred to as successful aging. The mechanisms underlying this 
phenomenon of successful aging are still under investigation. Various studies have 
identified several genes thought to be responsible for dementia-free aging and extended 
longevity, but since no single gene can be found responsible for modulating successful 
human aging, it is thought that this process occurs possibly through multiple routes. To 
further investigate this phenomenon, we have carried out a proteomic expression profile 
analysis on brain proteins in the frontal cortex of 5 nonagenarian (mean age ± SD, 94.8 ± 
2.9) with AD and 4 normal non-demented age matched control nonagenarians (mean age 
± SD, 94.5 ± 1.3). In addition, we have evaluated biomarkers of oxidative stress as 
measured by the levels of protein oxidation and lipid peroxidation, i.e., protein carbonyls 
and protein-bound 4-hydroxynonenal (HNE), isoprostanes (F2-IsoP) and neuroprostanes 
(F4-NP). There was no significant difference in the levels of protein carbonyls, HNE, F2-
IsoP and F4-NP when the two groups were compared. However, using proteomics we 
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were able to identify six proteins that were differentially expressed. Among these, we 
observed a significant decrease in the expression of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), ATP synthase H+ transporting, human peroxiredoxin 5 
(PRDX5) and malate dehydrogenase (MDH) in the non-demented nonagenarian 
compared to those with AD. However, the levels of protein expression for fructose 
bisphosphate aldolase (FBP1) and ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) 
were found to be significantly increased when the same groups were compared. In 
addition, the severity of cognitive decline (MMSE) and amyloid beta-peptide (Aβ) levels 
correlated with these changes in protein expression. These results show that though the 
levels of oxidative stress were comparable between age-matched non-demented and 
demented nonagenarians, the differential expression of proteins related to energy 
metabolism and antioxidant systems could contribute to the mechanisms that result in 
extended longevity and maintenance of cognitive reserve and functional capacity in this 
rising population of non-demented nonagenarians and centenarians. 
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6.2 Introduction 
Aging is defined as the gradual alteration in structure and function that occurs 
over time, eventually leading to an increased probability of death not associated with 
disease or trauma, and it can be considered to be a product of an interaction between 
genetic, environmental and lifestyle factors (Ashok and Ali, 1999; Gonos, 2000). Aging 
is usually characterized by impairments in physiological functions, such as impairments 
in the brain, increased susceptibility to dementia and neurodegenerative disorders, i.e., 
Alzheimer’s disease (AD), Parkinson disease (PD), Huntington’s disease HD, and 
amyotrophic lateral sclerosis (ALS), among others (Poon et al., 2004b). Centenarians are 
the fastest growing age-group in the USA, and it is projected that there will be more than 
400,000 in the next 30 years (Silver et al., 2002). Studies have shown that there is an 
increase in the incidence of dementia among people aged 85 years and above (Silver et 
al., 2001; Perls, 2004b, a), and most people believe that dementia is inevitable to people 
in this age group (Blansjaar et al., 2000; Snowdon, 2003; Perls, 2004a). However, various 
studies on nonagenarians and centenarians have shown that approximately 30% of 
centenarians are cognitively intact and that among those who are demented, 90% show a 
delay in the time they present signs of cognitive impairments well into their 90’s 
(Hagberg et al., 2001; Silver et al., 2001; Perls, 2004b, a). As a result, the increasing 
number of non-demented nonagenarians and centenarians disputes the notion that 
dementia is inevitable as one becomes older (Green et al., 2000; Perls, 2006). This rising 
number of the oldest-old provides a unique resource for the study of dementia-free aging 
and related disorders.  
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The ability to achieve extreme old age while still maintaining intact cognitive 
function appears to be the result of a complex combination of factors such as genetics, 
environment, and lifestyle, among others, showing the complexity of understanding the 
mechanisms for successful aging process in the human population (Perls, 2005; Perls, 
2006). Various studies have shown the gene expression profiles in the aging brain 
(Galvin and Ginsberg, 2005), but few have been able to show the protein expression 
profile in the cognitively intact nonagenarians. Therefore, to better understand the 
cellular and biochemical mechanisms involved in the brains of cognitively intact 
nonagenarians, a differential expressional proteomic study on brain from nonagenarians 
who had undergone successful aging and were non-demented compared to their 
demented aged-matched controls was performed in the current study.  
Our laboratory has previously used proteomics to identify proteins that have 
undergone oxidative modifications or significant differential expression in AD subjects 
compared to age-matched controls. These studies among others have continued to 
provide evidence that energy metabolism and maintenance of ATP levels plays an 
integral role in the pathological and biochemical pathways of age-related 
neurodegenerative disorders (Castegna et al., 2002b; Castegna et al., 2002a; Castegna et 
al., 2003; Sultana et al., 2006d; Sultana et al., 2006c; Sultana et al., 2006a; Sultana et al., 
2006b). Though we have been successful in these studies, having non-demented 
nonagenarians and age-matched subjects with AD is a unique resource that was 
previously not available to us. Hence, this current study is the first report using 
proteomics to investigate possible mechanisms that are involved in successful aging of 
cognitively intact nonagenarians. We identified six brain proteins that were significantly 
 186
differentially expressed. We observed a significant decrease in the expression of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATP synthase, H+ transporting 
protein, human peroxiredoxin 5 (PRDX5), and malate dehydrogenase (MDH) in the non-
demented nonagenarian compared to those with AD. On the other hand, the levels of 
protein expression of fructose bisphosphate aldolase (FBP1) and ubiquitin carboxyl-
terminal hydrolase L1 (UCHL1) were found to be significantly increased when the same 
groups were compared. Further, we found that the severity of cognitive decline (MMSE) 
correlated with these changes in protein expression and that the extent of Aβ was also 
linked to protein expression. These results show that though the levels of oxidative stress 
were comparable, the increased expression of proteins related to energy metabolism and 
antioxidant systems in the demented brain of nonagenarians compared to their non-
demented aged-matched nonagenarians could contribute to the mechanisms that result in 
extended longevity and maintenance of cognitive reserve in the successful aging 
population. 
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6.3 Experimental procedures 
6.3.1 Subjects  
Subjects in the study were participants in the 90+ study, a population based investigation 
of aging and dementia in the oldest old. In the early 1980s, residents of Leisure World, a 
retirement community in southern California, were mailed a health questionnaire.  Those 
who completed and returned the questionnaire became members of the Leisure World 
Cohort Study.  Of the members of the Leisure World Cohort, those who were alive and 
aged 90 years or older on January 1, 2003 were eligible to participate in The 90+ Study.  
Participants in the 90+ study were given neuropsychological testing every 6 months until 
their death. A subset of these participants agreed to brain autopsy and tissue donation.  
The subjects in this study were selected from the first 19 cases to come to autopsy.  
Subjects were selected based on their clinical and neuropathological diagnoses.  The 
subject demographics are summarized in Table 6.1. The neuropsychological testing and 
neuropathology diagnosis were performed by Dr Daniel J. Berlau at the Institute for 
Brain Aging and Dementia, Department of Neurology, University of California, Irvine, 
California.   
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6.3.2 Neuropsychological testing 
The Mini-Mental State Exam (MMSE) was administered to the participants in the 
90+ study every 6 months as a measure of overall cognitive status.  Only the data from 
their final examination was used for statistical analysis in this study.  The MMSE score is 
out of 30 possible points and includes the following sections: temporal orientation, spatial 
orientation, attention, mental reversal, recall, naming, repetition, writing, reading and 
obeying a command, constructional praxis, and visual construction (Folstein, 1975).  
6.3.3 Neuropathology diagnosis 
Each brain was weighed at autopsy and one cerebral hemisphere (together with 
the brainstem and cerebellum) was fixed in 4% paraformaldehyde for 2 weeks, and the 
contralateral hemisphere was coronally sectioned and frozen at -80°C. Cortical and 
subcortical regions were dissected and paraffin embedded for histological and 
immunohistochemical examination. Modified Bielschowsky, hematoxylin-eosin and 
immunostains for tau, α-synuclein, ubiquitin, glial fibrillary acidic protein (GFAP-
astrocytosis) and CD68 (activated microglial cells) were applied.  Microscopically, 
neuritic plaque formation and neurofibrillary degeneration was categorized according to 
Braak & Braak staging (Braak and Braak, 1991; Braak and Braak, 1995). The final 
neuropathology diagnosis was established using NIA/Reagan criteria (disease, 1997). 
6.3.4 Sample preparation 
Brain samples were minced and suspended in 10 mM HEPES buffer (pH 7.4) 
containing 137 mM NaCl, 4.6 mM KCl, 1.1 mM KH2PO4, 0.1 mM EDTA, and 0.6 mM 
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MgSO4 as well as proteinase inhibitors: leupeptin (0.5 mg/mL), pepstatin (0.7 µg/mL), 
type II S soybean trypsin inhibitor (0.5 µg/mL), and PMSF (40 µg/mL). Homogenates 
were centrifuged at 14,000 × g for 10 min to remove debris. Protein concentration in the 
supernatant was determined by the BCA method (Pierce, Rockford, IL, USA). 
6.3.5 Measurement of protein carbonyls 
Protein carbonyls are an index of protein oxidation and were determined as 
described previously (Butterfield and Stadtman, 1997). Briefly, samples (5 µg of protein) 
were derivatized with 10 mM 2, 4-dinitrophenylhydrazine (DNPH) in the presence of 5 
µL of 12% sodium dodecyl sulfate for 20 min at room temperature (23°C). The samples 
were then neutralized with 7.5 µL of the neutralization solution (2 M Tris in 30% 
glycerol). Derivatized protein samples were then blotted onto a nitrocellulose membrane 
with a slot-blot apparatus (250 ng per lane). The membrane was then washed with wash 
buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20) and blocked by 
incubation in the presence of 5% bovine serum albumin, followed by incubation with 
rabbit polyclonal anti-DNPH antibody (1: 100 dilution) as the primary antibody for 1 h. 
The membranes were washed with wash buffer and further incubated with alkaline 
phosphatase-conjugated goat anti-rabbit antibody as the secondary antibody for 1 h. Blots 
were developed using fast tablet (BCIP/NBT; Sigma-Aldrich) and quantified using Scion 
Image (PC version of Macintosh-compatible NIH Image) software. 
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6.3.6 Lipid peroxidation 
6.3.6.1 Measurement of protein-bound 4-hydoxynonenal (HNE) 
HNE is a marker of lipid oxidation and the assay was performed as previously 
described (Lauderback et al., 2001). Briefly, 10 µl of sample were incubated with 10 µl 
of Laemmli buffer containing 0.125 M Tris base pH 6.8, 4 % (v/v) SDS, and 20% (v/v) 
glycerol. The resulting sample (250 ng) was loaded per well in the slot blot apparatus 
containing a nitrocellulose membrane under vacuum pressure. The membrane was 
blocked with 3% (w/v) bovine serum albumin (BSA) in phosphate buffered saline 
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST) for 1 h and 
incubated with a 1:5000 dilution of anti-4-hydroxynonenal (HNE) polyclonal antibody in 
PBST for 90 min. Following completion of the primary antibody incubation, the 
membranes were washed three times in PBST. An anti-rabbit IgG alkaline phosphatase 
secondary antibody was diluted 1:8000 in PBST and added to the membrane. The 
membrane was washed in PBST three times and developed using Sigmafast Tablets 
(BCIP/NBT substrate).  Blots were dried, scanned with Adobe Photoshop, and quantified 
by Scion Image. 
6.3.6.2 Measurement of Neuroprostanes and Isoprostanes 
Dr. J.D Morrow at the Vanderbilt University School of Medicine quantified the 
levels of Isoprostanes (F2-IsoPs) and Neuroprostanes (F4-NPs) in brain specimens of the 
oldest old. This was done using highly precise and accurate mass spectrometric assays 
applying stable isotope dilution techniques, as described previously (Morrow and 
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Roberts, 1999; Musiek et al., 2004).  Briefly, specimens were dissected from frozen 
middle frontal gyrus of individual cases and lipids were extracted from specimens by the 
method of Folch and colleagues (Folch et al., 1957).  F2-IsoP and F4-NPs were esterified 
in tissue and hydrolyzed by chemical saponification, extracted using C18 and silica Sep-
Pak cartridges (Waters Corporation, Milford, MA), purified by thin-layer 
chromatography, converted to pentafluorobenzyl ester trimethylsilyl ether derivatives, 
and quantified using gas chromatography/negative ion chemical ionization/mass 
spectrometry.  The stable isotope dilution techniques used [2H4]-8-iso-PGF2a as an 
internal standard for F2-IsoPs and [18O2]17-F4c-NP as an internal standard for F4-NPs.   
6.3.7 Two-dimensional electrophoresis 
Brain samples (200 µg) were incubated with 4 volumes of 2N HCL at room for 
electrophoresis. Proteins were then precipitated by the addition of ice-cold 100% 
trichloroacetic acid (TCA) to obtain a final concentration of 15% TCA. Samples were 
then placed on ice for 10 min and precipitate centrifuged at 16,000 g for 3 min. The 
resulting pellet was then washed three times with a 1:1(v/v) ethanol/ethyl acetate 
solution. The samples were then suspended in 200 µl of rehydration buffer composed of a 
1:1 ratio (v/v) of the zwittergent solubilization buffer (7M urea, 2M thiourea, 2% Chaps, 
65 mM DTT, 1% zwittergent 0.8% 3-10 ampholytes and bromophenol blue) and ASB-14 
solubilization buffer (7M urea, 2M thiourea 5Mn TCEP, 1% (w/v) ASB-14, 1% (v/v) 
Triton X-100, 0.5% Chaps, 0.5% 3-10 ampholytes) for 1 h. 
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6.3.8 First dimension electrophoresis 
For the first-dimension electrophoresis, 200 µL of sample solution was applied to 
a 110-mm pH 3–10 ReadyStrip™ IPG strips (Bio-Rad, Hercules CA). The strips were 
then actively rehydrated in the protean IEF cell (Bio-Rad) at 50 V for 18 h. The 
isoelectric focusing was performed in increasing voltages as follows; 300 V for 1 h, then 
linear gradient to 8000 V for 5 h and finally 20 000 V/h. Strips were then stored at –80 
°C until the 2nd dimension electrophoresis was to be performed. 
6.3.9 Second dimension electrophoresis 
For the second dimension, the IPG® Strips, pH 3–10, were equilibrated for 10 min 
in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium dodecyl sulfate 
(SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15 min in 
same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient 
precast criterion Tris–HCl gels (8–16%) (Bio-Rad) were used to perform second 
dimension electrophoresis. Precision Protein™ Standards (Bio-Rad, CA) were run along 
with the sample at 200 V for 65 min. 
6.3.10 SYPRO ruby staining 
After the second dimension electrophoresis, the gels were incubated in fixing 
solution (7% acetic acid, 10% methanol) for 20 min and stained overnight at room 
temperature with 50 ml SYPRO Ruby gel stains (Bio-Rad). The SYPRO ruby gel stain 
was then removed and gels stored in deionized water. 
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6.3.11 Image analysis 
The nitrocellulose blots (oxyblots) were scanned and saved in TIFF format using 
Scan jet 3300C scanner (Hewlett Packard, CA). SYPRO ruby-stained gel images were 
obtained using a STORM phosphoimager (Ex. 470 nm, Em. 618 nm, Molecular 
Dynamics, Sunnyvale, CA, USA) and also saved in TIFF format. PD-Quest (Bio-Rad) 
imaging software was then used to match and analyze visualized protein spots among 
differential 2D gels for each group of subjects. 
6.3.12 In-gel trypsin digestion 
Samples were digested by trypsin using protocols previously described 
(Thongboonkerd et al., 2002). Briefly, spots of interest were excised using a clean blade 
and placed in Eppendorf tubes, which were then washed with 0.1 M ammonium 
bicarbonate (NH4HCO3) at room temperature for 15 min. Acetonitrile was then added to 
the gel pieces and incubated at room temperature for 15 min. This solvent mixture was 
then removed and gel pieces dried. The protein spots were then incubated with 20 µL of 
20 mM DTT in 0.1 M NH4HCO3 at 56 °C for 45 min. The DTT solution was removed 
and replaced with 20 µL of 55 mM iodoacetamide in 0.1 M NH4HCO3. The solution was 
then incubated at room temperature for 30 min. The iodoacetamide was removed and 
replaced with 0.2 mL of 50 mM NH4HCO3 and incubated at room temperature for 
15 min. Acetonitrile (200 µL) was added. After 15 min incubation, the solvent was 
removed, and the gel spots were dried in a flow hood for 30 min. The gel pieces were 
rehydrated with 20 ng/µL modified trypsin (Promega, Madison, WI) in 50 mM 
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NH4HCO3, with the minimal volume enough to cover the gel pieces. The gel pieces were 
incubated overnight at 37 °C in a shaking incubator. 
6.3.13 Mass spectrometry 
A MALDI-TOF mass spectrometer in the reflectron mode was used to generate 
peptide mass fingerprints. Peptides resulting from in-gel digestion with trypsin were 
analyzed on a 384 position, 600 µm AnchorChipTM Target (Bruker Daltonics, Bremen, 
Germany) and prepared according to AnchorChip recommendations (AnchorChip 
Technology, Rev. 2, and Bruker Daltonics, Bremen, Germany). Briefly, 1 µL of digestate 
was mixed with 1 µL of alpha-cyano-4-hydroxycinnamic acid (0.3 mg/mL in ethanol: 
acetone, 2:1 ratio) directly on the target and allowed to dry at room temperature. The 
sample spot was washed with 1 µL of a 1% TFA solution for approximately 60 seconds.  
The TFA droplet was gently blown off the sample spot with compressed air. The 
resulting diffuse sample spot was recrystallized (refocused) using 1 µL of a solution of 
ethanol: acetone: 0. 1 % TFA (6:3:1 ratio). Reported spectra are a summation of 100 laser 
shots. External calibration of the mass axis was used for acquisition and internal 
calibration using either trypsin autolysis ions or matrix clusters and was applied post 
acquisition for accurate mass determination.  
6.3.14 Analysis of peptide sequences 
Peptide mass fingerprinting was used to identify proteins from tryptic peptide 
fragments by utilizing the MASCOT search engine based on the entire NCBI and 
SwissProt protein databases. Database searches were conducted allowing for up to one 
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missed trypsin cleavage and using the assumption that the peptides were monoisotopic, 
oxidized at methionine residues, and carbamidomethylated at cysteine residues. Mass 
tolerance of 150 ppm, 0.1 Da peptide tolerances and 0.2 Da fragmentation tolerances was 
the window of error allowed for matching the peptide mass values. Probability-based 
MOWSE scores were estimated by comparison of search results against estimated 
random match population and were reported as -10*log10 (p), where p is the probability 
that the identification of the protein is a random event. MOWSE scores greater than 63 
were considered to be significant (P < 0.05). All protein identifications were in the 
expected size and isoelectric point (pI) range based on the position in the gel. 
6.3.15 Aβ ELISA  
Dr. Elizabeth Head of the University of California Irvine performed the Aβ 
ELISA assay described here. Aβ was sequentially extracted from approximately 200 mg 
of frozen midfrontal cortex taken adjacent to cortex for proteomics experiments in 0.1M 
Tris pH = 6.8 with 1% SDS and a Protease inhibitor Cocktail Kit (MP Biochemicals Inc.) 
containing 0.4 mg/ml AEBSF, 1mg/ml EDTA-Na2, 1µg/ml Leupeptin and Pepstatin A) 
at 1 mL buffer/150mg wet weight tissue using Potter Elevehjem 10 ml Wheaton glass 
tube and centrifuged at 4° C at 100 000 x g for 1 hour. The pellet was resuspended in 
70% formic acid and sonicated on ice.  After centrifugation at 4° C at 100 000 x g for 1 
hour, the supernatant was collected and stored at –80°C until assayed.  Brain samples 
were run in triplicate on ELISA plates coated with a monoclonal anti-Aβ1-16 antibody 
(kindly provided by Dr. William Van Nostrand, Stony Brook University, Stony Brook, 
NY) and detection was by monoclonal HRP conjugated anti-Aβ1-40 (MM32-13.1.1) and 
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anti-Aβ1-42 (MM40-21.3.1) antibodies (kindly provided by Dr. Christopher Eckman, 
Mayo Clinic Jacksonville, Jacksonville, CA) (Das et al., 2003; Kukar et al., 2005; 
McGowan et al., 2005).  For standards, Aβ1-40 and Aβ1-42 (Bachem California, Inc., 
Torrance, CA) were used after a pretreatment with HFIP to prevent fibril formation.  
6.3.16 Statistical analysis 
Statistical analysis of differentially expressed protein levels matched with spots 
on 2D-gels from brain samples from cognitive intact nonagenarians and demented age-
matched subjects were used and carried out using Student's t-tests. A value of p < 0.05 
was considered statistically significant. Only proteins that are considered significantly 
different by Student's t-test in the brains of the old normal versus the old with AD were 
subjected to in-gel trypsin digestion and subsequent proteomic analysis. This is the 
normal procedure for proteomics studies, since sophisticated statistical analysis used for 
microarray studies are not applicable for proteomics studies (Maurer et al., 2005). To 
analyze the association between proteomic outcome measures and clinical and 
neuropathological characteristics of autopsy cases used in the current study, we 
calculated Spearman Rho’s correlation co-efficients. 
6.3.17 Protein Interacteome 
  The functional protein interacteome was obtained by using the Interaction 
Explorer TM Software Pathway Assist software package (Stratagene, La Jolla, CA). 
Pathway Assist is software for functional interaction analysis. It allows for the 
identification and visualization of pathways, gene regulation networks and protein 
interaction maps (Donninger et al., 2004). The proteins are first imported as the gene 
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symbols as a set of data. This data set is then searched against ResNet, a database 
containing over 500,000 biological interactions built by applying the MedScan text-
mining algorithms to all PubMed abstracts. These interactions are then visualized by 
building interaction networks with shortest-path algorithms. This process can graphically 
identify all known interaction among the proteins. The information of the function of 
these proteins and their relevance to diseases are then obtained by using the BIOBASE's 
Proteome BioKnowledge Library form Incyte Corporation (Incyte, Wilmington, DE) 
(Hodges et al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 199
6.4 Results 
6.4.1 Pathology of brain from oldest-old cognitively normal and AD subjects  
As shown in Table 6.2, nondemented and demented individuals were not different 
in education level (t (7) =1.38 p=0.21), age (t (7) =0.28 p=0.79), post mortem interval 
(t(7)=0.33 p=0.75) or interval between last clinic assessment and death (t(7)=1.25 
p=0.25).  Nondemented subjects selected for this study had Braak & Braak tangle stages 
between III and IV whereas those with dementia had Braak & Braak tangle stages V and 
VI.   Individuals with AD had significantly lower MMSE scores (t (7)=6.19 p<. 0005) but 
not brain weights (t (7)=1.89 p=0.10).  The short post-mortem intervals employed 
suggests little oxidative damage or degradation occurred following death prior to 
harvesting the brain (Butterfield et al., 2003; Butterfield, 2004; Poon et al., 2005a; Poon 
et al., 2005b). 
6.4.2 Protein oxidation levels in the demented and nonagenarians 
Oxidative stress and the resulting damage has been shown to be one of the main 
mechanisms contributing to neurodegeneration and cognitive decline in a number of age-
related neurodegenerative disorders such as AD (Aksenov et al., 1998b; Aksenov et al., 
2000; Aksenov et al., 2001; Butterfield et al., 2001; Butterfield and Lauderback, 2002). 
Protein carbonylation is one of the markers of protein oxidation (Butterfield and 
Stadtman, 1997). There was no significant difference in both the levels of protein 
carbonyls among the subjects investigated (Fig.6.1).  
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6.4.3 Levels of lipid peroxidation in the demented and nonagenarians  
4-hydroxynonenal HNE is a marker of lipid oxidation (Lauderback et al., 2001). 
HNE binds to proteins by Michael addition (Butterfield and Stadtman, 1997), altering 
their conformation, and thereby reducing there activity (Subramaniam et al., 1997; 
Lauderback et al., 2001). In the current study there was no significant differences 
observed in the levels of lipid peroxidation markers as measured by HNE, isoprostanes 
and neuroprostanes between the non-demented nonagenarians and the demented aged-
matched nonagenarians (Fig.6.2) This is consistent with a previous study that showed no 
significant increase in the levels of malondialdehyde (MDA), another measure of lipid 
peroxidation in nondemented nonagenarians compared to septo/octogenarians (Rea et al., 
2004).  
6.4.4 Differential expression of protein levels in the demented and non-demented 
nonagenarians 
Two-dimensional electrophoresis offers an excellent tool for the screening of 
abundant protein changes in various disease states (Butterfield et al., 2003; Butterfield, 
2004; Poon et al., 2006b; Poon et al., 2006a). To assess whether there were any changes 
in the proteomic profile in the brains of cognitively intact nonagenarians in the present 
study, we investigated the pattern of protein expression in the frontal cortex from the 
demented nonagenarians compared to the age-matched cognitively intact nonagenarians. 
Comparing the densitometric intensities of individual spots on the gels, four proteins 
were expressed at significantly lower levels, and two proteins were expressed at 
significantly higher levels in the brains of the nonagenarians with AD compared to the 
non-demented nonagenarians. Fig 6.3 shows SYPRO ruby stained 2D gels of the old 
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normal (A) vs. old AD (B) groups mentioned above, with identified protein boxed and 
labeled. The brain proteins identified with decreased expression in the non-demented 
nonagenarians compared to aged-matched AD were: peroxiredoxin 5 (PRDX5), malate 
dehydrogenase (MDH), ATP Synthase H+ transporting protein, and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). In contrast, two proteins, ubiquitin carboxyl-
terminal hydrolase L1 (UCHL1) and fructose bisphosphate aldolase (FBP1) were 
identified by proteomics to have increased expression in the non-demented nonagenarians 
compared to the demented nonagenarians. These proteins identified by mass 
spectrometry are shown in Table 6.3. Table 6.4 provides the changes in protein levels 
expressed as percent control ± S.E.M.  
6.4.5 Correlations between changes in protein expression, Aβ and cognitive status. 
Table 6.5 shows that several significant correlations were observed between Aβ, 
MMSE scores and protein expression levels.  Overall, Aβ 40 either in the soluble or 
insoluble fractions was associated with protein expression of GAPDH, MDH and FBP.  
In contrast, the amount of soluble or insoluble Aβ 42 did not correlate with any of the 
observed changes in protein expression.  Further, MMSE scores were significantly 
associated with MDH such that higher MMSE scores (better cognition) was linked to 
lower MDH, which is consistent with overall lower levels of MDH in nondemented 
nonagenarians.  Despite the small sample size used for these correlation analyses, the 
general trends appear to be promising.   
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6.4.6 Protein interacteome 
Fig 6.4 shows the protein interacteome of proteomics-identified proteins 
differentially expressed in the brains of cognitively intact and demented nonagenarians. 
The Interaction Explorer PathwayAssist (Stratagene) software shows that the proteins 
identified in this study are related to regulation of signal transduction, energy 
metabolism, and chaperone activity among others. As a result, the present findings 
suggest that in brains of non-demented nonagenarians, cognitive functions and memory 
are preserved in part via pathways associated with these functions.  
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Figure 6.1  
 
                  
 
 
 
 
 
 
Figure 6.1 Shows protein carbonyl levels. There was no significant difference in the 
levels of protein carbonyls measured in both the old nonagenarians with AD compared to 
their age-matched normal nonagenarians.  
 
 
 
 
Protein Carbonyls
0
20
40
60
80
100
120
140
160
Old Normal Old AD
%
 A
D
 205
Figure 6.2 
 
 
 
 
 
 
 
          Figure 6.2 Shows lipid peroxidation levels as measured by 4-hydroxynonenal 
(HNE), isoprostanes (IP) and neuroprostanes (NP). There were no significant differences 
in the levels of all lipid peroxidation biomarkers in the old nonagenarians with AD 
compared to their age-matched normal old nonagenarians. 
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Figure 6.3 
 
 
 
 
 
 
 
 
 
 
Figure 6.3 Shows SYPRO Ruby-stained 2D-gels maps of brain samples from normal old 
(A) nonagenarians vs. old nonagenarians with AD (B). Proteins identified by mass 
spectrometry showing differential expression are presented as the boxed spots. 
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* Represents significant correlation 
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Figure 6.4 
 
 
Figure 6.4 Schematic diagram of a functional interacteome of all proteins identified to be 
differentially expressed in the brains of cognitively intact nonagenarians compared to 
their demented age-matched controls. This diagram was generated by the interaction 
explorer ™ Pathway Module (Stratagene), indicating that all the proteins are directly or 
indirectly associated with cellular process shown.  
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6.5 Discussion 
Some centenarians and nonagenarians escape or delay the onset of age-related 
disorders such as stroke, diabetes, cancer and AD (Perls et al., 2002a). The mechanism 
for the delay or escape of cognitive impairments in this group of individuals is still not 
well understood. Genetic predisposition seems to play a significant role in the 
mechanisms of dementia-free longevity, but the identification of a single gene 
responsible for this is still far from being archived (Gonos, 2000; Perls et al., 2000; Perls, 
2001). As a result, the mechanism for cognitive preservation in the oldest-old is thought 
to follow multiple routes (Perls, 2004a; Galvin and Ginsberg, 2005). To better understand 
the mechanisms through which the oldest-old remain cognitively intact and maintain 
functional reserve, we analyzed the levels of oxidative damage by measuring the levels of 
protein carbonyls and protein-bound 4-hydroxynonenal (HNE), F2-IsoP and F4-NPs, all 
being biomarkers of oxidative stress. We also carried out a proteomic study to investigate 
differentially expressed proteins in the brains of age-matched non-demented and 
demented nonagenarians. There were no significant changes in the levels of protein 
oxidation as measured by the levels of protein carbonyls. In addition, there also were no 
significant changes observed in the levels of lipid peroxidation as measured by the levels 
of HNE, F2-IsoP and F4-NPs between these two groups. These results are consistent with 
a previous study that showed no changes in the levels of malondialdehyde (MDA) in 
nonagenarians (Rea et al., 2004). We speculate that elevated oxidative stress in brains of 
subjects with cognitive normality is the same as that from subjects with elevated 
oxidative stress in AD brains (Butterfield and Lauderback, 2002). However, using 
proteomics, we were able to identify four proteins whose expressions were significantly 
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decreased in the non-demented nonagenarians compared to nonagenarians with AD; these 
included: PRDX5, MDH, ATP synthase, and GAPDH. We also identified two proteins 
UCHL1 and FBP1 whose expressions were significantly increased in the cognitively 
intact nonagenarians compared to frontal cortex in age-matched AD individuals. The 
proteins identified were related to the antioxidant system, proteosome function and 
energy metabolism. The consequences of their differential expressions are discussed here 
with relevance to successful aging.  
  Peroxiredoxins (Prdxs) are a family of peroxidases that act as antioxidants by 
reducing hydrogen peroxide (H2O2), and alkyl hydroperoxides (Kim et al., 2000a). This is 
achieved with the use of reducing equivalents derived from thiol-containing donor 
molecules, such as thioredoxin. Prdxs have been identified in a variety of organisms 
ranging from prokaryotes to mammals (Chae et al., 1994), and to date, six distinct groups 
of mammalian prdxs (I–VI) have been identified. Prdxs I, II and VI are localized 
predominantly to the cytosol, while Prdxs III and V are largely detected in the organelles 
(Kang et al., 1998; Seo et al., 2000). Prdx2 expression has been shown to be significantly 
increased in AD, ALS, Down’s syndrome and Parkinson’s disease (PD) most probably as 
a compensatory mechanism (Kim et al., 2001; Allen et al., 2003; Krapfenbauer et al., 
2003). Our laboratory has previously shown that prdx2 is significantly oxidized in the 
brain of the gracile axonal dystrophy (gad) mouse and is implicated as a possible 
mechanism of oxidative stress-induced neurodegeneration (Castegna et al., 2004). In the 
brain of senescence-accelerated mice prone 8 (SAMP8) mice, we have shown that 
following administration of antisense oligonucleotide directed at the Aβ region of 
amyloid precursor protein (APP), there is a significant decrease in the protein carbonyl 
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levels of prxd2, which could elevate antioxidant levels, thereby contributing to the 
observed improvements in learning and memory in the mice (Poon et al., 2005d). From 
the present study, we have observed a significant decrease in the expression levels of 
prdx5 in the brains of non-demented nonagenarians compared to the aged-matched 
demented nonagenarians. This results continues to support our previous study that 
showed an increase in expression in AD patients as a possible compensatory mechanism 
(Krapfenbauer et al., 2003), this in effect would  provide  protection against apoptosis by 
blocking of TNF-induced AP-1 activation  (Shau et al., 1998) and in essence lead to 
improved cellular and biological functions contributing to maintenance of cognitive 
function observed in the normal nonagenarians.  
Malate dehydrogenase (MDH) is a mitochondrial metabolic enzyme involved in 
the malate-aspartate shuttle that links glycolysis to the mitochondria electron transport 
chain (ETC), by transferring NADH to the electron transport complex 1, resulting into 
increased ATP synthesis (Poon et al., 2005a). The activity of MDH has previously been 
shown to be decreased during aging, probably through oxidative modification 
(Hrachovina and Mourek, 1990). Our laboratory has previously shown that MDH 
expression is significantly increased in the olfactory bulb of old mice possibly to 
compensate for reduced activity of ATP synthase seen in this model (Poon et al., 2006a).  
We have also shown that there is reduced nitration of MDH in the hippocampus of aged 
rats on caloric restriction (Poon et al., 2006b). In the present study, we observed a 
significant decrease in the levels of MDH in the brains of successfully aged 
nonagenarians. This decrease in expression conceivably would mean that normal 
nonagenarians compared to their demented controls have sufficient levels of MDH 
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resulting in an increased supply of NADH to the ETC leading to more production of 
ATP, maintaining energy metabolism, improved neuronal function and maintenance of 
cognitive function and reserve in these successfully aged individuals.  This is consistent 
with our additional observations that higher MMSE scores were associated with lower 
MDH and similarly, higher amounts of Aβ 40 are linked to lower MDH protein 
expression. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a glycolytic enzyme 
located in the cytosol that catalyzes the conversion of glyceraldehyde-3-phosphate to 1, 
3-phosphoglycerate, the first oxidation-reduction reaction in the glycolytic pathway. The 
activity  of GAPDH has been found to be reduced in AD (Mazzola and Sirover, 2001) 
and its accumulation together with other glycolytic enzymes such as α-enolase and γ-
enolase has been shown in AD brain (Schonberger et al., 2001), possibly as compensation 
for altered energy metabolism seen in AD (Vanhanen and Soininen, 1998; Messier and 
Gagnon, 2000; Scheltens and Korf, 2000). GAPDH has been identified as one of the 
nitrated proteins in AD (Sultana et al., 2005b). GAPDH was also identified to be oxidized 
by intracerebral injection of amyloid beta-peptide Aβ (1-42) into rat brain, likely 
explaining the possible loss or reduced activity of the enzyme in AD (Boyd-Kimball et 
al., 2005c). In the present study, we report GAPDH as one of the proteins whose 
expression is significantly decreased in the brain of cognitively intact nonagenarians and 
further, we observed a significant positive correlation between GAPDH and the amount 
of soluble Aβ1-40 extracted from the brain. As a result, normal nonagenarians possibly 
have enough levels and activity of GAPDH thus not necessitating increased expression 
which would lead to increased ATP production consequently leading to improved 
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function of ATP dependent cellular pathways related to maintenance of memory and 
cognitive function for the demented nonagenarians. 
ATP synthase F1 subunit (ATP5A1) is a component of the mitochondrial ATP 
synthase complex. ATP synthase uses the electrochemical proton gradient established 
across the mitochondria membrane for synthesis of ATP from ADP and inorganic 
phosphate Pi (Leyva et al., 2003). Our laboratory has previously shown that ATP 
synthase is significantly oxidized in the gracile axonal dystrophy (gad) mouse brain 
(Castegna et al., 2004), a condition resulting from defective ubiquitin carboxyl hydrolase 
(UCHL-1) enzyme and proteosomal dysfunction. ATP synthase deficiency has been 
associated with an increase in oxidative stress, as observed in PD (Basso et al., 2004). In 
the aging human brains, the protein levels of ATP5A1 have been shown to be down-
regulated (Lu et al., 2004) and its expression has been shown to be decreased in the 
olfactory bulb of the aging mice (Poon et al., 2006a). In the present study, we identified 
ATP5A1 as one of the proteins whose expression was significantly decreased in the 
brains of non-demented nonagenarians. We believe that this decrease in protein 
expression of ATP5A1 just like the rest of the proteins discussed above shows that due to 
successful aging cognitively intact nonagenarians don’t require compensation for ATP 
synthesis like the aged-matched demented nonagenarians thus, the decrease in the 
expression of the above proteins in the cognitively intact nonagenarians compared to the 
age-matched demented nonagenarians should not seem unusual. The presence of Aβ in 
AD potentially necessitates for a compensatory mechanism to counter the effects of Aβ 
induced oxidative stress and possible cognitive decline. On the other hand, in the normal 
nonagenarians though there could be Aβ, its levels might not be sufficient to warrant for 
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this compensation mechanism hence the observed decrease in their expression during 
successful aging.      
In the present study, we also identified UCHL1 and FBP1 as two proteins that 
were significantly increased in the brains of cognitively intact nonagenarians compared to 
aged-matched AD. UCH L-1 is an enzyme involved in the process of proteolytic 
degradation of misfolded or damaged proteins by the enzymatic complex, the proteosome 
(Kornitzer and Ciechanover, 2000). Proteolytic degradation is usually signaled by the 
covalent conjugation of ubiquitin to damaged proteins and is catalyzed by specific 
ubiquitin-transferring enzymes (Hershko and Ciechanover, 1998). As aging occurs, there 
is accumulation of misfolded, damaged or oxidized proteins and hence there is a need for 
their degradation since their accumulation could contribute to the increase in the number 
of oxidized proteins observed in AD among other deleterious effects (Keller et al., 2000; 
Castegna et al., 2004). UCHL1 has previously been shown to be oxidatively modified in 
AD (Castegna et al., 2002b), and point mutations in its gene cause familial PD (Leroy et 
al., 1998; Zhang et al., 2000). In addition, mutations in a gene encoding UCHL1 in the 
gracile axonal dystrophy (gad) mutant mouse results in brain axonal degeneration, severe 
motor neuronal impairment and Aβ deposition in the brain (Saigoh et al., 1999; Kurihara 
et al., 2001). The increased expression of UCHL-1 in successful aging observed here may 
reflect the observation that proteosomal activity is elevated in normal controls compared 
to AD brains (Keller et al., 2000; Castegna et al., 2004), and we speculate that though 
there could be possibly  less oligomeric Aβ (1-42) in the normal nonagenarians relative to 
AD brain where copious amounts of oligomeric Aβ (1-42) occur (Butterfield and 
Lauderback, 2002), there could still be a relatively large amount of oxidized or damaged 
 217
proteins in the normal non-demented nonagenarians brain  thereby necessitating for more 
expression of UCHL1 thus contributing to successful aging. 
Fructose bisphosphate aldolase C (FBP) on the other hand is a glycolytic enzyme 
that catalyses the reversible aldol cleavage or condensation of fructose-1, 6-bisphosphate 
into dihydroxyacetone-phosphate and glyceraldehyde 3-phosphate (Perham, 1990).  The 
role of FBP in aging and age-related disorders is still not well established, though we 
speculate that an increased expression would result into possibly increased activity and an 
increase in energy metabolism.  FBP protein expression may be at least partially linked to 
the extent of Aβ as we observed a significant correlation between higher levels of 
insoluble Aβ 40 and lower FBP. The identification of these differentially expressed 
proteins in the brains of cognitively intact nonagenarians seems unusual. However, with 
advanced age and the presence of neurodegenerative disorders such as AD, there is a 
decrease in energy metabolism and accumulation of damaged proteins as previously 
mentioned (Vanhanen and Soininen, 1998; Messier and Gagnon, 2000) and as a 
compensatory response, we expect to observe a global increase expressions of proteins 
related to these functions. However, as observed in the present study this is not 
necessarily the case adding to the complexities in the mechanisms involved in successful 
aging. 
 In an extreme case from the Nuns study in which despite genetic predisposition 
to AD and presence of AD pathology in the neocortex, this part of the brain remained 
perfectly preserved, suggesting that her neocortex was resistant to Alzheimer-related 
neurodegeneration (Snowdon et al., 1997; Snowdon, 2003). In addition, a study on 
neuropathology on cognitively normal older adults has shown that brains of many 
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nondemented elderly individuals contain variable numbers of senile plaques. This has 
been known as pathologic aging, referring to a form of senile cerebral amyloid not 
associated with clinical manifestations of AD (Crystal et al., 1988; Dickson et al., 1992; 
Crystal et al., 1993). Therefore, the presence of neurofibrillary tangles NFT and senile 
plaques and other AD-related pathology and the lack of a correlation between dementia 
and neuropathology in the brain of non-demented centenarians and nonagenarians, could 
possibly suggest impairment in the proteosome functions in the brain.  Hence, we expect 
an increase in the expression of proteins related to proteosomal function such as UCHL1. 
Thus, despite an increase in damaged proteins as observed in the pathology, cognition is 
still maintained. In addition, it has been established that the role of AD pathology on 
cognition is a discontinuous process and until a certain threshold is reached, this 
pathology has no significant effect on cognition (Knopman et al., 2003) thus, this 
findings could not be so unusual. Most recently, it has been established that UCHL1 is 
required for normal synaptic and cognitive function (Gong et al., 2006). As a result, the 
increased expression of UCHL-1 in successful aging observed here may reflect that one, 
the proteosomal activity is elevated in normal controls compared to AD brains (Keller et 
al., 2000; Castegna et al., 2004),  and two that synaptic function is well maintained 
leading to improvements and maintenance of cognitive function. On the other hand, the 
increase in expression of FBP might have a significant but subtle effect in the increment 
of energy levels, especially since we have also seen a significant decrease in the 
expression of more proteins related to energy metabolism in the present study. 
This study therefore, has provided us with possible additional mechanisms and 
insights on how the oldest-old are able to remain cognitive intact. It has previously been 
 219
established that there is a significant increase in the levels of oxidative stress associated 
with advanced age; we have also shown that key proteins undergo significant oxidative 
modification leading to a loss in function in most neurodegenerative disorders(Butterfield 
and Castegna, 2003a; Boyd-Kimball et al., 2005c; Poon et al., 2005d; Butterfield et al., 
2006d; Poon et al., 2006b; Poon et al., 2006a; Sultana et al., 2006a). In the present study 
there was no significant difference observed in the levels of oxidative stress biomarkers, 
protein carbonyl, HNE, F2-IsoP and F4-NPs in the brains of age-matched cognitively 
intact and demented nonagenarians. This finding was consistent with a previous study 
that showed no significant increase in the levels of MDA, another measure of lipid 
peroxidation in cognitively intact nonagenarians compared to septo/octogenarians (Rea et 
al., 2004). As a result, we can conclude that oxidative stress did not play a significant role 
in the maintenance of cognitive function in the non-demented nonagenarians. In addition, 
it has been reported that there is altered energy metabolism in AD (Vanhanen and 
Soininen, 1998; Messier and Gagnon, 2000; Scheltens and Korf, 2000). The reduction in 
the levels of ATP could potentially lead to dysfunction in electrochemical gradients, ion 
pumps, and ion channels among others. This would eventually lead to loss in synaptic 
plasticity, neuronal dysfunction and loss in long-term potentiation and eventual loss in 
memory and cognition (Michaelis, 1997; Boyd-Kimball et al., 2005c). In the present 
study, we have shown that there is a significant increase in the expression of proteins 
related to energy metabolism and antioxidant system in the demented nonagenarians 
compared to the age-matched normal nonagenarians and we believe that one mechanism 
for the maintenance of neuronal function hence cognitive and memory function is 
through, but not exclusively, maintenance of ATP levels. Also using correlation analyses, 
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we have shown that there is a general trend of association between protein expression 
levels and intact cognition. In particular, MMSE scores were significantly associated with 
MDH, i.e., higher MMSE scores (better cognition) was linked to lower MDH, which is 
consistent with overall lower levels of MDH in nondemented nonagenarians. On 
analyzing our current results using the Interaction Explorer Software PathwayAssist 
(Stratagene), as shown in (Fig 6.4), the proteins identified in this study are related to 
regulation of signal transduction, energy metabolism, and chaperone activity among other 
cellular process relevant to the maintenance or improvement of cognitive function. Since 
we have previously seen that there is altered ATP production in the aging brain, the 
increased expression of energy metabolism related proteins can improve ATP production 
leading to neuronal recovery and improved cognitive function as seen in the cognitive 
intact nonagenarians and centenarians. Therefore, in addition to genetic, environmental 
and other factors in playing a role in achieving dementia-free aging, we believe that by 
maintaining sufficient ATP levels through efficient energy metabolism and improving 
antioxidant reserves, one is capable of maintaining synaptic plasticity, neuronal function 
through long-term potentiation and eventually improving memory and cognitive function 
(Michaelis, 1997). Thus, centenarians/nonagenarians have the potential to represent a 
model of resistance to age-related diseases and successful aging. 
A possible caveat in this study could be the number of subjects used. We had four 
non-demented and five aged-matched demented nonagenarians; this may be a small data 
set to provide global interpretations. Also the short post mortem intervals (PMI) used in 
obtaining tissues and the low standard deviations obtained within each group provide 
additional confidence that the number of subject used is sufficient enough to provide a 
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model to study and understand events taking place in disease-free aging. In our previous 
proteomics studies, the use of five subjects per group was acceptable for statistical 
analysis, considering also that in most proteomic studies, the use of sophisticated 
statistical analysis like those used for micro array studies are not applicable.  Therefore, 
we have confidence in the observations we have made and we believe that our present 
findings are able to provide a good representation of events and mechanisms taking place 
in successful aging. 
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Figure 6.5 Summary of the functional consequence for the differential expression of 
proteins in the cognitively intact nonagenarians. 
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CHAPTER SEVEN 
Proteomic Identification of Oxidized Mitochondrial-related Proteins Following 
Experimental Traumatic Brain Injury (TBI) 
 
7.1 Overview 
Experimental traumatic brain injury (TBI) has been know to result into a 
significant loss of cortical tissue at the site of injury and in the ensuing hours and days a 
secondary injury exacerbates this primary injury resulting into a massive loss of tissue 
leading into significant neurological dysfunction. The mechanism of the secondary injury 
is not well understood, but is thought to be mediated by the mitochondria. This 
mitochondrial dysfunction is believed to involve excitatory amino acids, disruption of 
Ca2+ homeostasis, production of reactive oxygen species (ROS), ATP depletion, oxidative 
damage of mitochondrial proteins and an overall breakdown of mitochondrial energetics 
and eventual cell death. The identity of proteins that undergo oxidative modification after 
TBI has not been known. As a result, in the present study we utilized a 3h post-injury 
controlled cortical impact (CCI) model of TBI, coupled with proteomics to identify these 
specific mitochondrial fraction proteins from the cortex and hippocampus that were 
oxidatively modified after injury. We were able to identify from the Cortex; Pyruvate 
dehydrogenase (lipoamide), Voltage dependent anion channel (VDAC), Fumarate 
hydratase 1, ATP synthase H+ transporting and prohibitin. From the hippocampus we 
identified; Cytochrome C Oxidase Va, Isovaleryl Coenzyme A Dehydrogenase, alpha 
enolase and Glyceraldehyde-3-phosphate dehydrogenase as proteins that had undergone 
oxidative modification following experimental TBI. In addition, we have also shown that 
following TBI, there is a reduction in the consumption of oxygen. Also, the activities of 
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complex I, complex IV, and pyruvate dehydrogenase (PDH), have been shown to be 
decreased. The present findings show that following TBI, the proteins of the electron 
transport chain and related ATP production mechanisms are highly oxidatively modified, 
leading to a massive breakdown of mitochondrial energetics and eventual cell death. The 
identification of these proteins provides new insights into the mechanisms that ensue 
following TBI and also provide avenues of possible therapeutic interventions after TBI. 
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7.2 Introduction 
 
Traumatic brain injury (TBI) is a serious health care problem in the United States, 
with more than 400,000 individuals hospitalized each year with an estimated annual cost 
of greater than 25 billion dollars. (Tibbs et al., 1998; McNair, 1999). As a result, there is 
an urgent need of therapeutic interventions to curb this growing epidemic. The discovery 
and development of possible therapeutics will only be achieved the mechanism involving 
the pathogenesis of TBI are completely or well understood. 
 Traumatic brain injury has been known to result in a rapid a significant loss 
cortical tissue through necrosis. In the ensuing hours and days, a secondary injury 
exacerbates this primary injury resulting in a significant neurological 
dysfunction.(Sullivan et al., 1998b; Sullivan et al., 1999) The neuropathology of TBI is 
believed to involve excitatory amino acids, a disruption in Ca2+ homeostasis, production 
of reactive oxygen species (ROS), depletion of ATP and an overall breakdown in 
mitochondria bioenergetics (Sullivan et al., 1998b; Scheff and Sullivan, 1999) 
       Mitochondria are known to serve a number of functions. Its principle role is that 
is acts as the powerhouse of the cell, generating the much need ATP that is necessary for 
normal physiological functions to occur.(Wallace, 1999; Szewczyk and Wojtczak, 2002). 
Other than its role in energy metabolism, the mitochondria also play a role in cell survival 
or cell death (apoptosis) process. The mitochondria act as Ca2+ sinks, maintaining Ca2+ 
homeostasis for normal cell functions. In the event of an excessive uptake of Ca2+and 
eventual overload, the mitochondria has been shown to increase the production of 
reactive oxygen species (ROS), that induces the opening of the mitochondrial 
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permeability pore (mPTP), release of cytochrome C, inhibition of ATP production and 
cell death.(Sullivan et al., 2005) 
Reactive oxygen species (ROS) are always produced as byproducts of ATP 
synthesis. It has been shown that following TBI there is an increase in the production of 
(ROS). (Zhang et al., 2005) The generation of these ROS and eventual oxidative stress 
has been reported in many animal models and human disorders to have effects in 
inactivation of various enzymes. This is believed to occur through oxidative 
modifications of DNA, RNA, Lipids, proteins, among others (Butterfield and 
Lauderback, 2002). Mitochondrial enzymes in particular have been found to be targets of 
oxidative stress in most neurodegenerative diseases(Gibson and Huang, 2004). A recent 
study of brain ischemia showed that Pyruvate dehydrogenase (PDH) is inactivated by an 
increase ROS (Martin et al., 2005), α-ketoglutarate dehydrogenase complex (KGDHC) 
activity has also been shown to be inhibited  under conditions of oxidative stress in AD 
(Gibson et al., 1998). In TBI, complex I respiration has been shown to be dramatically 
decreased, with a possible involvement of inhibition of PDH being evoked leading to 
reduction in ATP production (Sullivan et al., 2005). 
All these studies have shown the inhibition or inactivation of these enzymes, but 
the mechanisms that ensue leading to inactivation are still speculative. Proteomics has 
recently been used with a lot of success in identifying various proteins that have been 
oxidatively modified hence inactivated in various neurodegenerative diseases and 
disorders such as, ALS, AD, Parkinson’s, among others. (Castegna et al., 2002a; 
Castegna et al., 2003; Boyd-Kimball et al., 2005b; Poon et al., 2005f). Gene expression 
analysis studies in the rat hippocampus following TBI have shown that there is 
 227
differential expression at both mRNA and protein levels of genes associated with energy 
metabolism (Li et al., 2004). Using proteomics, we report for the first time the significant 
oxidation of  Pyruvate dehydrogenase (lipoamide), Voltage dependent anion channel 
(VDAC), Fumarate hydratase 1,ATP synthase H+ transporting, Prohibitin, Cytochrome C 
Oxidase Va, Isovaleryl Coenzyme A Dehydrogenase, alpha enolase and Glyceraldehyde-
3-phosphate dehydrogenase following experimental TBI. In addition, we also report the 
decreased activity of PDH, complex I and IV. These findings are discussed here to 
provide new insights into the mechanisms of TBI and also provide possible new targets 
for therapeutic interventions. 
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7.3 Experimental Procedures 
7.3.1 Animal and surgical procedures 
 
All procedures using animals were approved by the University of Kentucky 
Animal Use and Care Committee. Approximately 20 young adult (250–300 g), male 
Sprague–Dawley rats (Harlan Laboratories, IN) were pooled giving n=5 with each animal 
acting as its own control. All animals were housed in group cages on a 12-h light/dark 
cycle with free access to water and food. Animals were subjected to a moderate unilateral 
cortical contusion as previously described (Sullivan et al., 1999; Sullivan et al., 2000). 
This cortical contusion results in severe behavioral deficits, significant loss of cortical 
tissue, blood–brain barrier disruption and a loss of hippocampal neurons (Sullivan et al., 
2002), mimicking some of the events that take place in human closed-head injury. 
Briefly, the subjects were anesthetized using isoflurane (2%) and placed in a stereotaxic 
frame (Kopf Instruments, Tujunga, CA). The head was positioned in the horizontal plane 
with the nose bar set at negative 5. Using sterile procedures, the skin was retracted and a 
craniotomy made with a hand-held trephine lateral to the sagittal suture and centered 
between Bregma and lambda. The skullcap was carefully removed without disrupting the 
underlying dura. The exposed brain was injured using a pneumatically controlled 
impacting device with a 5-mm beveled tip, which compressed the cortex at 3.5 m/s to a 
depth of 1.5 mm (Baldwin and Scheff, 1996; Sullivan et al., 1999). After injury, Surgicel 
(Johnson and Johnson, Arlington, TX) was laid on the dura and the skullcap replaced. A 
thin coat of dental acrylic was then spread over the craniotomy site and allowed to dry 
before the wound was stapled closed. After 3 h animals were then anesthetized and 
samples harvested.  
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7.3.2 Mitochondria isolation. 
 
Isolation of total mitochondria was carried out as previously described (Sullivan 
et al., 2003; Sullivan et al., 2004b; Sullivan et al., 2004a). At 3 h post injury, the injured 
cortex and hippocampi from the ipsilateral and corresponding contralateral regions were 
dissected using a cork punch (d=8 mm) that was centered over the impact area, the tissue 
minced, and then homogenized separately in a glass dounce homogenizer containing 
approximately five times the volume of isolation buffer with 1 mM EGTA (215 mM 
mannitol, 75 mM sucrose, 0.1% BSA, 20 mM HEPES, 1 mM EGTA, pH 7.2). The 
homogenate was spun twice at 1300 × g for 3 min in an eppendorf microcentrifuge at 
4◦C. The supernatant were then transferred to new tubes, topped off with isolation buffer 
with EGTA and spun at 13,000 × g for 10 min. The resulting supernatant was discarded 
and the pellet resuspended in 500 µL of isolation buffer with EGTA. The resulting pellet 
was then resuspended in 0.5 ml of mitochondrial isolation buffer (215 mM mannitol, 75 
mM sucrose, 0.1% bovine serum albumin, 1 mM EGTA, 20 mM HEPES, pH 7.2), and 
the plasma membranes were ruptured by nitrogen decompression (Parr Cell Disruption 
Bomb) at 1000 p.s.i. for 5 min (Brown et al., 2004). The homogenized tissue and an equal 
volume of 30 % Percoll in isolation buffer was added (~4 ml). The resultant homogenate 
was layered on a discontinuous Percoll gradient with the bottom layer containing 40 % 
Percoll solution in isolation buffer, followed by a 24 % Percoll solution, and finally the 
sample in a 15 % Percoll solution. The density gradients were spun in a Sorvall RC-5C 
plus super speed refrigerated centrifuge (Asheville, NC) in a fixed angle SE-12 rotor at 
30,400 x g for 10 minutes.  Following centrifugation, band 3 (Sims, 1990) were 
separately removed from the density gradient. The samples were washed by 
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centrifugation at 16,700 x g for 15 minutes. The supernatant was discarded and the loose 
pellet was resuspended in the 1 ml of isolation buffer. The mitochondrial fractions were 
then placed in separate 15 ml conical tubes and an equal volume of 30 % Percoll was 
added to each sample and discontinuous Percoll density gradient centrifugation was 
performed again as described above. Band 3 was obtained from the gradients and 10 ml 
of isolation buffer without EGTA (215 mM mannitol, 75 mM sucrose, 0.1 % BSA, 20 mM 
HEPES, pH is adjusted to 7.2 with KOH) was added. The fractions were centrifuged at 
16,700 x g for 15 minutes and subsequently at 11,000 x g for 10 minutes. The resultant 
pellet was resuspended in 1 ml of isolation buffer without EGTA and centrifuged at 
10,000 x g for 10 minutes. The final mitochondrial pellet was resuspended in isolation 
buffer without EGTA to yield a protein concentration of ~10mg/ml and stored on ice for 
respiration assays or resuspended in lysis buffer (10 mM HEPES, 137 mM NaCl, 4.6 mM 
KCl, 1.1 mM KH2PO4, 0.6 mM MgSO4 and 0.5 mg/mL leupeptin, 0.7 µg/mL pepstatin, 
0.5 µg/mL trypsin inhibitor, and 40 µg/mL PMSF) for subsequent assays. Protein 
concentration was assayed using the Pierce BCA method. 
7.3.3 Mitochondria respiration assay 
 
Mitochondrial oxygen consumption was measured by using a Clark-type 
electrode in a continuously stirred, thermostated sealed chamber (Oxytherm System; 
Hansatech Instruments Ltd.) at 37°C as previously described (Brown et al., 2004; Jin et 
al., 2004; Sullivan et al., 2004b). Isolated mitochondrial protein (~30 µg) was suspended 
in respiration buffer (215 mM mannitol, 75 mM sucrose, 20 mM HEPES, 2 mM MgCl2, 
2.5 mM inorganic phosphate, 0.1% BSA, pH 7.2) in a final volume of 0.25 ml. The 
respiratory control ratio (RCR) was calculated as the ratio of oxygen consumption in the 
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presence of 10 mM pyruvate and 5 mM malate or 10 mM succinate in the presence of 
ADP (state III) and in the absence of ADP (State IV).  
7.3.4 Measurement of protein carbonyls 
 
Protein carbonyls are an index of protein oxidation and were determined as 
described previously (Butterfield and Stadtman, 1997). Briefly, the mitochondrial 
samples n=5 (5 µg of protein) were derivatized with 10 mM 2, 4-dinitrophenylhydrazine 
(DNPH) in the presence of 5 µL of 12% sodium dodecyl sulfate for 20 min at room 
temperature (23°C). The samples were then neutralized with 7.5 µL of the neutralization 
solution (2 M Tris in 30% glycerol). Derivatized protein samples were then blotted onto a 
nitrocellulose membrane with a slot-blot apparatus (250 ng per lane). The membrane was 
then washed with wash buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 
20) and blocked by incubation in the presence of 5% bovine serum albumin, followed by 
incubation with rabbit polyclonal anti-DNPH antibody (1: 100 dilution) as the primary 
antibody for 1 h. The membranes were washed with wash buffer and further incubated 
with alkaline phosphatase-conjugated goat anti-rabbit antibody as the secondary antibody 
for 1 h. Blots were developed using Sigma-fast tablet (BCIP/NBT; Sigma-Aldrich) and 
quantified using Scion Image (PC version of Macintosh-compatible NIH Image) 
software. 
7.3.5 Measurement of 3-nitrotyrosine (3-NT) 
Nitration of proteins is another form of protein oxidation (Castegna et al., 2003). 
The nitrotyrosine content was determined immunochemically as previously described 
(Drake et al., 2003b). Briefly, samples were incubated with Laemmli sample buffer in a 
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1:2 ratio (0.125 M Trizma base, pH 6.8, 4% sodium dodecyl sulfate, 20% glycerol) for 
20 min. Protein (250 ng) was then blotted onto the nitrocellulose paper using the slot-blot 
apparatus and immunochemical methods as described above for protein carbonyls. The 
mouse anti-nitrotyrosine antibody (5: 1000 dilutions) was used as the primary antibody 
and alkaline phosphatase-conjugated anti-mouse secondary antibody was used for 
detection. Blots were then scanned using scion imaging and densitometric analysis of 
bands in images of the blots was used to calculate levels of 3-NT. 
7.3.6 Measurement of 4-hydoxynonenal (HNE) 
HNE is a marker of lipid oxidation and the assay was performed as previously 
described (Lauderback et al., 2001). Briefly, 10 µl of sample were incubated with 10 µl 
of Laemmli buffer containing 0.125 M Tris base pH 6.8, 4 % (v/v) SDS, and 20% (v/v) 
Glycerol.  The resulting sample (250 ng) was loaded per well in the slot blot apparatus 
containing a nitrocellulose membrane under vacuum pressure.  The membrane was 
blocked with 3% (w/v) bovine serum albumin (BSA) in phosphate buffered saline 
containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST) for 1 h and 
incubated with a 1:5000 dilution of anti-4-hydroxynonenal (HNE) polyclonal antibody in 
PBST for 90 min.  Following completion of the primary antibody incubation, the 
membranes were washed three times in PBST.  An anti-rabbit IgG alkaline phosphatase 
secondary antibody was diluted 1:8000 in PBST and added to the membrane.  The 
membrane was washed in PBST three times and developed using Sigmafast Tablets 
(BCIP/NBT substrate).  Blots were dried, scanned with Adobe Photoshop, and 
quantitated with Scion Image.   
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7.3.7 Two-dimensional electrophoresis 
Mitochondrial proteins (200 µg) were incubated with 4 volumes of 2N HCL at 
room for electrophoresis or 20mM DNPH for western blotting at room temperature for 20 
min. Proteins were concentrated through precipitation by the addition of ice-cold 100% 
trichloroacetic acid (TCA) to obtain a final concentration of 15% TCA. Samples were 
then placed on ice for 10 min and precipitate centrifuged at 16,000 g for 3min. The 
resulting pellet was then washed three times with a 1:1(v/v) ethanol/ethyl acetate 
solution. The samples were then suspended in 200 µl of rehydration buffer composed of a 
1:1 ratio (v/v) of the Zwittergent solubilization buffer (7M urea, 2M thiourea, 2% Chaps, 
65 mM DTT, 1% Zwittergent 0.8% 3-10 ampholytes and bromophenol blue) and ASB-14 
solubilization buffer (7M urea, 2M thiourea 5Mn TCEP, 1% (w/v) ASB-14, 1% (v/v) 
Triton X-100, 0.5% Chaps, 0.5% 3-10 ampholytes) for 1 h. 
7.3.7.1 First dimension electrophoresis 
For the first-dimension electrophoresis, 200 µl of sample solution was applied to a 
110-mm pH 3–10 ReadyStrip™ IPG strips (Bio-Rad, Hercules CA). The strips were then 
actively rehydrated in the protean IEF cell (Bio-Rad) at 50 V for 18 h. The isoelectric 
focusing was performed in increasing voltages as follows; 300 V for 1 h, then linear 
gradient to 8000 V for 5 h and finally 20 000 V/h. Strips were then stored at –80 °C until 
the 2nd dimension electrophoresis was to be preformed. 
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7.3.7.2 Second dimension electrophoresis 
For the second dimension, the IPG® Strips, pH 3–10, were equilibrated for 10 min 
in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium dodecyl sulfate 
(SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15 min in 
the same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient 
precast criterion Tris–HCl gels (8–16%), 13.3 x 8.7 cm (W x L) (Bio-Rad) were used to 
perform second dimension electrophoresis. Precision Protein™ Standards (Bio-Rad, CA) 
were run along with the sample at 200 V for 65 min. 
7.3.8 SYPRO ruby staining 
After the second dimension electrophoresis, the gels were incubated in fixing 
solution (7% acetic acid, 10% methanol) for 20 min and stained overnight at room 
temperature with 50ml SYPRO Ruby gel stain (Bio-Rad). The SYPRO ruby gel stain was 
then removed and gels stored in DI water. 
7.3.9 Western Blotting 
Mitochondrial proteins (200 µg) incubated with 20mM DNPH were used for 
western blotting. The strips and gels were run as described (Sections 7.3.7.1 and 7.3.7.2) 
above. After the second dimension, the proteins from the gels were transferred onto 
nitrocellulose papers (Bio-Rad) using the Transblot-Blot® SD semi-Dry Transfer Cell 
(Bio-Rad), at 15 V for 4 h. The 2,4-dinitrophenyl hydrazone (DNP) adduct of the 
carbonyls of the proteins was detected on the nitrocellulose paper using a primary rabbit 
antibody (Chemicon, CA) specific for DNP-protein adducts (1:100), and then a 
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secondary goat anti-rabbit IgG (Sigma, MO) antibody was applied. The resulting stain 
was developed by application of Sigma-Fast (BCIP/NBT) tablets. 
7.3.10 Image analysis 
The nitrocellulose blots (oxyblots) were scanned and saved in TIFF format using 
Scanjet 3300C (Hewlett Packard, CA). SYPRO ruby-stained gel images were obtained 
using a STORM phosphoimager (Ex. 470 nm, Em. 618 nm, Molecular Dynamics, 
Sunnyvale, CA, USA) and also saved in TIFF format. PD-Quest (Bio-Rad) imaging 
software was then used to normalize the gels and blots using the total spot density option, 
match and analyze visualized protein spots among differential 2D gels and 2D oxyblots, 
with one blot and one gel for each individual sample. The spot intensity of the gel 
corresponded to the protein levels, while the spot intensity if the blot corresponded to the 
carbonyl levels. 
7.3.11 In-gel trypsin digestion 
Samples were digested by trypsin using protocols previously described and 
modified by (Thongboonkerd et al., 2002). Briefly, spots of interest were excised using a 
clean blade and placed in Eppendorf tubes, which were then washed with 0.1 M 
ammonium bicarbonate (NH4HCO3) at room temperature for 15 min. Acetonitrile was 
then added to the gel pieces and incubated at room temperature for 15 min. This solvent 
mixture was then removed and gel pieces dried. The protein spots were then incubated 
with 20 µL of 20 mM DTT in 0.1 M NH4HCO3 at 56 °C for 45 min. The DTT solution 
was removed and replaced with 20 µl of 55 mM iodoacetamide in 0.1 M NH4HCO3. The 
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solution was then incubated at room temperature for 30 min. The iodoacetamide was 
removed and replaced with 0.2 mL of 50 mM NH4HCO3 and incubated at room 
temperature for 15 min. Acetonitrile (200 µL) was added. After 15 min incubation, the 
solvent was removed, and the gel spots were dried in a flow hood for 30 min. The gel 
pieces were rehydrated with 20 ng/µL-modified trypsin (Promega, Madison, WI) in 
50 mM NH4HCO3 with the minimal volume enough to cover the gel pieces. The gel 
pieces were incubated overnight at 37 °C in a shaking incubator. 
7.3.12 Mass spectrometry 
A MALDI-TOF mass spectrometer in the reflectron mode was used to generate 
peptide mass fingerprints. Peptides resulting from in-gel digestion with trypsin were 
analyzed on a 384 position, 600 µm AnchorChipTM Target (Bruker Daltonics, Bremen, 
Germany) and prepared according to AnchorChip recommendations (AnchorChip 
Technology, Rev. 2, Bruker Daltonics, Bremen, Germany).  Briefly, 1 µL of digestate 
was mixed with 1 µL of alpha-cyano-4-hydroxycinnamic acid (0.3 mg/mL in ethanol: 
acetone, 2:1 ratio) directly on the target and allowed to dry at room temperature. The 
sample spot was washed with 1 µL of a 1% TFA solution for approximately 60 seconds.  
The TFA droplet was gently blown off the sample spot with compressed air.  The 
resulting diffuse sample spot was recrystallized (refocused) using 1 µL of a solution of 
ethanol: acetone: 0. 1 % TFA (6:3:1 ratio).  Reported spectra are a summation of 100 
laser shots.  External calibration of the mass axis was used for acquisition and internal 
calibration using either trypsin autolysis ions or matrix clusters and was applied post 
acquisition for accurate mass determination.  
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7.3.13 Analysis of peptide sequences 
 
Peptide mass fingerprinting was used to identify proteins from tryptic peptide 
fragments by utilizing the MASCOT search engine based on the entire NCBI and 
SwissProt protein databases. Database searches were conducted allowing for up to one 
missed trypsin cleavage and using the assumption that the peptides were monoisotopic, 
oxidized at methionine residues, and carbamidomethylated at cysteine residues. Mass 
tolerance of 150 ppm, 0.1 Da peptide tolerance and 0.2 Da fragmentation tolerance was 
the window of error allowed for matching the peptide mass values. Probability-based 
MOWSE scores were estimated by comparison of search results against estimated 
random match population and were reported as -10*log10 (p), where p is the probability 
that the identification of the protein is a random event. MOWSE scores greater than 63 
were considered to be significant (P < 0.05). All protein identifications were in the 
expected size and isoelectric point (pI) range based on the position in the gel. 
7.3.14 Immunoprecipitation  
Immunoprecipitation of specific proteins was performed as previously described 
(Sultana and Butterfield, 2004). Mitochondria samples (200 µg) from control or injured 
animals were incubated overnight at 4 oC with respective antibodies of identified 
proteins. The antibody–antigen complexes were collected with protein A/G–Sepharose-
conjugated beads. This was followed by three washing steps with buffer B (50Mm Tris 
Hcl (pH-8.0), 150 Mm NaCl, and 1% NP40). The proteins were resolved by SDS-PAGE 
followed by immunoblotting on a nitrocellulose membrane (BioRad). The proteins were 
then detected with alkaline phosphate labeled secondary antibody (Sigma).  
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7.3.15 Statistical analysis 
Statistical analysis of specific protein carbonyl levels matched with anti-DNP-
positive spots on 2D-oxyblots from mitochondria from the ipsilateral cortex (IC) and 
hippocampus (IH) with contralateral cortex (CC) and hippocampus (CH), was carried out 
using Student's t-tests. That is, each animal served as its own control, the contralateral 
side being the control for the ipsilateral side. A value of p < 0.05 was considered 
statistically significant. Only proteins that are considered significantly different by 
Student's t-test were subjected to in-gel trypsin digestion and subsequent proteomic 
analysis. This is the normal procedure for proteomics studies, sophisticated statistical 
analysis used for micro array studies are not applicable for proteomics studies.(Maurer et 
al., 2005) 
 
7.3.16 Protein Interacteome 
  The functional protein interacteome was obtained by using Interaction Explorer 
TM Software Pathway Assist software package (Stratagene, La Jolla, CA). Pathway Assist 
is software for functional interaction analysis. It allows for the identification and 
visualization of pathways, gene regulation networks and protein interaction maps 
(Donninger et al., 2004). The proteins are first imported as the gene symbols as a set of 
data. This data set is then searched against ResNet, a database containing over 500,000 
biological interactions built by applying the MedScan text-mining algorithms to all 
PubMed abstracts. These interactions are then visualized by building interaction networks 
with shortest-path algorithms. This process can graphically identify all known interaction 
among the proteins. The information of the function of these proteins and their relevance 
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to diseases are then obtained by using the BIOBASE's Proteome BioKnowledge Library 
form Incyte Corporation (Incyte, Wilmington, DE) (Hodges et al., 2002). 
 
7.3.17 Complex I assay: 
Complex I activity was measured in isolated mitochondria as the rotenone-
sensitive decrease in NADH absorption at 340 nm with ubiquinone-1 as the final 
acceptor, as previously described (Sriram et al., 1998) with some slight modifications 
(Sullivan et al., 2004b). Briefly, mitochondria were freeze-thawed and sonicated three 
times and diluted 1 µg/µl in 10 mM KPO4 buffer. The assay was performed in 25 mM 
KPO4 buffer (pH 7.2) containing mitochondrial protein (6 µg), 5 mM MgCl2, 1 mM 
KCN, 1 mg/ml BSA, and 150 µM NADH. The reaction was preincubated for 2 minutes 
at 30°C, the baseline established, and the reaction initiated by addition of coenzyme Q-1 
(50 µM). The activity was measured by monitoring NADH fluorescence (340 nm 
excitation, > 450 nm emission) over time under the same conditions as described above. 
The assay was also performed in the presence of rotenone (10 µM) to determine the 
rotenone-insensitive activity and the rotenone-sensitive complex I enzyme activity 
calculated by subtracting the rotenone-insensitive activity from the total activity. All the 
assay protocol for a 96-well plate performed with BioTek Synergy HT plate reader 
(Winooski, VT, USA). 
 
7.3.18 Pyruvate Dehydrogenase complex (PDHC) assay: 
 
PDHC activity was measured with previously protocol previously described 
(Starkov et al., 2004) with slight modification using increment in fluorescence 
measurement of NADH with BioTek Synergy HT plate reader (Winooski, VT, USA). 
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Briefly, mitochondria were freeze thawed and sonicated for 3 cycles. About 8 µg of 
double ficoll gradient purified mitochondrial protein were added into the buffer 
containing final concentration of 50mM KCl, 10mM HEPES pH 7.4, 0.3mM thiamine 
pyrophosphate (TPP), 10µM CaCl2, 0.2mM MgCl2, 5mM pyruvate, 1 µM rotenone and 
0.2mM NAD+. Reaction started by addition of 0.14mM CoASH and assay was performed 
at Exλ 340 nm/ Emλ 460nm and increase in fluorescence was observed at 1 min interval at 
300C. The PDHC activity calculated and expressed as nmol/mg protein. 
 
7.3.19 Complex IV assay:  
Cytochrome C Oxidase (Complex IV) of mitochondrial electron transport chain 
component activity was as previously described (Wharton and Tzagoloff, 1967) with 
slight modification using  BioTek Synergy HT plate reader (Winooski, VT, USA). 
Briefly, mitochondria were freeze thawed and sonicated for 3 cycles. About 8 µg of 
double ficoll gradient purified mitochondrial protein were added into the 10mM KPO4 
buffer pH 8.0, 50µM reduced cytochrome c and the decrease in absorbance was observed 
with difference with and without addition of Cytochrome C at 1 min interval at 370C at 
550nm. First the rate constant k was calculated for oxidation reaction of ferricytochrome 
c calculated and the specific activity were expressed as (k/mg protein) for cytochrome c 
oxidase.  
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7.4 Results 
7.4.1 Reduction in mitochondrial bioenergetics following TBI. 
 
Mitochondrial bioenergetics was measured following TBI. As illustrated in Figure 
7.1, mitochondria isolated 3h post injury from the ipsilateral cortex of TBI animals show 
a reduction in the rate of respiration in the presence of ADP (state III) or FCCP (state V) 
compared to mitochondria isolated from contralateral cortex or sham-operated animals. 
Mitochondria from TBI animals demonstrated a significant reduction in state III 
respiration and a significant loss in the electron transport chain (ETC) capacity, as 
measured by the rate of respiration in the presence of the uncoupler FCCP (state V; in 
excess) when driven by the complex-I substrates pyruvate/malate or the complex-II 
substrate succinate (Figure 7.1B).  As demonstrated in Figure 7.1 C, there was also a 
significant decline in the respiratory control ratio (RCR) in the mitochondria isolated 
from the ipsilateral cortex compared to those from the contralateral and sham operated 
animals. No difference in respiration rates were observed between contralateral 
mitochondria or mitochondria isolated from sham-operated animals (Figure 7.1B).  It is 
also apparent that the loss bioenergetics was not due to a disruption in the inner 
membrane since states II and IV (absence of ADP) are not significantly altered, 
indicating that a loss of ADP phosphorylation and ETS activity was the underlying cause.                  
7.4.2 Increase in oxidative stress levels from mitochondria isolated after TBI 
 
To determine if the cause of this loss of ETS activity and bioenergetics could be 
related to oxidative damage to the mitochondrial proteins, the level of protein carbonyls, 
3NT and HNE as indicators of oxidative stress were measured in mitochondrial proteins 
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isolated from the cortex and hippocampus of TBI animals. Fig.7.2 shows that, following 
TBI, there is a significant increase in the levels of 3NT, HNE and protein carbonyls 
measured from mitochondria isolated from the ipsilateral hippocampus (IH) compared to 
the contralateral (CH) hippocampus. Fig.7.3 shows that the levels of 3NT, HNE and 
protein carbonyl from the cortical IC vs. CC were increased, but these changes were not 
significant. Together, these results extend previous findings of an increase protein and 
lipid oxidation following TBI (Braughler and Hall, 1992; Sullivan et al., 1998a; Sullivan 
et al., 1999; Sullivan et al., 2000; Lifshitz et al., 2004b).  
7.4.3 Mass spectrometry analysis of mitochondrial proteins from the hippocampus 
and cortex. 
 
Mass spectrometry analysis and data base searches allowed for the identification 
of these protein spots from the cortex (Table 7.1) and hippocampus (Table 7.2). From the 
cortex, the following mitochondrial proteins were identified as being oxidatively 
modified in TBI: pyruvate dehydrogenase, voltage dependent anion channel-2 (VDAC-
2), fumarate hydratase 1, ATP synthase H+ transporting F1 alpha subunit, all of which are 
proteins involved in ATP production, transport or the activity of the ETS, and prohibitin. 
From the hippocampus, cytochrome C oxidase Va, Isovaleryl coenzyme A 
dehydrogenase, enolase-1 and glyceraldehyde-3-phosphate dehydrogenase were 
identified as being oxidatively modified in TBI. As can be seen in tables 7.1 and 7.2, the 
probability of a random identification is exceedingly low.  
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7.4.4 Redox proteomics identification of mitochondrial proteins from the 
hippocampus and cortex following TBI   
 
Proteomics has previously been used to identify brain proteins that have 
undergone oxidative modifications in different human diseases and models thereof 
(Butterfield et al., 2003; Butterfield and Castegna, 2003a; Butterfield, 2004; Butterfield 
and Boyd-Kimball, 2004b). Here, we used a similar approach, with slight modifications, 
to identify oxidized mitochondrial proteins following TBI. Protein oxidation levels in the 
mitochondria isolated from the cortex and hippocampus were measured by identifying 
carbonylated proteins using anti-DNPH immunochemical detection of 2D-oxyblots from 
the cortex (Fig 7.4) and hippocampus (Fig 7.5). Using PD-Quest (Bio-Rad) imaging 
software, protein spots were matched between 2D-PAGE maps and the 2D-oxyblots. The 
immunoreactivity of each spot was normalized using total spot density option to the 
protein content in the 2D-PAGE. Only protein spots that showed a significant increase in 
protein carbonylation in the ipsilateral side compared to the contralateral side were 
excised from the gels and subjected to in-gel trypsin digestion. Tables 7.3 and 7.4 provide 
a summary of the levels of oxidation for individual proteins.  
7.4.5 Validation of identified protein spots 
 
Prior experience from our laboratory has demonstrated validation of each 
proteomic-identified protein by immunochemical means with no exceptions.  In this 
study, VDAC-2 was probed with anti-VDAC antibody. Figure 7.6 shows validation of 
VDAC-2 through western blot analysis Figure 7.6 (b) and immunoprecipitation Figure 
7.6(c). Thus, we are confident that the protein identifications reported are correct.  
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7.4.6 Decreased Complex I, Complex IV and PDH activities following TBI 
 
The activities of complex I, complex IV and pyruvate dehydrogenase (PDH) were 
measured following 3 h post TBI. As shown in Figure 7.7 (a) and 7.7 (b), there is a 
significant decline in the activities of complex I and complex IV respectively, from the 
mitochondria isolated from ipsilateral cortex compared to those isolated from 
contralateral cortex. Figure 7.7 (c) on the other hand, illustrates the enzymatic activity of 
PDH. As shown, there was a decline in the activities of PDH following TBI from 
mitochondria isolated from the ipsilateral cortex compared to mitochondria isolated from 
the contralateral cortex; however this decline in activity was not significant. These results 
confirm our previous findings showing that the loss in mitochondrial bioenergetics 
observed is most likely due to a decline in the activities of the ETC complexes.  
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Figure 7.1 
 
 
Figure 7.1 Traumatic brain injury (TBI) significantly impairs mitochondrial 
bioenergetics.  As illustrated in panel A, TBI results in a loss of mitochondrial function 
demonstrated by reduction in oxygen consumption.  Animals were injured (1.5 mm) and 
mitochondria isolated 3 hrs post-injury from the ipsilateral or contralateral cortex as well 
as sham-operated animals.  Respiration rates were quantified and expressed as nmols 
O2/min/mg consumed under various experimental conditions (panel B).  TBI significantly 
reduced mitochondrial oxygen consumption in the presence of ADP (state III), indicating 
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a reduction in the ability to phosphorylate ADP.  Significant differences were also 
apparent when the mitochondrial electron transport system (ETS) was uncoupled (excess 
FCCP) from the ATP synthase, a measure of maximum ETS capacity.  This loss in ETS 
capacity was demonstrated when the ETS was driven via NADH-linked, complex-I 
substrates (pyruvate/malate; P/M) or the FADH-linked, complex-II, substrate (succinate; 
Succ).  Panel C demonstrate the reduction in RCR ratio in mitochondria isolated from the 
ispi lateral relative to those isolated from sham and contralateral. Bars are group means, 
SEM. *p < 0.05 using a Neuman-Keuls post hoc. 
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Figure 7.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2 Protein carbonyls, 3NT and HNE levels of hippocampal mitochondria. There 
was a significant increase in the levels of all parameters measured from the contralateral 
and ipsilateral regions (CH vs. IH) of rats that had undergone TBI. Data are represented 
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as % control; error bars indicate the SEM for animals in each group. Measured values are 
normalized to the CC values (n=5) * p <0.05. 
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Figure 7.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3 Protein carbonyls, 3NT and HNE levels of cortical mitochondria. There was 
an increase in the levels of all parameters measured from the contralateral and ipsilateral 
regions (CC vs. IC) of rats that had undergone TBI, but these levels were not significant. 
Data are represented as % control; error bars indicate the SEM for animals in each group. 
Measured values are normalized to the CC values. 
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Figure 7.4 
 
 
 
 
 
 
 
 
 
 
Figure 7.4 2D-oxyblots of cortical mitochondrial samples CC vs. IC. Proteins identified 
by mass spectrometry are presented as the boxed spots. 
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Figure 7.5 
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Figure 7.5 2D-oxyblots of hippocampal mitochondrial samples CH vs. IH. Proteins 
identified by mass spectrometry are presented as the boxed spots 
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Figure 7.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.6 Validation of protein identified by MS. (a) Cortex mitochondria gel showing 
position of VDAC (b) blots probed with anti VDAC antibody (c) shows gel of cortex 
mitochondria immunoprecipitated with anti-VDAC antibody. 
 
 
 
(a) 
(b) 
(c) 
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Figure 7.7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7 Shows the activity of Complex I (a), Complex IV (b) and Pyruvate 
dehydrogenase (PDH) (c) as a percentage of sham. There was a significant 
decline in the activities of Complex IV following TBI in the IC compared to 
the CC. There was also a reduction in the activities of complex I and the 
activity of PDH though not significant. 
*
(b) 
(c) 
(a) 
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7.5 Discussion 
 
The present study demonstrates that following TBI, critical mitochondrial fraction 
proteins from the cortex and hippocampus involved in energy metabolism are susceptible 
to oxidative damage, and hence inactivation. We demonstrate that these proteins are 
significantly and rapidly oxidized, presenting a possible mechanism for the decreased 
mitochondrial bioenergetics as seen particularly in the cortical mitochondria following 
TBI. Following TBI, there is an increase in the production of ROS (Braughler and Hall, 
1992; Sullivan et al., 1998a; Sullivan et al., 1999; Sullivan et al., 2000; Lewen et al., 
2001; Lifshitz et al., 2004b), which has been established to contribute to 
neuropathological events observed following TBI and other brain injury models (Sullivan 
et al., 1998b; Sullivan et al., 2002; Fiskum et al., 2003; Martin et al., 2005; Sullivan et al., 
2005). In addition to increase in ROS, there is reduced mitochondrial bioenergetics 
following experimental TBI. This loss in the capacity of the ETC to consume oxygen has 
been shown to be an etiology observed in most CNS injuries (Lifshitz et al., 2004b; 
Sullivan et al., 2005). The present study extends these findings to show elevated 
oxidative stress levels following TBI and is the first to report the identification of specific 
mitochondrial-related proteins that are significantly oxidized following TBI and 
following this modification there is decreased activity of key enzymes and ETC 
complexes. The implications for the identification of these proteins are discussed below.  
Pyruvate dehydrogenase (PDH) is a mitochondrial multienzyme complex composed of 
pyruvate dehydrogenase (E1), a dihydrolipoamide S-acetyltransferase (E2) and 
dihydrolipoamide dehydrogenase (E3). It catalyses the irreversible conversion of 
pyruvate, NAD+ and CoA to acetyl CoA, NADH and CO2 making it the central link 
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between glycolysis and TCA cycle (Zaidan et al., 1998; Martin et al., 2005). The activity 
of PDH is usually regulated through events of continuous phosphorylation (inactivation) 
and dephosphorylation (activation) by the enzymes pyruvate dehydrogenase kinases and 
phosphatases respectively (Holness and Sugden, 2003). Inactivation of PDH or its 
deficiency has been reported in several studies of models of ischemia-reperfusion and 
human diseases (De Meirleir et al., 1993; Zaidan et al., 1998; Hard et al., 2001). Leading 
to metabolic failure, secondary lactic acidosis (Hard et al., 2001), increase in ROS 
production (oxidative stress) leading to cellular damage and death (Bogaert et al., 2000). 
Following canine cardiac arrest and resuscitation, it has been reported that there is a 
selective loss of PDH activity in different neuronal subclasses (Bogaert et al., 2000), 
short-term forebrain ischemia in rats, causes a partial inactivation of PDH activity 
(Zaidan et al., 1998) and low levels of PDH have been associated with various 
neurodegenerative disorders such as Alzheimer’s disease (Sheu et al., 1985), 
Huntington’s disease (Sorbi et al., 1983), Wernicke-korsakoffsyndrome (Lavoie and 
Butterworth, 1995) and other hereditary ataxias (Sheu et al., 1989).  
One mechanism for inactivation of PDH has been hypothesized to be the 
oxidative modification of the enzyme, involving possible site-specific protein oxidation 
of critical sulfhydryl groups (Tabatabaie et al., 1996). Or possibly due to metal-catalyzed 
oxidation of susceptible amino acids (Bogaert et al., 1994). The activity of PDH in 
different models of TBI has been extensively studied. In a recent micro array study of 
gene expression in the hippocampus following experimental TBI,  PDH E1 α-subunit 
gene was found to be down regulated after moderate injury but unregulated in severe 
injury (Li et al., 2004). A study of rat hippocampus after chronic antidepressant 
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treatment, showed that PDH EI complex had undergone modulation (Khawaja et al., 
2004). While in another proteomic study of an animal model for schizophrenia, protein 
levels of PDH complex E2 were found to be decreased (Paulson et al., 2003; Paulson et 
al., 2004). These studies provide evidence that different subunits of the PDH complex are 
susceptible to modulation during conditions of oxidative stress, and as had been 
established, inactivation of one subunit of the complex renders the whole enzyme 
complex inactive (Zaidan et al., 1998). 
In the present proteomic study we found PDH lipoamide beta complex to be 
significantly oxidized following TBI.  In addition, we have also shown that following 
experimental TBI the activity of PDH is also decreased though not significantly. As a 
consequence of these events, the activity of complex I was also found to be decreased, 
this would therefore disrupt the supply of NADH, a required substrate for complex I, 
contributing to the NADH-linked impairment of mitochondrial bioenergetics as seen in 
Fig. 7.1.  
Voltage dependent anion channel-2 (VDAC) are pore-forming proteins (porins) 
found in the outer mitochondrial membrane of all eukayotes (Yoo et al., 2001). VDAC in 
conjunction with adenine nucleotide translocator (ANT), mediate the exchange of 
adenine nucleotides between the cytosol and the matrix (Vander Heiden et al., 2000). 
VDAC has also been known to form part of a mega pore known as the mitochondrial 
permeability transition pore mPTP, which mediates the release of cytochrome c from the 
mitochondria to the cytosol in early events of apoptosis leading to activation of the 
caspase cascade (Sullivan et al., 2002). VDAC has also been found to interact with Bcl-2 
family of proteins regulating mitochondrial potential and release of cytochrome c 
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(Vander Heiden et al., 2001). Pro-apoptotic proteins Bax and Bid have been shown to 
accelerate the opening of the pore while anti-apoptotic protein BcL-2 binds directly to 
VDAC hence closing it (Yoo et al., 2001). 
Impairment in ATP-ADP exchange by the closure of VDAC inhibits the activity 
of F1F0-ATPase. This leads to the inhibition of proton H+ re-entry, hyperpolarization of 
the inner mitochondrial membrane, which promotes osmotic matrix swelling, rupturing 
the outer membrane releasing cytochrome c and activation of the caspase cascade. In a 
recent report (Liberatori et al., 2004), VDAC proteins were found to be involved in the 
loss of mitochondrial potential and neurodegeneration during ischemia reperfusion. In 
patients with AD and Downs syndrome, the expression of VDAC proteins has been found 
to be significantly reduced (Yoo et al., 2001). Other than its role in being part of mega 
pore mPTP, the activity of VDAC in brain injury models has not been extensively 
studied, the only reports provided confirm the presence of VDAC as part of the that is 
involved in release of cytochrome c. 
In the present study, we show for the first time that VDAC-2 is significantly 
oxidized following TBI. The oxidation of VDAC posses a number of possible 
consequences. The conformational changes of the porin after oxidation could leave the 
channel in an open state; this could lead to entry of solutes into the mitochondria leading 
to swelling and eventual rupture of the outer mitochondrial membrane and release of 
cytochrome c. The conformational change might also leave VDAC in a closed state, 
preventing the exchange of ATP-ADP leading to hyperpolarization and activation of 
caspase cascade and eventual cell death. As a result oxidation of VDAC after TBI can be 
one of the causes for injury induced cell death following TBI.  
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ATP synthase (Complex V) is a multicatalytic subunit enzyme made up of two 
portions, the F0, an integral membrane complex responsible for translocation of protons 
and the larger extra membrane complex, FI, which is composed of five subunits (α3β3γδε) 
(Kanski et al., 2005). ATP synthase uses the electrochemical proton gradient established 
across the mitochondria membrane during respiration for the synthesis of ATP from ADP 
and inorganic phosphate Pi (Leyva et al., 2003). The mechanism of ATP synthesis 
involves sequences of coordinated conformational changes of the α and β subunits.  
Human diseases associated with a deficiency in ATP synthase show that there is 
no complete loss but a partial loss of the ATP synthase enzyme activity. This deficiency 
results from mutations in MTATP6, a mitochondrial encoded component (De Meirleir et 
al., 2004). ATP synthase deficiency has been associated with and increase in oxidative 
stress as seen in Parkinson’ disease (Basso et al., 2004). Our laboratory has shown that 
ATP synthase is significantly oxidized in gracile axonal dystrophy (gad) mouse 
(Castegna et al., 2004). ATP synthase has also been found to be a target for cysteine 
oxidation of proteins during renal oxidative stress (Eaton et al., 2003). A study of rat 
cardiac proteins, recently identified ATP synthase as one of the proteins significantly 
nitrated as a function of age (Kanski et al., 2005). In a proteomic study after an 
inflammatory challenge, ATP synthase was again identified as one of the proteins that’s 
was significantly nitrated (Aulak et al., 2001). A proteomic study of Muscles of A 
Diabetes Model Otsuka Long-Evans Tokushima Fatty (OLETF) rat (Oh-Ishi et al., 2003) 
found ATP synthase to be significantly oxidized. These studies have shown that ATP 
synthase is susceptible to oxidation and hence inactivation under conditions of oxidative 
stress.  
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In the present study, we identified ATP synthase as one of the mitochondrial 
proteins that were significantly oxidized following TBI. The oxidation of this subunit will 
as a result inhibit the activity of this enzyme compromising a crucial cellular process of 
ATP generation after brain injury eventually leading to neuronal cell death. 
Cytochrome C Oxidase Va (COX) is also known as Complex IV. This is the 
terminal enzyme complex of the electron transport chain (ETC). It transfers reducing 
equivalents from cytochrome c to oxygen that is then reduced to water (Harris et al., 
2001). COX is composed of 13 subunits. Three subunits form the catalytic core of the 
enzyme and are encoded by the mtDNA, while the rest are nuclear encoded and are 
involved in the assembly and regulation of the enzyme (Mootha et al., 2003). Human 
COX deficiency results into a condition known as Leigh syndrome, French-Canadian 
type (LSFC). It is characterized by a subacute neurodegeneration of the brainstem and 
basal ganglia and recurrent episodes of acute and often fatal metabolic acidosis and coma 
(Mootha et al., 2003). 
 The activity of COX has been shown to be reduced in drosophila, as an effect of 
oxidative stress and age (Schwarze et al., 1998). A recent review found a possible role for 
COX in stress induced apoptosis and degenerative diseases (Kadenbach et al., 2004). In 
Alzheimer’s disease, various studies have shown an impairment of cytochrome c oxidase 
activity and depletion of ATP (Kim et al., 2000c). The activity of COX in various models 
of brain injury has also been extensively established. In one study, it was shown that 
following TBI there is a reduction of gene expression and activity of COX (Harris et al., 
2001). Earlier fluid percussion injury studies of concussive brain injury in rats, found that 
after concussion, the cerebral cortex ipsilateral to the site of injury showed a decrease in 
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the activity of COX, this began as soon as one day and lasting for up to 10 days after the 
injury. The ipsilateral dorsal hippocampus also showed a decrease in COX activity, but 
not as severe as in the cortex (Hovda et al., 1991). COX activity in injured animals 24 h 
following an ablation of rat sensorimotor cortex was found to be significantly reduced 
throughout the cerebral cortex and particularly at the hemisphere ipsilateral to the 
ablation (Sutton et al., 2000). The above studies among others have provided evidence for 
the reduction in activity of COX after brain injury. These studies have though come short 
at presenting mechanisms that ensue in the inactivation of this enzyme. In the present 
study, we identify a subunit of COX as one of the proteins that was significantly oxidized 
following TBI, and as was discussed, oxidation of a single subunit could render the whole 
enzyme inactive. COX is the terminal complex of the ETC and as we have seen, it is a 
key site in the regulation of energy metabolism. Its oxidation would therefore lead to a 
reduction in the membrane potential; a compromise in ATP production and the 
generation of more ROS. This could in part be of the possible mechanisms of 
neurodegeneration observed after TBI. 
Prohibitin is an evolutionarily conserved protein with homologues from yeast to 
man. Its exact physiological function has been difficult to define. Despite this, it has been 
demonstrated that prohibitin is involved in many cellular processes, such as cell cycle 
regulation, senescence, transcription regulation and tumor suppression (Coates et al., 
2001). Recently, it has been established that PHB is located in the inner mitochondria 
membrane and that it acts as a chaperone in the assembly of subunits of mitochondrial 
respiratory chain complexes and stabilization of membrane proteins (Nijtmans et al., 
2000; Nijtmans et al., 2002). Impaired assembly of ATP synthase is associated with 
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neurological muscle weakness, ataxia and retinitis pigmentosa (NARP) syndrome, a 
possible role of disruption of PHB (Nijtmans et al., 2001). A disruption on the PHB genes 
has been shown to have a decreased replicative lifespan in yeast, due to a gradual decline 
in cellular metabolic capacity (Coates et al., 1997) and a larval arrest in fruit fly (Eveleth 
and Marsh, 1986). In higher organism therefore, disruption of PHB could possibly have 
greater metabolic effect. It should be noted however that its involvement in TBI is still 
speculative. 
It has recently been demonstrated that prohibitin can be induced by metabolic 
stress (Liu et al., 2004), its expression is increased in apoptotic cells and that it might 
play a role in regulation of the mitochondrial respiratory activity (Liu et al., 2004). These 
roles suggest that PHB is a critical mitochondrial protein required to maintain normal 
mitochondrial homeostasis. In the present study, we identified prohibitin as one of the 
proteins that were significantly oxidized following TBI. Oxidation of prohibitin may 
disrupt its functions of the assembly of ETC, leading to a breakdown in energy 
metabolism.  
Isovaleryl Coenzyme A dehydrogenase (IVD). This is a nucleus-encoded, 
homotetrameric mitochondrial flavoprotein, which is found in the third step of the leucine 
catabolism pathway. It is a member of the acyl-CoA dehydrogenase (ACD) family of 
enzymes, all of which employ a similar enzyme mechanism for the α, β-dehydrogenation 
of acyl-CoA substrates (Mohsen et al., 2001). IVD catalyzes the conversion isovaleryl-
CoA to 3-methylcrotonyl-CoA and transfers electrons to the electron-transferring 
flavoprotein (ETF). A specific ETF dehydrogenase then shifts the electrons to coenzyme 
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Q in the electron-transport chain for ATP synthesis (Mohsen et al., 1998; Volchenboum 
and Vockley, 2000).  
   A common disorder associated with a deficiency of this enzyme is Isovaleric 
academia (Mohsen et al., 1998). Isovaleric acidemia is a rare inborn error of metabolism 
caused by a deficiency of isovaleryl-CoA dehydrogenase (IVD). The activity of IVD has 
been extensively studied in both humans and plant physiology (Daschner et al., 1999; 
Daschner et al., 2001) but no study has reported its role in TBI or any other brain injury 
models. 
IVD was one of the mitochondrial proteins that were found to be significantly 
oxidized following TBI. We report here for the first time its involvement in brain injury. 
It is possible that following TBI there is a reduced amount of ATP being generated from 
the ETC, leading to the dependence on other pathways for the supply of substrates for 
energy production. Here we see the possible involvement of the leucine catabolism 
pathway, which also gets inhibited due to the oxidation of IVD a key enzyme in this 
pathway. The oxidation of IVD following brain injury could as a result lead to a critical 
compromise of the total bioenergetics homeostasis and eventual cell death following TBI. 
 
Fumarate hydratase (FH) also known as fumarase is an enzyme of the 
Tricarboxylic Acid Cycle (TCA), which catalyzes the conversion of Fumarate to L-
malate. FH is also found in the glyoxylate and urea cycles (Pollard et al., 2003). The 
intracellular localization of this enzyme is not limited to the mitochondria, it can also be 
found in the cytosol as was found in rat liver, its function here is still unknown (Tuboi et 
al., 1990). A deficiency of this enzyme or mutations in the genes encoding this enzyme 
have been known to be the cause of Multiple cutaneous and uterine leiomyomata 
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MCUL1 (uterine fibroids), skin leiomyoma, and papillary type II renal cell cancer 
(Tomlinson et al., 2002).  Recent proteomic study on mitochondrial proteins in 
cardiomyocytes from chronic stressed rat, showed a decrease in expression of Fumarate 
hydratase-1 after chronic restrain stress and a decrease in energy metabolism (Liu et al., 
2004). 
 In the present study, we found Fumarate hydratase-1 as one of the key 
mitochondrial proteins that were significantly oxidized after TBI. The resulting 
consequence of this would be a breakdown of the TCA cycle and its inability to supply 
necessary substrates required for energy metabolism leading into an overall breakdown of 
bioenergetics and eventual cell death as observed in TBI. 
Enolase-1 and Glyceraldehyde-3-phosphate dehydrogenase GAPDH 
Enolase and GAPDH are glycolytic enzymes known to be located in the cytosol. 
Enolase interconverts 2-phosphoglycerate and phosphoenolpyruvate while GAPDH 
catalyzes the NAD+ dependent oxidation of glyceraldehyde-3-phosphate to 1,3-
bisphosphoglycerate and NADH in the second phase of glucose catabolism. GADPH has 
been typically known for its role in glycolysis but recent studies are now supporting the 
idea that it has diverse activities. Possible roles include regulation of the cytosol, 
membrane fusion and transport, accumulation of glutamate into presynaptic vesicles a, 
binding to low molecular weight G-protein and acting as a cellular sensor of oxidative 
stress. It is also thought that GADPH forms an integral part of apoptosis and may 
participate in neuronal death in some age related neurodegenerative diseases (Chuang et 
al., 2004). These emerging roles of GADPH raise questions on its cellular localization. 
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Enolase and GADPH are not typical mitochondrial proteins, but evidence has it 
that some glycolytic proteins can be localized in the mitochondria (Liaud et al., 2000; 
Taylor et al., 2003). A well-known glycolytic enzyme found in the mitochondria is 
hexokinase. Hexokinase has been found to be associated with the outer mitochondrial 
membrane where its activity has been implicated in regulation of ATP synthesis.  It has 
also been found to promote closure of VDAC and prevent apoptosis (Azoulay-Zohar et 
al., 2004). In a recent proteomic study of the human heart mitochondrial proteome, 
(Taylor et al., 2003) 4% of total proteins identified were found to be associated with 
glycolysis. In another study (Liaud et al., 2000), GADPH and TPI were shown to be 
imported to the mitochondria of diatom Phaeodactylum tricornutum as a GADPH-TPI 
fusion. Another plant mitochondrial proteomic study GADPH and enolase were among 
the glycolytic proteins identified from the mitochondria, this study was even able to show 
that these protein were attached to the outer membrane of the mitochondria (Giege et al., 
2003). 
 Taken together, the above studies continue to provide increasing evidence for the 
mitochondrial localization of glycolytic proteins. The purpose for this localization is not 
well known, but studies speculate that the whole glycolytic pathway could be associated 
with the OMM or IMS. This could be possible because most glycolytic enzymes have 
hydrophobic regions that could form membrane-spanning domains (Giege et al., 2003).  
This localization would be to provide pyruvate directly and at high concentrations where 
it can be taken up as substrate for respiration and ATP generation. When levels of ATP 
are reduced the mitochondria might initiate the interaction of glycolysis and the OMM to 
compensate for the reduction in energy production. 
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 There is increasing evidence that GADPH and enolase –dependent pathways are 
being associated with different pathologies that involve oxidative stress. Our lab has 
previously identified α-enolase, as one of the enzymes one that was significantly oxidized 
in AD (Castegna et al., 2002a) and SAMP8 mice (Poon et al., 2004d). Our lab has also 
identified GAPDH as one of the proteins found to be significantly oxidized by Aβ(1–
42)(Boyd-Kimball et al., 2005b). In recent proteomics study of Staphylococcus aureus 
(Weber et al., 2004), it was shown that oxidative stress triggers thiol oxidation of 
GADPH consistent with previous reports of the oxidation of glycolytic enzymes . 
Recently enolase was also found to be oxidatively modified in rat skeletal muscle 
(Kanski et al., 2005), this same study also identified GADPH as a target for protein 
nitration another example of protein oxidation.  
 In the present study we identified two glycolytic proteins enolase and GADPH 
from a mitochondrial preparation, as “mitochondrial” proteins that had been significantly 
oxidized following TBI. Oxidation of these proteins will most probably inactivate these 
enzymes hence inhibiting their glycolytic functions, reducing the amount of pyruvate 
supplied to the TCA leading to a reduction in ATP production and eventual cell death. 
Following TBI, alterations in excitatory amino acids, increased ROS and 
disruption of Ca2+ homeostasis have been found to contribute to the cellular damage and 
eventual neurological dysfunction. The sequel of events that ensue following TBI have 
though not been well understood though the mechanism of this neurodegeneration is 
believed to be mediated in part by the mitochondria via an oxidative stress pathway. 
Mitochondrial bioenergetics plays a critical role in the normal physiology of cells. With a 
loss in the respiration capacity of the ETC and production of ROS after TBI (Sullivan et 
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al., 2005), it has been hypothesized that various mitochondrial proteins could be 
oxidatively modified and inactivated (Bogaert et al., 2000; Fiskum et al., 2004; Martin et 
al., 2005). This proteomics study is the first to provided new insights into the 
mechanisms of oxidative cellular damage after TBI.  
 We have demonstrated that following TBI and isolation of total mitochondria, 
key components of the ETC are oxidatively modified. Specifically, we have shown that 
the activities of PDH, complex I, and complex IV are reduced following TBI. This 
continues to support the notion that oxidative modification of proteins tends to lead to 
their inactivation. Additionally, we also have identified other proteins associated with 
energy metabolism that are significantly oxidized following TBI, which interact directly 
or indirectly with cellular bioenergetics pathways. The Stratagene software to determine 
the “interacteome” of the proteomics identified oxidatively modified proteins following 
TBI was determined. The oxidation of these identified proteins are of significant 
importance, due to their involvement with the ETS and/or apoptotic pathways, as well as 
their roles in the maturation and assembly process of key mitochondrial proteins. The 
identification of these oxidatively modified proteins present the first causal evidence for 
the significant loss of mitochondrial function that has been demonstrated to occur after 
TBI (Figure 7.1). They may also provide new insights into the mechanism of cellular 
damage after TBI and also provide novel targets for potential therapeutic interventions in 
this significant health problem. A summary of our working hypothesis involving 
oxidative damage to mitochondrial-related proteins is provided in Fig 7.8 below. 
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          Figure 7.8 Summary of mechanisms that ensue following experimental TBI  
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CHAPTER EIGHT 
Conclusions and Future Studies 
8.1 Conclusions 
The work presented in this dissertation examined the mechanisms of improved 
cognitive function following intervention with a diet rich in antioxidants and a program 
of behavioral enrichment in a canine model of human aging. Additionally, the 
mechanisms of successful aging were also investigated. Through a proteomic analysis, 
we also examined the role of oxidative stress in traumatic brain injury specifically 
looking at oxidatively modified mitochondrial proteins. 
Investigation on the role of an antioxidant fortified diet and a program of behavioral 
enrichment in the improvement of memory and cognitive function in the aging canine was 
examined. It was demonstrated that there was a significant decrease in the levels of oxidative 
stress as measured by protein carbonyls and 3NT in the parietal cortex of aged dogs that had a 
combination of these interventions (EA) compared to the other paradigms used, i.e., CC, EC and 
CA. Additionally, a proteomic analysis showed that there was a significant increase in the 
expression of Cu/Zn superoxide dismutase, fructose-bisphosphate aldolase C, creatine kinase, 
glutamate dehydrogenase and glyceraldehyde-3-phosphate dehydrogenase, proteins related to 
energy metabolism, antioxidant system and detoxification mechanisms. Further redox proteomic 
analysis identified glutamate dehydrogenase [NAD (P)], glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), α-enolase, neurofilament triplet L protein, glutathione S-transferase 
(GST) and fascin actin bundling protein, as proteins that were significantly less oxidized 
following an examination of the EA and CC treated canine. An examination of the enzymatic 
activity of some of these identified proteins determined that there was a significant increase in 
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the activities of glutathione-S-transferase (GST) and total superoxide dismutase (SOD following 
the EA treatment compared to control. A significant correlation was also obtained between the 
levels of protein expression, oxidative damage, antioxidant activity and the improvement in 
cognitive function. We conclude that the combination of an antioxidant fortified diet and a 
program of behavioral enrichment in the aging canines may be translated to humans, providing a 
possible intervention for those at risk for developing age-related neurodegenerative disorders, 
including Alzheimer’s disease. 
  The possible mechanisms involved in successful aging were explored. Frontal 
cortex samples from cognitively intact nonagenarian and those of demented 
nonagenarians were examined. Analysis of the level of oxidative stress in these groups of 
individual determined that there were no significant differences in protein oxidation as 
measured by the levels of protein carbonyls and lipid peroxidation as indexed by the 
levels of isoprostanes, neuroprostanes and HNE. However, proteomic analysis showed 
that there was a significant increase in the expression of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), ATP synthase H+ transporting, human peroxiredoxin 5 
(PRDX5) and malate dehydrogenase (MDH) in the brains of demented nonagenarians 
compared to the cognitively intact nonagenarians. On the other hand the protein levels of 
fructose bisphosphate aldolase (FBP1) and ubiquitin carboxyl-terminal hydrolase L1 
(UCHL1) were found to be increased in the cognitively intact nonagenarians compared to 
the demented age matched control. The consequence of this is still unknown; however, a 
recent study supports the role of UCHL-1 in normal synaptic and cognitive function. As a 
result, the increased differential expression of these proteins and in particular UCHL-1 
observed here may reflect the following, one, the proteosomal activity is elevated in 
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normal controls compared to AD brains, and two that synaptic function is well 
maintained leading to improvements and maintenance of cognitive function in the normal 
nonagenarians. In addition, using correlation analyses, we have shown that there is a 
general trend of association between protein expression levels and intact cognition. In 
particular, MMSE scores were significantly associated with MDH, i.e., higher MMSE 
scores (better cognition) was linked to lower MDH, which is consistent with overall 
lower levels of MDH in nondemented nonagenarians. We conclude that this increase in 
the expression of key proteins may play a key role in the mechanisms leading to 
successful aging. 
 Lastly, the role of oxidative stress in experimental traumatic brain injury (TBI) 
was examined. Analysis of the oxygen consumption capacity of these mitochondria 
revealed that there was a significant decline in the respiratory capacity of brain 
mitochondria isolated from the ipsilateral cortex (IP) compared to those isolated from the 
contralateral cortex (CC) 3 h following experimental TBI. There were no differences in 
the respiratory capacities between mitochondria isolated from sham-operated animals 
compared to those from the CC animals. This investigation demonstrated that there was a 
significant increase in the levels of oxidative stress in the brain mitochondria isolated 
from the IP compared to those isolated from the contralateral cortex CC of rat after 3h 
following controlled cortical impact injury.  We further explored the identity of key 
mitochondrial proteins that would have undergone possible oxidative modification 
following TBI from the cortex and hippocampus. We identified Cytochrome C Oxidase 
Va, Isovaleryl Coenzyme A Dehydrogenase, alpha enolase and Glyceraldehyde-3-
phosphate dehydrogenase from the hippocampus and Pyruvate dehydrogenase 
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(lipoamide), Voltage dependent anion channel (VDAC), Fumarate hydratase 1, ATP 
synthase H+ transporting and prohibitin from the cortex. Further examination of 
enzymatic activities demonstrated that there was a decline in the activities of pyruvate 
dehydrogenase and a significant decline in the activities of complex I and IV of the 
electron transport chain. We conclude that oxidative stress plays a significant role in the 
pathogenesis of TBI and it contributes to the oxidative modification of key 
mitochondrial-related proteins leading to a loss in mitochondrial bioenergetics and 
possible cell death. 
 Taken together, these studies continue to support the role of oxidative stress in 
neurodegenerative disorders and that intervention with antioxidant contribute to the 
maintenance of memory and cognitive function providing a possible avenue for the 
development of therapeutic interventions for oxidative stress mediated disorders and in 
particular to the aging population at risk for developing AD and those prone to CNS 
injury. 
 
 8.2 Future Studies 
Based on the findings in this dissertation, the following experiments may warrant further 
exploration: 
1.  Based on the findings of increased oxidative stress following TBI and also the 
significant oxidative modification of key mitochondrial-related proteins, an 
expressional proteomic analysis of brain proteins and/or plasma following TBI 
would provide further insight into on the disorder and possible development of 
potential biomarkers. 
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2.  Also since oxidative stress plays a key role in TBI, intervention with possible 
antioxidants or antioxidant related compounds such as brain soluble D609 and the 
identity of mitochondrial proteins protected should be further examined. 
3.  The findings of differentially expressed proteins in the cognitively intact 
nonagenarians though promising were not complete due to the limited number of 
subjects. With the increase in the number of subjects, this would provide further 
insight into the biochemical mechanisms that lead to successful aging. 
4.  Though there were no differences in the levels of oxidative stress between the 
cognitively intact nonagenarians and the demented controls, a redox proteomics 
analysis would be able to identify the redox status of key proteins hence providing 
additional insight into the successful aging process.  
5.  The availability of plasma extracted from the aging canines undergoing the 
combined therapy of antioxidant diet and a behavioral enrichment program is a 
unique resource that warrants further examination with a possibility of developing 
potential biomarkers for age-related disorders AND in particular AD. 
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Appendix A 
 
Nucleoside Reverse Transcriptase Inhibitor (NRTI) - 2', 3’-dideoxycytidine (ddC) 
Induce Oxidative Stress: Relevance to HIV Dementia 
  
A1. Overview  
 
  Human immunodeficiency virus dementia (HIVD) is the most common 
form of dementia occurring among young adults. In HIVD, neuronal cell loss occurs in 
the absence of neuronal infection. With the advent of highly active anti-retroviral therapy 
(HAART), the incidence of HIVD has drastically reduced, though prevalence of milder 
forms of HIVD continues to rise. Though these agents have been used successfully in 
suppressing viral production, they have also been associated with a number of side 
effects. Here, we examine the possible role of NRTI’s, in particular 2', 3’-
dideoxycytidine (ddC), in the neuropathology of HIVD. Synaptosomes and isolated 
mitochondria treated and incubated for 6 h with CSF-achievable concentrations of ddC, 
i.e., 6-11ng/ml, were found to show a significant increase in oxidative stress with 40 nM 
ddC as measured by protein carbonyls and 3-nitrotyrosine (3NT). Protection against 
protein oxidation induced by ddC was observed when mitochondria isolated from gerbil 
brain 1 h after injection i.p with the brain accessible antioxidant and glutathione mimetic 
tricyclodecan-9-yl-xanthogenate (D609). In addition, there is a significant reduction in 
the levels of anti-apoptotic protein Bcl-2 and a significant increase in cytochrome-c 
release and also a significant increase in the expression of pro-apoptotic protein caspase-3 
were observed after mitochondria were treated with 40 nM ddC. The results reported 
show that ddC at 40 nM can induce oxidative stress, cause the release of cytochrome c, 
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and in addition, reduce the levels of anti-apoptotic proteins leading to a induction of 
apoptosis. These findings provide evidence for a possible role of the NRTI’s, and in 
particular, ddC, in the mechanisms involved in HIVD. 
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A2. Introduction 
 
       Infection of the brain with HIV often results in a dementing disorder known as HIV-
dementia (HIVD), the most common form of dementia occurring in human populations 
of less than 60 years of age. This dementia is marked by loss in memory and impaired 
cognitive function, among other indices of dementia (Navia and Price, 1987). 
Pathologically, reactive astrocytosis, myelin pallor, infiltration by macrophages and 
multinucleated giant cells, among others, characterize HIVD (Nath et al., 998). Since the 
neuronal loss and dysfunction observed in HIVD occurs, though the virus rarely infects 
neurons (Mattson et al., 2005), the mechanism of this neurodegeneration is still not 
known. Several studies have implicated the involvement of HIV viral proteins such as 
Tat, gp120 and gp 41, as well as neurotoxins that are produced from activated astrocytes 
and microglia, in the pathways leading to neurodegeneration (Adamson et al., 1996; 
Cheng et al., 1998; Nath et al., 2000; Pocernich et al., 2005). 
           In recent years, the use of highly active antiretroviral therapies (HAART) has 
revolutionized the treatment of AIDS, with a suppression of viral load and consequent 
reduction in complications observed in the late-stages of the disease (Gray et al., 2003). 
HAART can suppress the replication of the virus in the long term, but this is often 
accompanied by significant toxicities that can compromise treatment (Egger et al., 1997; 
Brinkman and Kakuda, 2000). Among the toxicities reported with the NRTI’s include: 
hepatic steatosis, lactic acidosis, encephalopathy, lipodystrophy, peripheral neuropathy, 
and myopathy (Scalfaro et al., 1998; Blanche et al., 1999). Anti-retrovirals such as the 
nucleoside reverse transcriptase inhibitors (NRTIs), which include, 2', 3’-dideoxycytidine 
(ddC), are of great significance and are an important component of HAART (White, 
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2001).The mechanisms of these toxicities has been found to involve inhibition of neurite 
regeneration and inhibition of DNA polymerase gamma, leading to inhibition of 
mitochondria DNA synthesis, resulting in oxidative stress and eventual mitochondrial 
dysfunction (Cui et al., 1997). But recently, Mallon et al. (2005) have shown that NRTIs 
could cause mitochondrial dysfunction through other mechanisms other than inhibition of 
DNA polymerase gamma (Mallon et al., 2005).  
With the advent of HAART, the incidence of HIVD has fallen, while the 
cumulative prevalence of HIVD has risen (Neuenburg et al., 2002). Despite the decline of 
HIVD incidence, neurological complications still remain an important cause of disability 
and death associated with AIDS (Kandanearatchi et al., 2003; McArthur et al., 2003). The 
rise in the prevalence of HIVD despite the use of HAART is consistent with the poor 
penetration of some of these anti-retrovirals into the CNS, hence increasing the longevity 
of the virus in the CNS (Deutsch et al., 2001). However, it has recently been reported that 
these drugs can effectively cross into the CNS, therefore, raising the question of their 
efficacy in the CNS and their possible role in HIVD (Enting et al., 1998; Sawchuk and 
Yang, 1999; Gibbs et al., 2003a; Gibbs et al., 2003b). For example, one treatment study 
showed variable results on the efficacy of NRTIs in the brain: one group of patients on 
HAART and having HIVD remained stable from cognitive impairment, while the other 
group showed signs of progressive neurological impairment even with treatment 
(Kandanearatchi et al., 2003). This disparity could possibly be due to the increased 
survival of the virus in the brain or could possibly be due to the NRTIs on their own 
being neurotoxic as has recently been shown with the increase in damage to brain 
mitochondria in HIV positive patients using NRTI’s (Schweinsburg et al., 2005). The 
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latter may be of particular concern, since several experimental strategies are currently 
being considered to increase the transport of NRTIs across the blood brain barrier.  
         Therefore, in the current study, we have investigated these NRTIs, and specifically 
ddC, with the hypothesis that NRTIs could in themselves be neurotoxic and thus play a 
role in the progression of HIVD through an oxidative stress mechanism, possibly 
involving mitochondria. We report here that ddC, at concentrations achievable in the 
CSF, induces oxidative stress when treated to synaptosomes and isolated mitochondria. 
The levels of oxidative stress as measured by protein carbonyls on synaptosomes were 
significantly reduced upon the use of a known brain accessible antioxidant and 
glutathione mimetic [D609] (Zhou et al., 2001; Lauderback et al., 2003; Sultana et al., 
2004). In addition, we observed a significant reduction in the levels of the anti-apoptotic 
protein Bcl-2, a significant release of cytochrome c and an equally significant increase in 
caspase-3 protein levels upon treatment of mitochondria with ddC. These results provide 
a possible mechanistic pathway for cell death through oxidative stress-induced apoptosis  
and are consistent with the notion of the possible contribution of ddC to HIVD. 
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A3. Experimental procedures 
 
Material and Methods 
 
Unless stated otherwise, all chemicals and antibodies were purchased from 
Sigma-Aldrich (St. Loius, MO). The oxidized protein detection kit was purchased from 
Intergen (Purchase, NY). The nucleoside reverse transcriptase inhibitor (NRTI), 2', 3’-
dideoxycytidine (ddC), was obtained from NIH AIDS Research and Reference Reagent 
Program, Division of AIDS, NIAID, NIH (NSC 606170). Assays for protein oxidation, 
lipid peroxidation, cytochrome c release and Bcl-2 levels were performed 6 h after NRTI 
treatment with some modifications as previously described (Butterfield et al., 1999a; 
Yatin et al., 1999; Butterfield and Lauderback, 2002).  
 
Animals 
 
The animal protocols were approved by the University of Kentucky Animal Care 
and Use Committee. For all studies in this paper, male Mongolian gerbils 3 months of 
age and approximately 100 g in weight were used. The rodents were housed in the 
University of Kentucky Central Animal Facility under 12-h light/dark conditions and fed 
standard Purina rodent laboratory chow.  
 
Isolation of synaptosomes 
Synaptosomes were isolated from three-month old male Mongolian gerbils as 
previously described (Whittaker, 1993).  Briefly, the gerbils (n=5) were sacrificed by 
decapitation and the brain immediately isolated and dissected. The cortex was placed in 
0.32 M sucrose isolation buffer containing 4 µg/ml leupeptin, 4 µg/ml pepstatin, 5 µg/ml 
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aprotinin, 2 mM ethylene di-amine tetra-acetic acid (EDTA), 2 mM ethylene glycol-bis-
tetraacetic acid (EGTA), 20 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid 
(HEPES), 20 µg/ml trypsin inhibitor, and 0.2 mM phenylmethanesulfonyl fluoride 
(PMSF), pH 7.4.  The tissue was homogenized by 20 passes with a Wheaton tissue 
homogenizer.  The homogenate was centrifuged at 1500 g for 10 minutes.  The 
supernatant was retained and centrifuged at 20,000 g for 10 minutes.  The resulting pellet 
was resuspended in ~1 ml of 0.32 M sucrose isolation buffer and layered over 
discontinuous sucrose gradients (0.85 M pH 8.0, 1.0 M pH 8.0, 1.18 M pH 8.5 sucrose 
solutions each containing 2 mM EDTA, 2 mM EGTA, and 10 mM HEPES) and spun at 
82,500 g for 1 hr at 4oC.  Synaptosomes were collected from the 1.0/1.18M sucrose 
interfaces, and washed in Locke’s buffer (154 mM NaCl, 5.6 mM KCl, 2.3 mM CaCl2, 
1.0 mM MgCl2, 3.6 mM NaHCO3, 5 mM glucose, 5 mM HEPES) twice for 10 minutes at 
32,000 g.  The resulting synaptosomal membranes were assayed for protein concentration 
by the Pierce BCA method. The synaptosomal preparation was relatively free of non-
synaptic moieties (Whittaker, 1993). 
 
Isolation of Mitochondria 
Mitochondria were isolated from gerbil brain following i.p. injection with saline 
(control) or with D609 (50 mg/ kg body wt), 1 h after injection as previously described 
(Sultana et al., 2004). The brain mitochondria were isolated as previously described with 
minor modifications (Sims, 1990). Briefly gerbils, (n=6) were decapitated and the whole 
brain was isolated on ice. Whole brain was homogenized in ice-cold isolation buffer (250 
mM sucrose, 10 mM HEPES, and 1 mM potassium EDTA, pH 7.2, 4 µg/ml leupeptin, 4 
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µg/ml pepstatin, 5 µg/ml aprotinin 20 µg/ml trypsin inhibitor) with 6 passes of a Wheaton 
tissue homogenizer. The homogenate was centrifuged for 3 min at 1,330× g at 4°C, and 
the resulting pellet was resuspended in isolation buffer and centrifuged at 1,330× g for 3 
min. The supernatants from both spins were combined and spun at 21,200x g for 10 min 
at 4°C. The pellet was resuspended in 15% Percoll solution (v/v in isolation buffer) and 
layered onto discontinuous Percoll gradients of 23 and 40% Percoll (v/v in isolation 
buffer). Gradients were centrifuged at 30,700× g for 5 min at 4°C. At the 23-40% Percoll 
interface, mitochondria were isolated and resuspended in respiration buffer (250 mM 
sucrose, 2 mM magnesium chloride, 20 mM HEPES, and 2.5 mM phosphate buffer, pH 
7.2) and centrifuged at 16,700× g for 10 min at 4°C. The pellet was resuspended in 
respiration buffer, centrifuged at 6,900× g for 10 min at 4°C, and the resulting pellet was 
washed in PBS at 6,900× g for 10 min at 4°C.  
Incubation of synaptosomes and mitochondria with ddC 
 
Stock solutions of ddC were diluted in phosphate buffered saline (PBS). 
Synaptosomal and mitochondrial concentrations of 4mg/ml were then treated with the 
ddC to a final concentration based on the CSF-achievable concentration range of 6-
11ng/ml (Sawchuk and Yang, 1999). These samples were then incubated for 6 h at 37oC 
with frequent vortexing. Controls were incubated with PBS. These samples were then 
frozen for subsequent assays. 
 
Oxidation of synaptosomes with Fe2+/H2O2 
Protein oxidation was initiated by addition of hydroxyl radical generating mixture 
(30 µM FeSO4/3 mM H2O2) as previously described (Pocernich et al., 2000). Briefly, 
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synaptosomes (4 mg proteins/ml) were suspended in 0.987 ml of lysing buffer and treated 
with 30 µM Fe2+ (FeSO4.7H2O) and 3 mM H2O2 (diluted from 30% H2O2), bringing the 
total volume to 1 ml, for 30 min at room temperature. Fe2+ reacting with H2O2 produce 
hydroxyl free radicals (Butterfield and Stadtman, 1997). The protein suspension was then 
washed four times with lysing buffer at 14,000 rpm for 4 min. This sample was used as a 
positive control for protein oxidation. 
 
Measurement of protein carbonyls  
 
Protein carbonyls are an index of protein oxidation and were determined as 
described previously (Butterfield and Stadtman, 1997). Briefly, 5µl of sample were 
derivatized with 10mM 2, 4-dinitrophenylhydrazine in the presence of 5µl of 12% SDS 
for 20 min at room temperature. The samples were neutralized with 7.5 µL of the 
neutralization solution (2 M Tris in 30% glycerol). Derivatized protein samples were 
blotted onto nitrocellulose membrane with a slot-blot apparatus (250 ng/lane). The 
membrane then was washed with wash buffer (10mM Tris-HCl (pH 7.5), 150mM NaCl, 
0.05% Tween 20), blocked by incubation of 5% BSA, followed by incubation with rabbit 
polyclonal anti-DNPH antibody as primary antibody for 1 h. The membranes were 
washed with wash buffer and further incubated with alkaline phosphatase (ALP)-
conjugated goat anti-rabbit antibody as the secondary antibody for 1 h. Blots were 
developed using Sigma fast tablets (BCIP/NBT) and were quantified using Scion Image 
(PC version of Macintosh compatible NIH Image) software.  
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Measurement of lipid peroxidation  
 
 4-Hydroxynonenal (HNE) levels 
HNE is a marker of lipid peroxidation, and this assay was performed as 
previously described (Lauderback et al., 2001). Briefly, 10 µl of sample both from cell 
culture or synaptosomes were incubated with 10 µl of Laemmli buffer containing 0.125 
M Tris base pH 6.8, 4 % (v/v) SDS, and 20% (v/v) Glycerol. The resulting sample (250 
ng) was loaded per well in the slot blot apparatus.  Samples were loaded onto a 
nitrocellulose membrane under vacuum pressure.  The membrane was blocked with 3% 
(w/v) BSA in phosphate buffered saline containing 0.01% (w/v) sodium azide and 0.2% 
(v/v) Tween 20 (PBST) for 1 hr and incubated with a 1:5000 dilution of anti-4-
hydroxynonenal (HNE) polyclonal antibody in PBST for 90 min.  Following completion 
of the primary antibody incubation, the membranes were washed three times in PBST.  
An anti-rabbit IgG alkaline phosphatase secondary antibody was diluted 1:8000 in PBST 
and added to the membrane.  The membrane was washed in PBST three times and 
developed using Sigma fast Tablets (BCIP/NBT substrate).  Blots were dried, scanned 
with Adobe Photoshop, and quantified with Scion Image.   
 
Measurement of cytochrome c release 
Cytochrome c release was detected as previously described with slight 
modifications (Yang et al., 1997). Briefly, after incubation and centrifugation of 
mitochondrial samples, the supernatant was used for Western blot analysis for 
cytochrome c release. The membrane was blocked in blocking buffer (3% bovine serum 
albumin) in PBS/Tween for 2 h and incubated with a 1:2000 dilution of anti-cytochrome 
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c polyclonal antibody (C-5723; anti-sheep; Sigma) in PBS/Tween for 2 h. The membrane 
then was washed in PBS/Tween for 5 min three times after incubation. The membrane 
was incubated for 1 h, after washing, with an anti-sheep IgG alkaline phosphatase 
secondary antibody diluted in PBS/Tween in a 1:8000 ratio. The membrane then was 
washed three times in PBS/Tween for 5 min and developed in Sigma Fast tablets. Blots 
were dried, scanned with Adobe PhotoShop, and quantified using Scion Image software. 
 
Measurement of Bcl-2 levels 
The levels of anti-apoptotic protein Bcl-2 were detected as previously described 
(Yang et al., 1997) with slight modification as described above, except a 1:2000 dilution 
of anti-Bcl-2 monoclonal antibody (AAM-072; anti- mouse; stressgen) in PBS/Tween for 
2 h was used.  
 
Statistical analysis 
 
Student’s t-test was used to assess statistical significance; p values < 0.05 were 
considered significant. 
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A4 Results 
Increased oxidative stress in synaptosomes following treatment with ddC  
Synaptosomes are a good model for studying neuronal synaptic function at nerve 
terminals and display markers of neurodegeneration upon treatment with various oxidants 
such as amyloid β-peptide (Aβ) (Butterfield and Boyd-Kimball, 2005). Hence, 
synaptosomes were used for the present study to determine if ddC caused oxidative 
damage. Oxidative stress can lead to a variety of detrimental effects on neurons including 
protein cross linking, decreased protein turnover, loss of protein function, altered redox 
potential, disruption of Ca2+ homeostasis, and ultimately cell death (Butterfield and 
Stadtman, 1997). As shown in Fig A1a, synaptosomes were exposed to a known hydroxyl 
radical generating mixture (30 µM FeSO4/1 mM H2O2) as a positive control and a range 
of ddC concentrations (29 nM- 52 nM). There was a significant increase in protein 
carbonyls levels on synaptosomes treated with 40 nM ddC p < 0.05. These levels were 
comparable to those of the synaptosomes treated with Fe2+/H2O2.  Fig A1b shows levels 
3-nitrotyrosine (3NT), another marker of protein oxidation, in ddC treated synaptosomes. 
A significant increase in the levels of 3NT with 40nM ddC was observed; however, there 
was no significant change in the levels of lipid peroxidation as indexed by HNE when 
synaptosomes were treated with ddC in all the concentration ranges Fig A1c.  
Increased oxidative stress in mitochondria following treatment with ddC  
Fig A2 shows the levels of protein carbonyls and HNE in mitochondria treated 
with ddC. Fig A2a shows a significant increase in the levels of protein oxidation as 
indexed by protein carbonyls. These results were significant at 40 nM ddC, seen 
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previously with synaptosomes. Fig A2b shows the levels of lipid peroxidation as indexed 
by HNE was unaffected when mitochondria were treated with a varying range of 
concentrations of ddC, consistent with the results with synaptosomes. 
D609 protects mitochondria from oxidative stress mediated by ddC 
The use of antioxidants has been shown to provide protection against oxidative 
insult in a number of models of neurodegenerative disorders (DeAtley et al., 1999; 
Calabrese et al., 2003a; Farr et al., 2003; Lauderback et al., 2003; Sultana et al., 
2005a).The levels of protein oxidation as indexed by protein carbonyls in mitochondria 
isolated from brain of gerbils injected 1 h before sacrifice with saline or D609 are shown 
in Fig. A3. These brain mitochondrial samples were subsequently treated with 40 nM 
ddC, the concentration that showed the most effect. The levels of protein carbonyls were 
significantly increased in mitochondria isolated from brain of saline-injected gerbils and 
treated with ddC compared to control. Mitochondria isolated from brain of D609-injected 
gerbils and subsequently treated with 40 nM ddC showed a significant decrease in the 
levels of protein carbonyl levels compared to mitochondria isolated from brain of saline-
injected gerbils and subsequently treated with 40 nM ddC.  
Increased cytochrome c release from mitochondria following treatment with ddC 
Mitochondria are the main source for the generation of reactive oxygen species 
(ROS), which has been known to contribute to the release of cytochrome c and 
subsequent induction of apoptosis (Sullivan et al., 1999). Fig. A4 shows the level of 
cytochrome c released from mitochondria isolated from gerbil brain and treated with 
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various CSF concentrations of ddC. There was a significant increase in the amount of 
cytochrome c released by mitochondria treated with 40nM ddC compared to control.  
Decreased levels of anti-apoptotic protein Bcl-2 following treatment with ddC 
Bcl-2 is a human proto-oncogene that modulates cell death or apoptotic pathways 
by regulating the release of pro-apoptotic molecules from the mitochondria.  Fig A5 
shows the level of Bcl-2 protein in mitochondria isolated from gerbil brain and treated 
with various CSF concentrations of ddC. Though there was a decrease in the levels of 
Bcl-2 with all concentrations of ddC used, there was a significant decrease in the levels of 
Bcl-2 with 52nM ddC treatment compared to control.   
Increased expression of pro-apoptotic protein caspase-3 after treatment with ddC 
 As an additional evidence of apoptotic events talking place after the treatment of 
mitochondria with ddC, we measured the levels of caspase-3 protein levels as shown in 
figure A6. There was an observable increase in the levels of caspase- 3 in all treatment 
but there was a higher increase in the 40nm ddC treated mitochondria. It should be noted 
that since this was just additional proof of apoptotic events taking place, and n = 4 was 
used. The changes observed are about 40% of control with statistical significance p< 
0.05. 
No effect on protein carbonyl levels following treatment with 3TC 
 
         As additional evidence for the oxidative stress-induced toxicities of NRTI’s we 
have shown that 3TC the most tolerable NRTI in HIV therapy did not induce oxidative 
stress in synaptosomes treated using concentrations achievable in the CSF compared to 
DDC Figure A7. As a result the oxidative stress-related effects we are observing in the 
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present study are specific to only ddC and not any other NRTI. It should be noted that 
n=4 
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Figure A1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A1 Protein oxidation and lipid peroxidation as indexed by protein carbonyls, 3NT 
and HNE in ddC treated synaptosomes. There is an increase in the levels of protein 
carbonyls (Fig A1a) and 3NT (Fig A1b) on synaptosomes treated with 40nM ddC. The 
levels of protein carbonyls were comparable to those of synaptosomes treated with the 
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positive control of the hydroxyl radical generating mixture of Fe2+/H2O2. Fig A1C shows 
the levels of lipid peroxidation as indexed by HNE; there was no significant difference 
among the treatments. Results here are given as the mean ± S.E.M. expressed as 
percentage of control values.  (*) p < 0.05 n=5.  
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Figure A2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A2 Protein oxidation and lipid peroxidation as indexed by protein carbonyls and 
HNE respectively on ddC treatment of isolated mitochondria. There is an increase in the 
levels of protein carbonyls (Fig A2a) on mitochondria treated with 40nM ddC. Fig A2b 
shows the levels of lipid peroxidation as indexed by HNE; there was no significant 
difference among the treatments. Results here are given as the mean ± S.E.M. expressed 
as percentage of control values.  (*) p < 0.05 n=6.  
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Figure A3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3. The levels of protein oxidation as indexed by protein carbonyl in 
mitochondria isolated from brain of gerbils injected with saline or D609. The levels of 
protein carbonyls were found to be significantly increased in mitochondria isolated from 
brain of saline- injected gerbils and treated with ddC compared to control. Mitochondria 
isolated from brain of D609-injected gerbils and treated with 52nM of ddC showed a 
significant decrease in the levels of protein carbonyl levels as compared to mitochondria 
isolated from brain of saline-injected gerbils brain and subsequently treated with 52nM 
ddC. Results here are presented as the mean ± S.E.M. expressed as percentage of control 
values.  (*) p < 0.05 n=6. D609 concentration used was 50 µM, chosen based on prior 
studies of this agent 
 Protein Carbonyls (DDC+D609)
0
20
40
60
80
100
120
140
160
180
200
Ctrl Fe2+/H2O2 D609 40 nM D609+ 40
nM DCC
Samples
%
 C
on
tr
ol
 296
Figure A4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A4. The level of cytochrome-c release from mitochondria isolated from gerbil 
brain and treated with different concentrations of ddC. There was a significant release in 
cytochrome-c when 40 nM ddC was added to isolated mitochondria. Data here are 
presented as the mean ± S.E.M. expressed as percentage of control values.  (*) p < 0.05 
n=4.  
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Figure A5 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A5. The protein levels of anti-apoptotic protein Bcl-2 in brain mitochondria 
isolated from gerbil brain and treated with ddC. There was a reduction in the levels of 
Bcl-2 in with all ddC concentrations used, but a significant reduction was observed with 
52 nM ddC. Data here are presented as the mean ± S.E.M. expressed as percentage of 
control values.  (*) p < 0.05 n=4.  
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Figure A6 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A6 The protein levels of pro-apoptotic protein Caspase-3 in brain mitochondria 
isolated f from gerbil brain and treated with ddC. There was an increase in the levels of 
caspase 3 in with all ddC concentrations used, with 40 nM ddC showing the highest level. 
Data here are presented as the expressed as percentage of control values.  n =4 p< 0.05 
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Figure A7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A7 Protein oxidation as indexed by protein carbonyls in ddC and 3TC treated 
synaptosomes. There is an increase in the levels of protein carbonyls (Fig A7a) on 
synaptosomes treated with 40nM ddC but no significant changes are observed in 3TC 
treated synaptosomes (Fig A7b). Results here are given as the mean ± S.E.M. expressed 
as percentage of control values.  n = 4(*) p< 0.05 
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A5 Discussion 
The findings reported here show that ddC, at physiologically relevant 
concentrations achievable in the CSF and especially at 40nM, is able to induce oxidative 
stress in both synaptosomes and isolated mitochondria, as measured by the elevated 
levels of protein oxidation. DDC also reduced the levels of the anti-apoptotic protein Bcl-
2, slightly increased the levels of Bax, induced the release of cytochrome c, and increased 
caspase-3 protein levels. These results implicate oxidative stress and the mitochondria as 
possible pathways involved in NRTI-induced neuronal death. 
Infection of the brain with HIV often results in a decline of neuropsychological 
performance, neurological impairments (McArthur et al., 1989; Karlsen et al., 1993, 
1995; Baldewicz et al., 2004), and a dementing disorder known as HIV-dementia 
(HIVD). HIVD is the most common form of dementia in young adults, and it is estimated 
that 30% of adults infected with HIV usually develop HIVD (Janssen et al., 1992; Nath 
and Geiger, 1998). The mechanism of this neurodegeneration remains unknown, since 
HIV rarely infects neurons (Nath and Geiger, 1998). Recent studies have proposed 
various mechanisms for HIVD, for example, HIV over-activates immune cells within the 
brain to produce cytokines or chemokines, which can inhibit the growth and survival of 
brain cells or trigger cell death and low levels of transforming growth factor β 1(TGF β 
1) may enhance brain cell damage in people with HIV infection (Ensoli et al., 1999; 
Letendre et al., 1999). HIV proteins such as Tat, nef, gp120, and gp 41, have also been 
implicated in the pathways leading to this neurological dysfunction (Adamson et al., 
1996; Cheng et al., 1998; Nath et al., 2000; Pocernich et al., 2004; Pocernich et al., 
2005). Oxidative stress has been found to play a major role in most neurodegenerative 
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disorders (Farr et al., 2003; Butterfield and Boyd-Kimball, 2005; Keller et al., 2005; 
Pocernich et al., 2005). This could be another possible mechanism involved in HIVD 
induced neurodegeneration, since recent studies have shown that there is increased 
oxidative stress in the brain and CSF of HIVD patients (Chauhan et al., 2003; Turchan et 
al., 2003). 
The NRTIs, including ddC, form the basis of the HAART therapy (White, 2001). 
These molecules are derivatives of nucleoside bases with varying modifications that give 
alternative substrates for the DNA polymerases. The most common chemical 
modification is the lack of 3’OH group of the sugar bases (Kakuda, 2000). The 
mechanism for action of ddC is through inhibiting the attachment of nucleic acids and at 
the same time terminating DNA chain elongation once incorporated (Balzarini, 1994). 
Just like endogenous nucleic acids, NRTIs have to undergo phosphorylation by a number 
of kinases to give the active triphosphorylated form (Kakuda, 2000). It is known that the 
concentrations of NRTIs decrease progressively as they move from the plasma to the 
CSF (Sawchuk and Yang, 1999; Kandanearatchi et al., 2003). The penetration of NRTIs 
into the CNS has been an issue to date (Enting et al., 1998; Sawchuk and Yang, 1999). 
An increase in the incidence of HIV dementia has been thought to be due to the 
prolonged survival of the HIV virus in the brain resulting from the poor penetration of the 
antiretroviral used in the therapy (Deutsch et al., 2001), but studies now suggest that 
some of these drugs do effectively penetrate the CNS (Enting et al., 1998; Arendt et al., 
2001; Gibbs et al., 2003a). DDC is transported to the CNS through organic anion 
transporters (Hedaya and Sawchuk, 1989). This could be a possible explanation for the 
lack of any significant difference observed in the levels of lipid peroxidation product 
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HNE measured in both synaptosomes and isolated mitochondria treated with ddC in the 
current study. For HNE to be generated, the oxidant must be capable of inserting itself 
into the lipid bilayer to trigger the cascade for lipid peroxidation (Butterfield and Boyd-
Kimball, 2005). Since the transport of ddC into the CNS is through organic anion 
transporters ddC may not get into the bilayer and thus not induce lipid peroxidation, 
though this is speculative at present. 
        Though NRTIs are capable of controlling the replication of the HIV virus, they also 
have adverse effects during therapy (Scalfaro et al., 1998; Blanche et al., 1999). 
Mitochondrial dysfunction has been previously observed with NRTIs, and extensive 
studies on the mechanism of NRTI toxicity has been linked to mitochondrial dysfunction, 
mutations in mtDNA and oxidative stress through inhibition of DNA polymerase gamma, 
which encodes 13 oxidative phosphorylation (OXPHOS) genes (Lewis et al., 2001; 
Lewis et al., 2003). It has recently been suggested that NRTIs could cause mitochondrial 
dysfunction through mechanisms other than inhibition of DNA polymerase gamma 
(Mallon et al., 2005). Of the above mechanisms of toxicity, oxidative stress seems to play 
a major role. Oxidative stress is an imbalance between reactive oxygen species and 
cellular antioxidant defenses (Butterfield and Stadtman, 1997). The role of HIV infection 
and NRTI on induction of oxidative stress has been known for a while, but has not been 
well explored (Droge, 2002). We have shown in the present study that, on treatment of 
synaptosomes and isolated mitochondria with CSF-achievable concentrations of ddC, 
there is a significant increase in the oxidative stress as indexed by the levels of protein 
oxidation biomarkers, i.e., protein carbonyls and 3NT. These results support the role 
NRTI induction of oxidative stress. DDC at lower concentrations had very little effect of 
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the induction of protein oxidation; however at 40nM of ddC there was a significant 
increase in the levels of protein oxidation, which on further increase in the concentration 
of ddC had no effect. This observed concentration-effect relationship could be possibly 
due the saturation of ddC transporters at 40 nM ddC.    
The use of antioxidants has been found to be protective in various models 
neurodegenerative disorders (DeAtley et al., 1999; Calabrese et al., 2003a; Farr et al., 
2003; Lauderback et al., 2003). Tricyclodecan-9-yl-xanthogenate (D609) is an inhibitor 
of phosphatidylcholine-specific phospholipase C, an antioxidant, anti-tumor and a 
glutathione (GSH) mimetic (Zhou et al., 2001; Lauderback et al., 2003; Sultana et al., 
2004). Mitochondria isolated from brain of D609-injected gerbils and treated with 52 nM 
ddC showed decreased oxidative stress as measured by the levels of protein carbonyls, 
demonstrating that though ddC can induce oxidative stress, these effects can be 
modulated when a brain accessible glutathione mimetic antioxidant is used. We 
previously suggested that D609 possibly could have therapeutic relevance in treating 
HIVD (Pocernich et al., 2005).  
Mitochondria are not only an essential component of the cell for energy 
generating capacity but are targets of oxidative stress because of their ability to generate 
ROS. In addition mitochondria also are prodigious regulators of cell death (Melov, 2000). 
Several molecules contained within the mitochondria, such as cytochrome c, have a pro-
apoptotic influence.  In contrast, Bcl-2 members regulate the pores in the inner membrane 
of the mitochondria, which when opened lead to release of pro-apoptotic molecules and 
induction of apoptosis (Stefanis, 2005). The inhibition of mtDNA replication can result in 
acquired defects that leads to most mitochondrial genetic diseases (Lewis et al., 2003). As 
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a result, NRTIs could thus generate phenotypic OXPHOS defects that would eventually 
compromise the electron transport chain (ETC), resulting in energy depletion and 
eventually cellular dysfunction. It is from this consideration that the phrase 
“mitochondrial dysfunction hypothesis” was introduced (Lewis et al., 2003), linking 
NRTI toxicity to their effects on the mitochondria (Moyle, 2000; Dalakas et al., 2001). In 
the present study, we have observed a significant decrease in the levels of anti-apoptotic 
protein Bcl-2 and consequently a significant increase in the release of cytochrome c, upon 
treatment of mitochondria with ddC. We also observed an increase in the protein levels of 
caspase-3. These results present a possible mechanism through which NRTIs could 
induce cell death and neuronal loss in HIV-related dementia. The decrease of Bcl-2 
protein, increase in cytochrome c and increase in caspase-3 provides a synergistic 
environment for the induction of apoptosis. The down regulation of Bcl-2 levels, leads to 
the release of cytochrome c, which binds to Apaf-1and pro-caspase 9 forming the 
apoptosome. Also the slight observation of the increase in Bax levels would lead to an 
increase in the permeability of the mitochondrial membrane possibly leading to the 
release of cytochrome c (Susin et al., 2000).  These mediators then activate caspase 9, 
which triggers the cascade of “effectors” caspases and eventual cell death (Stefanis, 
2005). Our findings are consistent with a recent report that showed that other than ddC, 
2’, 3’-didehydro-3'-deoxythymidine (d4T), also caused apoptosis in rat dorsal root 
ganglion neuronal cell cultures in HIV free environments (Bodner et al., 2004). 
Despite the use of HAART, neurological complications still remain an important 
cause of disability and death associated with AIDS (Kandanearatchi et al., 2003; 
McArthur et al., 2003). The efficacy of these drugs in the brain is still controversial and 
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research into the effect of HAART on the signs and symptoms of HIVD has resulted into 
a number of conflicting findings. For example, there are reports showing that HAART is 
capable of reducing HIV encephalitis and leukoencephalopathy, improving 
neurocognitive function, mental concentration, speed of mental processing, memory, and 
visuo-spatial and constructional abilities (Gendelman et al., 1998; Dougherty et al., 2002; 
Vago et al., 2002). Another study reports a partial improvement of clinical abnormalities 
after patients were on HAART (Stankoff et al., 2001). A study by (Bouwman et al., 
1998)) has reported that after HAART treatment some patients remained free of cognitive 
impairment with prolonged life span, while others become neurologically impaired. 
Dougherty et al. (2002) treated 96 HIV- demented patients with HAART, and of the 30 
patients that had adequate follow-up data, 60% showed neurological improvement 
(Dougherty et al., 2002). These studies among others continue to raise the question on the 
effect of the antiretroviral therapy on the incidence and prevalence of HIVD and the 
efficacy of the NRTIs in the brain, therefore supporting the possibility that these drugs 
could themselves contribute to the neurological impairments. In a recent study, it has 
been shown that there is brain mitochondrial injury in HIV positive patients who are on 
NRTI therapy (Schweinsburg et al., 2005), this provides additional support for the 
present study of the possible involvement of NRTI’s in HIV-dementia. 
As a result, the current study was an effort at studying a possible toxic effect of 
NRTI’s and in particular ddC, with oxidative stress and mitochondrial dysfunction as the 
key mechanism of toxicity. Synaptosomes provide a good model of the synapse and 
display markers of neurodegeneration upon treatment with various oxidants. Equally, 
isolated mitochondria provide a good model to study mechanisms of neurodegeneration 
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since they are a source of ROS and control cell death through regulation of apoptosis 
(Butterfield et al., 1999a; Lauderback et al., 2001; Lauderback et al., 2003; Brito et al., 
2004; Pocernich et al., 2004; Butterfield and Boyd-Kimball, 2005). As noted above, 
despite the reduction of late stage HIV complications with the use of antiretroviral 
treatment, neurological complications are still being reported, questioning the efficacy of 
these drugs in the brain (Bouwman et al., 1998). It is therefore our view that in addition 
to the prolonged survival of the HIV virus in the brain (Deutsch et al., 2001) and 
increased  penetration of the antiretrovirals to the CNS (Enting et al., 1998; Sawchuk and 
Yang, 1999), these NRTIs could by themselves contribute to this neurological 
complication through increased oxidative stress as shown by the increase in oxidative 
stress biomarkers measured here. It is also possible that ddC could potentiate and act 
synergistically with other compounds such as Tat, gp120 and gp41 in inducing 
mechanisms implicated in HIVD (Pocernich et al., 2005). This is particularly possible 
since Bonder et al (2004) have recently reported that there exists a possible synergy in 
toxicity to DRG neuronal cell cultures by gp120 and another NRTI, d4T. In addition, a 
recent study has also provided evidence for the injury to brain mitochondria from patients 
taking NRTI’s (Schweinsburg et al., 2005) and that NRTI-oxidative stress-induced DNA 
damage through inhibition of repair mechanism could lead to oxidative stress-induces 
apoptosis in neurons (Hashiguchi et al., 2004; Harrison et al., 2005). Therefore, evidence 
provided in the present study suggests that ddC could possibly contribute to the 
mechanisms involved in HIVD through induction of oxidative stress, reduction in anti-
apoptotic protein Bcl-2, release of cytochrome c and increase in caspase 3 and bax 
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proteins making this study the first to establish the possible involvement of NRTIs in 
HIV related dementia. 
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Appendix B 
 
Analysis of Protein Expression Levels in Brain of NF-Kβ P50 Heterozygous 
Knockout Mice 
 
B1 Overview 
 
Nuclear factor kappa B (NF-κB) is an important transcriptional factor. Its role in 
oxidative stress, and most recently in pro- and anti-apoptotic related mechanistic 
pathways, have well been established, however, there still lacks a complete understanding 
of the roles its various subunits play in normal human physiology or disease. Because of 
the dual nature of NF-κB, the wide range of genes it regulates and the plethora of 
stimulus that activates it, various studies addressing the functional role of NF-κB proteins 
have resulted in a number of differing findings. As a result, in this dissertation, we 
undertook to examine the effect of a stimulus-free environment on the frontal cortex of 
mice brain with the p50 subunit of NF-κB partially knocked p50 (-/+). Heterozygous p50 
mice knockout (KO) and wild type (WT) were used, and at 7-9 weeks they were 
sacrificed and various brain regions dissected. We analyzed the levels of oxidative 
damage in the frontal cortex of both the p50 (-/+) and WT mice; measuring the levels of 
4-hydroxynonenal (HNE), 3-nitrotyrosine (3NT) and protein carbonyls. There was a 
significant reduction in the levels of all oxidative stress parameters analyzed in the p50 (-
/+) mice when compared to the WT. We further carried out a proteomic profile analysis 
to identify proteins that were differentially expressed in these two groups of animals. We 
identified proteins whose expressions were significantly increased in the p50 (-/+) mice 
compared to the WT. These identified proteins were: ATP synthase gamma chain, 
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Ubiquinol-cyt-C reductase, Heat shock protein 10 (Hsp10), Fructose Bisphosphate 
aldolase C, and NADH-ubiquinone oxidoreductase. We have therefore established that 
partial knock out of the p50 subunit of NF-κB results in a reduction in the levels of 
oxidative stress. In addition, there is a significant increase in the expression of key 
proteins in the p50 (-/+) brain compared to that of the WT. These findings suggest that 
the p50 subunit is an essential component of NF-κB transcription factor that potentially 
can be targeted for the development of therapeutic interventions in disorders where 
oxidative stress plays a key role. 
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B2 Introduction  
Nuclear factor kappa B (NF-κB) is a key transcription factor that was earlier 
known to regulate the immune and inflammatory processes and viral replication 
(Baeuerle and Henkel, 1994; Baldwin, 1996). The NF-κB family of transcription factors 
plays key roles in the regulation of cell growth, activation, differentiation, and survival 
(Santoro et al., 2003). In addition, an increasing amount of evidence suggests that NF-κB 
plays an important role in synaptic plasticity and long-term memory formation (Albensi 
and Mattson, 2000; Mattson et al., 2000). The activation of NF-κB is responsible for 
transcription of various genes like: TNFα, interleukins, such as IL1, IL2, and IL6; 
chemokines, adhesion molecules, such as ICAM-1 VCAM, and E-selectin; enzymes such 
as iNOS, COX-2 and proliferation-related proteins such as Cyclin D1 among many others 
(Karin et al., 2002; Ferrucci et al., 2004; Chung et al., 2005). The dysregulation of NF-κB 
activity has been shown to play a critical role in many inflammatory diseases and in 
various neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease (Hunot 
et al., 1997; Kaltschmidt et al., 1997; Yoshidome et al., 1999). 
NF-κB transcription factor represents a group of both homodimeric and 
heterodimeric complexes. In mammals, this family of NF-κB consists of several proteins, 
which include NF-κB1 (p50), NF-κB2 (p52), RelA (p65), c-Rel (Rel), and RelB (Hayden 
and Ghosh, 2004). A hallmark of this family of proteins is that they contain a highly 
conserved domain of ~300 amino acids, termed the Rel homology domain, which 
contains sequences important for dimerization, DNA binding, and nuclear localization 
(Grilli et al., 1993; Hayden and Ghosh, 2004). The classical and well studied NF-κB 
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heterodimer, which is also a potent activator of gene expression, is composed of p50 and 
p65 subunits. Unlike p65, p50 and p52 subunits lack transactivation domains and are 
produced either by the proteolytic processing of the precursor molecules p105 and p100 
in the presence of ATP (Ghosh et al., 1998; Sun and Andersson, 2002) or as has been 
suggested, cotranslationally from incompletely synthesized molecules by the proteosome 
(Moorthy et al., 2006). 
NF-κB is expressed in many cell types in the nervous system and is constitutively 
active in subsets of cells in the cortex and hippocampus of the rodent brain at comparably 
low levels (Kaltschmidt et al., 1994; O'Neill and Kaltschmidt, 1997). In resting cells, the 
classical NF-κB heterodimer p65/p50 is complexed with the inhibitor protein IκB and 
sequestered as an inactive complex in the cytoplasm. Activation or stimulation of NF-κB 
in the cells leads to the phosphorylation and immediate proteosomal-mediated 
degradation of IκB. This leads to the nuclear translocation of NF-κB which then binds to 
the regulatory region and transcription of various responsive genes (May and Ghosh, 
1998; Santoro et al., 2003; O'Donnell et al., 2005). NF-κB can be activated in both 
transcriptional activating and repressing forms. In systems in which NF-κB is activated 
during apoptosis, NF-κB can either prevent or potentiate cell death signaling (Beg and 
Baltimore, 1996; May and Ghosh, 1998). For example, a pro-apoptotic role for NF- B in 
ischemia or glutamate-related damage has been reported (Grilli et al., 1996), while on the 
other hand, there is evidence from cell culture models that NF-κB may counteract cell 
death in neurons induced by β-amyloid (Mattson et al., 1997; Lezoualc'h et al., 1998). 
Hence, depending on the experimental settings NF-κB and can either be pro- or anti-
apoptotic. This dual role of NF-κB has indeed presented considerable complexities and 
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difficulties in studies that try to examine the mechanisms of the action of this 
transcription factor. In addition, the wide range of stimuli capable of activating NF-κB, 
and also the large number of genes it regulates, differing results have been reported on 
the roles of specific subunits of NF-κB. As a result the precise role of NF-κB and its 
related mechanistic pathways have been difficult to study and have not been completely 
established. 
Although classical NF-κB is a heterodimer composed of the p50 and p65 
subunits, little is known about gene regulation involving other hetero- and homodimeric 
forms of NF-κB which contain trans-activation domains and can act as activators or 
inhibitors of transcription (Gadjeva et al., 2004). In an effort to determine the various 
roles of the subunits that mediate the observed regulation of NF-κB activity, various mice 
with certain subunits knocked out have been used. In particular, since the p65/p50 
heterodimeric form is the most predominant and the indispensable component of NF-κB, 
knockouts of these two subunits have been developed (Flohe et al., 1997). However, p65 
knockouts have been found to have defects during development and they die prematurely 
of liver apoptosis (Beg et al., 1995; Hayden and Ghosh, 2004), hence not many studies of 
p65 knockouts have been carried out. On the other hand, although p50 deficient mice 
have been shown to display functional defects in immune response, they develop 
normally (Beg et al., 1995), and also, since neurons from animals genetically ablated for 
p50 survive well in culture and are no more sensitive or resistant to neuronal death than 
wild type neurons (Aleyasin et al., 2004), they provide the best avenue to study various 
mechanisms of NF-κB-related activity. Of the two subunits, less is known regarding the 
precise role of p50 in NF-κB-mediated inhibition of apoptosis, and at present, the 
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importance of the NF-κB signaling pathway is still in question especially since various 
studies of p50 knockout mice carried out so far have presented contradictory findings.  
For example, in one study, the absence of the p50 subunit of NF- B resulted in a 
significant reduction in infarct size in parts of the vascular territory of the middle cerebral 
artery (Kawano et al., 2006). Also, in an initial report of mice with targeted disruption of 
the NF-κB1 subunit, p50 (p50 −/− mice), it was discovered that while these mice are 
more susceptible to certain bacterial pathogens, they are resistant to murine 
encephalomyocarditis virus (EMCV) infections causing myocarditis and dilated 
cardiomyopathy that kills normal healthy mice (Schwarz et al., 1998). On the other hand, 
it has been shown that mice depleted of the p50 subunit have been more susceptible to 
neuronal injury when exposed to a wide range of toxins and stimulants (Yu et al., 1999; 
Pennypacker et al., 2001; Kassed et al., 2002). 
Considering the above, the present study involved further analysis of the p50 
subunit of NF-κB. Since most studies on p50 knockout mice have so far been carried out 
using a wide range of stimuli (Weih et al., 1997; Iimuro et al., 1998; Pennypacker et al., 
2001; Mabley et al., 2002; Gadjeva et al., 2004; Kassed and Herkenham, 2004), the 
present study provided a unique opportunity for investigating the role of p50 subunit in a 
stimulus-free experimental environment hopefully providiing us with additional evidence 
on the mechanism of NF-κB activation. We hypothesized that the partial knock out of the 
p50 (-/+) subunit could potentially be protective in a stimulus-free environment through 
an oxidative stress mechanism. To test our hypothesis, we measured the levels of 
oxidative stress biomarkers in the brain of WT and p50 (-/+) mice and observed a 
significant reduction in the levels of lipid peroxidation as measured by HNE and the 
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levels of protein oxidation as measured by the levels of 3NT and protein carbonyls in the 
p50 (-/+) mice compared to the WT. We further carried out a differential expression 
proteomic analysis on the p50 (-/+) mice. Proteomics has recently been successfully used 
in our laboratory to identify various proteins that have undergone modifications in 
various disease states and models thereof (Butterfield, 2004; Butterfield et al., 2006a; 
Butterfield et al., 2006c; Sultana et al., 2006b). As a result, using proteomics we 
identified five proteins to be significantly increased in expression in the p50 (-/+) mice 
when compared to the WT. Therefore, the lack of the p50 subunit makes the brain of 
mice less susceptible to oxidative stress and also activates the expression of key proteins 
involved in energy metabolism and antioxidant activity. Hence, this study has provided 
insights into the role of NF-κB and especially the role of the p50 subunit of NF-κB. 
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B3 Experimental procedures 
Animals and experimental protocols 
Male wild type and NF-κB p50 -/+ mice were received from Jackson Laboratory at 4-6 
weeks and were sacrificed at 7-9 weeks. They were housed in a temperature and humidity 
controlled room with a 12:12 h light: dark cycle, with food and water available ad 
libitum. All procedures and protocols were approved by the Institutional Animal Care and 
Use Committee. These were performed in Dr Charles Rammasamy’s laboratory at INRS-
Institut Armand-Frappier, and INAF, University Laval, Québec, Canada. 
Measurement of protein carbonyls 
 
Protein carbonyls are an index of protein oxidation and were determined as 
described previously (Butterfield and Stadtman, 1997). Briefly, samples (5 µg of protein) 
were derivatized with 10 mM 2, 4-dinitrophenylhydrazine (DNPH) in the presence of 5 
µL of 12% sodium dodecyl sulfate for 20 min at room temperature (23°C). The samples 
were then neutralized with 7.5 µL of the neutralization solution (2 M Tris in 30% 
glycerol). Derivatized protein samples were then blotted onto a nitrocellulose membrane 
with a slot-blot apparatus (250 ng per lane). The membrane was then washed with wash 
buffer (10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20) and blocked by 
incubation in the presence of 5% bovine serum albumin, followed by incubation with 
rabbit polyclonal anti-DNPH antibody (1: 100 dilution) as the primary antibody for 1 h. 
The membranes were washed with wash buffer and further incubated with alkaline 
phosphatase-conjugated goat anti-rabbit antibody as the secondary antibody for 1 h. Blots 
were developed using fast tablet (BCIP/NBT; Sigma-Aldrich) and quantified using Scion 
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Image (PC version of Macintosh-compatible NIH Image) software. No non-specific 
background binding of the primary or secondary antibodies was found. 
Measurement of 3-nitrotyrosine (3-NT) 
Nitration of proteins is another form of protein oxidation (Castegna et al., 2003). 
The nitrotyrosine content was determined immunochemically as previously described 
(Drake et al., 2003b). Briefly, samples were incubated with Laemmli sample buffer in a 
1:2 ratio (0.125 M Trizma base, pH 6.8, 4% sodium dodecyl sulfate, 20% glycerol) for 
20 min. Protein (250 ng) was then blotted onto the nitrocellulose paper using the slot-blot 
apparatus and immunochemical methods as described above for protein carbonyls. The 
mouse anti-nitrotyrosine antibody (5: 1000 dilutions) was used as the primary antibody 
and alkaline phosphatase-conjugated anti-mouse secondary antibody was used for 
detection. Blots were then scanned using scion imaging and densitometric analysis of 
bands in images of the blots was used to calculate levels of 3-NT. No non-specific 
binding of the primary or secondary antibodies was found. 
Measurement of 4-hydoxynonenal (HNE) 
HNE is a marker of lipid oxidation and the assay was performed as previously 
described (Lauderback et al., 2001). Briefly, 10 µl of sample were incubated with 10 µl 
of Laemmli buffer containing 0.125 M Tris base pH 6.8, 4 % (v/v) SDS, and 20% (v/v) 
Glycerol. The resulting sample (250 ng) was loaded per well in the slot blot apparatus 
containing a nitrocellulose membrane under vacuum pressure. The membrane was 
blocked with 3% (w/v) bovine serum albumin (BSA) in phosphate buffered saline 
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containing 0.01% (w/v) sodium azide and 0.2% (v/v) Tween 20 (PBST) for 1 h and 
incubated with a 1:5000 dilution of anti-4-hydroxynonenal (HNE) polyclonal antibody in 
PBST for 90 min. Following completion of the primary antibody incubation, the 
membranes were washed three times in PBST. An anti-rabbit IgG alkaline phosphatase 
secondary antibody was diluted 1:8000 in PBST and added to the membrane. The 
membrane was washed in PBST three times and developed using Sigmafast Tablets 
(BCIP/NBT substrate).  Blots were dried, scanned with Adobe Photoshop, and quantified 
by Scion Image. A small background of the primary antibody binding to the membrane 
was found, but this was the same in both control and subject blots. 
Two-dimensional electrophoresis 
Brain samples (200 µg) were incubated with 4 volumes of 2N HCl at room for 
electrophoresis. Proteins were then precipitated by the addition of ice-cold 100% 
trichloroacetic acid (TCA) to obtain a final concentration of 15% TCA. Samples were 
then placed on ice for 10 min and precipitate centrifuged at 16,000 g for 3min. The 
resulting pellet was then washed three times with a 1:1(v/v) ethanol/ethyl acetate 
solution. The samples were then suspended in 200 µl of rehydration buffer composed of a 
1:1 ratio (v/v) of the Zwittergent solubilization buffer (7M urea, 2M thiourea, 2% Chaps, 
65 mM DTT, 1% Zwittergent 0.8% 3-10 ampholytes and bromophenol blue) and ASB-14 
solubilization buffer (7M urea, 2M thiourea 5Mn TCEP, 1% (w/v) ASB-14, 1% (v/v) 
Triton X-100, 0.5% Chaps, 0.5% 3-10 ampholytes) for 1 h. 
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First dimension electrophoresis 
For the first-dimension electrophoresis, 200 µL of sample solution was applied to 
a 110-mm pH 3–10 ReadyStrip™ IPG strips (Bio-Rad, Hercules CA). The strips were 
then actively rehydrated in the protean IEF cell (Bio-Rad) at 50 V for 18 h. The 
isoelectric focusing was performed in increasing voltages as follows; 300 V for 1 h, then 
linear gradient to 8000 V for 5 h and finally 20 000 V/h. Strips were then stored at –80 
°C until the 2nd dimension electrophoresis was to be performed. 
Second dimension electrophoresis 
For the second dimension, the IPG® Strips, pH 3–10, were equilibrated for 10 min 
in 50 mM Tris–HCl (pH 6.8) containing 6 M urea, 1% (w/v) sodium dodecyl sulfate 
(SDS), 30% (v/v) glycerol, and 0.5% dithiothreitol, and then re-equilibrated for 15 min in 
the same buffer containing 4.5% iodoacetamide instead of dithiothreitol. Linear gradient 
precast criterion Tris–HCl gels (8–16%) (Bio-Rad) were used to perform second 
dimension electrophoresis. Precision Protein™ Standards (Bio-Rad, CA) were run along 
with the sample at 200 V for 65 min. 
SYPRO ruby staining 
After the second dimension electrophoresis, the gels were incubated in fixing 
solution (7% acetic acid, 10% methanol) for 20 min and stained overnight at room 
temperature with 50ml SYPRO Ruby gel stain (Bio-Rad). The SYPRO ruby gel stain was 
then removed and gels stored in DI water. 
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Image analysis 
SYPRO ruby-stained gel images were obtained using a STORM phosphoimager 
(Ex. 470 nm, Em. 618 nm, Molecular Dynamics, Sunnyvale, CA, USA) and also saved in 
TIFF format. PD-Quest (Bio-Rad) imaging software was then used to match and analyze 
visualized protein spots among differential 2D gels with one gel for each individual 
sample. 
In-gel trypsin digestion 
Protein spots statistically different that controls were digested in-gel by trypsin 
using protocols previously described and modified by (Thongboonkerd et al., 2002). 
Briefly, spots of interest were excised using a clean blade and placed in Eppendorf tubes, 
which were then washed with 0.1 M ammonium bicarbonate (NH4HCO3) at room 
temperature for 15 min. Acetonitrile was then added to the gel pieces and incubated at 
room temperature for 15 min. This solvent mixture was then removed and gel pieces 
dried. The protein spots were then incubated with 20 µL of 20 mM DTT in 0.1 M 
NH4HCO3 at 56 °C for 45 min. The DTT solution was removed and replaced with 20 µL 
of 55 mM iodoacetamide in 0.1 M NH4HCO3. The solution was then incubated at room 
temperature for 30 min. The iodoacetamide was removed and replaced with 0.2 mL of 
50 mM NH4HCO3 and incubated at room temperature for 15 min. Acetonitrile (200 µL) 
was added. After 15 min incubation, the solvent was removed, and the gel spots were 
dried in a flow hood for 30 min. The gel pieces were rehydrated with 20 ng/µL-modified 
trypsin (Promega, Madison, WI) in 50 mM NH4HCO3 with the minimal volume enough 
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to cover the gel pieces. The gel pieces were incubated overnight at 37 °C in a shaking 
incubator. 
Mass spectrometry 
A MALDI-TOF mass spectrometer in the reflectron mode was used to generate 
peptide mass fingerprints. Peptides resulting from in-gel digestion with trypsin were 
analyzed on a 384 position, 600 µm AnchorChipTM Target (Bruker Daltonics, Bremen, 
Germany) and prepared according to AnchorChip recommendations (AnchorChip 
Technology, Rev. 2, Bruker Daltonics, Bremen, Germany).  Briefly, 1 µL of digestate 
was mixed with 1 µL of alpha-cyano-4-hydroxycinnamic acid (0.3 mg/mL in ethanol: 
acetone, 2:1 ratio) directly on the target and allowed to dry at room temperature. The 
sample spot was washed with 1 µL of a 1% TFA solution for approximately 60 seconds.  
The TFA droplet was gently blown off the sample spot with compressed air. The 
resulting diffuse sample spot was recrystallized (refocused) using 1 µL of a solution of 
ethanol: acetone: 0. 1 % TFA (6:3:1 ratio). Reported spectra are a summation of 100 laser 
shots. External calibration of the mass axis was used for acquisition and internal 
calibration using either trypsin autolysis ions or matrix clusters and was applied post 
acquisition for accurate mass determination.  
Analysis of peptide sequences 
Peptide mass fingerprinting was used to identify proteins from tryptic peptide 
fragments by utilizing the MASCOT search engine based on the entire NCBI and 
SwissProt protein databases. Database searches were conducted allowing for up to one 
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missed trypsin cleavage and using the assumption that the peptides were monoisotopic, 
oxidized at methionine residues, and carbamidomethylated at cysteine residues. Mass 
tolerance of 150 ppm, 0.1 Da peptide tolerance and 0.2 Da fragmentation tolerance was 
the window of error allowed for matching the peptide mass values (Butterfield and 
Castegna, 2003b). Probability-based MOWSE scores were estimated by comparison of 
search results against estimated random match population and were reported as -
10*log10 (p), where p is the probability that the identification of the protein is a random 
event. MOWSE scores greater than 63 were considered to be significant (p < 0.05). All 
protein identifications were in the expected size and isoelectric point (pI) range based on 
the position in the gel. 
Statistical analysis 
Statistical analysis of differentially expressed protein levels matched with spots 
on 2D-gels from frontal cortex brain samples of the p50 (-/+) and wild type (WT) were 
used and carried out using Student's t-tests. Here we report a comparative proteomics 
analysis of p50 (-/+) vs. WT. A value of p < 0.05 was considered statistically significant. 
Only proteins that are considered significantly different by Student's t-test were subjected 
to in-gel trypsin digestion and subsequent proteomic analysis. This is the normal 
procedure for proteomics studies, since sophisticated statistical analysis used for micro 
array studies are not applicable for proteomics studies (Maurer et al., 2005). 
Protein Interacteome 
  The functional protein interacteome was obtained by using Interaction Explorer 
TM Software Pathway Assist software package (Stratagene, La Jolla, CA). Pathway Assist 
is software for functional interaction analysis. It allows for the identification and 
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visualization of pathways, gene regulation networks and protein interaction maps 
(Donninger et al., 2004). The proteins are first imported as the gene symbols as a set of 
data. This data set is then searched against ResNet, a database containing over 500,000 
biological interactions built by applying the MedScan text-mining algorithms to all 
PubMed abstracts. These interactions are then visualized by building interaction networks 
with shortest-path algorithms. This process can graphically identify all known interaction 
among the proteins. The information of the function of these proteins and their relevance 
to diseases are then obtained by using the BIOBASE's Proteome BioKnowledge Library 
form Incyte Corporation (Incyte, Wilmington, DE) (Hodges et al., 2002). 
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B4 Results 
Decreased levels of oxidative stressing p50 (-/+) mice and compared to WT 
The levels of protein carbonyls, 3NT and HNE as indicators of oxidative stress 
were measured in the frontal cortex of p50 (-/+) mice and compared to WT. Fig.B1 
shows total protein oxidation measured by the accumulation of protein carbonyls and 
3NT and also the levels of lipid peroxidation as measured by protein-bound HNE. There 
was a significant decrease in the levels of all oxidative stress parameter measured in the 
p50 (-/+) mice compared to WT.  
Increased protein expression levels in p50 (-/+) mice compared to the wild type 
Two-dimensional electrophoresis offers an excellent tool for the screening of 
abundant protein changes in various disease states (Butterfield, 2004). To assess whether 
there were any changes in the proteomic profile in the brain of p50 (-/+) mice in the 
present study, we investigated the pattern of protein expression in the frontal cortex from 
the p50 (-/+) mice compared to the wild type. Comparing the densitometric intensities of 
individual spots on the gels, five proteins were expressed at significantly higher levels in 
the frontal cortex of p50 (-/+) mice compared to the wild type. Fig A2 shows SYPRO 
ruby stained 2D gels of the p50 (-/+) mice (A) vs. wild type (B) groups, with identified 
protein boxed and labeled. The brain proteins identified with increased expression in the 
p50 (-/+) mice were: ATP synthase gamma chain, Ubiquinol-cyt-C reductase, Heat shock 
protein (Hsp10), Fructose Bisphosphate aldolase C, and NADH-ubiquinone 
oxidoreductase. These proteins identified by mass spectrometry are shown in Table A1. 
Table A2 provides the changes in protein levels expressed as arbitrary units (A.U) ± 
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S.E.M. Table A1 shows that the mowse scores obtained are all highly significant and that 
the probability of a random identification using proteomics is exceedingly small in this 
study. 
Protein interacteome 
Fig B3 shows the protein interacteome of proteomics-identified proteins 
differentially expressed in the frontal cortex of p50 (-/+) mice. The Interaction Explorer 
PathwayAssist (Stratagene) software shows that the proteins identified in this study are 
related to regulation of signal transduction, energy metabolism, and chaperone activity 
among others. As a result, the present findings suggest that the partial knock out p50 
subunit of NF-κB leads to the expression of proteins that are involved in various 
pathways that provide normal development and protection against oxidative stress.  
 
 
 
 
 
 
 
 
 
 325
Figure B1 
 
 
 
 
 
 
 
 
Figure B1 Shows protein carbonyl, 3NT and HNE levels in the frontal cortex of p50 (-/+) 
compared to wild type. There was a significant reduction in the levels of protein 
carbonyls, 3NT and HNE in the p50 (-/+) mice compared to the wild type. Data are 
represented as % control; error bars indicate the SEM for each group measured (* p<0.05 
n=5).  
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Figure B2 
 
 
 
 
 
 
 
 
 
Figure B2 Shows SYPRO Ruby-stained 2D-gels maps of frontal cortex brain samples 
from Wild-type (A) vs. p50 (-/+) mice (B). Proteins identified by mass spectrometry 
showing differential expression are presented as the boxed spots. 
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Figure B3 
 
 
Figure B3 Schematic diagram of a functional interacteome of all proteins identified to be 
differentially expressed in the brains of p50 (-/+) compared to wild type. This diagram 
was generated by the interaction explorer ™ Pathway Module (Stratagene), indicating  
that all the proteins are directly or indirectly associated with cellular process shown.  
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B5 Discussion 
In the present study we have found that the partial knock out of the p50 subunit 
and a stimulus-free experimental set-up, lead to a reduction in the levels of oxidative 
damage in the p50 (-/+) mice brain when compared to that of the wild type mouse. We 
observed a significant reduction in the levels of oxidative stress biomarkers, i.e., protein 
carbonyls, 3NT and lipid peroxidation product HNE. In addition, we carried out a 
proteomic profile analysis of the frontal cortex of the p50 (-/+) mice brain and compared 
it to the wild type. We found that there was a significant increase in the expression of 
proteins related to energy metabolism and antioxidant activity in the p50 (-/+) mice brain 
compared to the wild type. These results present an intriguing finding and are discussed 
here with relevance to the mechanism of NF-κB transcription factor, and the role of the 
p50 subunit in oxidative stress.  
NF-κB has been known to transcribe a wide range of genes with different and 
sometimes opposite functions. NF-κB is involved in transcribing both pro-apoptotic 
genes such as p53, Fas and FasL (Matsui et al., 1998; Kirch et al., 1999) and anti-
apoptotic genes such as, Bcl-2, Bcl-x and SOD2 (Lipton, 1997; Mattson et al., 1997; 
Tamatani et al., 1999). NF-κB activity is regulated by various factors, such as stress and 
injury related stimuli, cell type, and organ type among others. The wide range of stress- 
and injury-related stimuli regulated by NF-κB present investigators with extreme 
difficulties in trying to elucidate mechanistic pathways of this transcription factor and has 
led to the generation of numerous differing findings. An understanding of its dual action 
might therefore be possible if we consider its various subunits and their role in regulating 
its activation. As mentioned earlier, NF-κB consists of several proteins, which include 
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NF-κB1 (p50), NF-κB2 (p52), RelA (p65), c-Rel (Rel), with the heterodimer p50/p65 
being the most predominant (Grilli et al., 1993; Ghosh et al., 1998; Santoro et al., 2003). 
Usually located in the cytosol, the presence of a stimulus triggers the translocation to the 
nucleus where it binds to promoter region of specific genes activating its transcription 
(Grilli et al., 1993).  
The role of its various subunits and in particular p50 in oxidative stress related 
mechanisms is still at question. Though the p50 subunit generated from precursor 
molecule p105 lacks a transactivation domain, its disruption in various experimental 
settings has generated a number of interesting findings. For example, in a model of 
Huntington’s disease p50 (-/-) mice have been shown to have increased oxidative stress, 
calcium dysregulation and increased damage to striatal neurons following treatment with 
mitochondrial toxin 3-nitropropionic acid (3NP) (Yu et al., 1999). It has also been shown 
that lack of p50 negatively modulates learning ability and hippocampal response to brain 
injury after chemical-induced lesion (Kassed et al., 2002). In addition, a higher 
constitutive expression of cyclooxygenase-2 (COX-2) in p50-/- mice following an acute 
inhalation of pulmonary irritant ozone has been observed (Mabley et al., 2002; 
Fakhrzadeh et al., 2004). It has also been reported that p50 is increased in neurons 
surviving hippocampal injury after middle cerebral artery occlusion (Pennypacker et al., 
2001) and that overexpression of p50  inhibits TNF- α gene expression following 
lipopolysaccharide (LPS) on p50-/-  splenocytes (Gadjeva et al., 2004). On the other 
hand, it has been shown that NF-κB p50-deficient mice show; reduced anxiety-like 
behaviors in tests involving exploratory drive and anxiety (Kassed and Herkenham, 
2004); reduced ischemic damage (Schneider et al., 1999); resistance to murine 
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enecephalomyocarditis virus (EMCV) infections that cause myocarditis and dilated 
cardiomyopathy which kill normal healthy mice (Schwarz et al., 1998); and reduced 
ventricular rupture and improved cardiac function and survival after myocardial 
infarction (MI) (Kawano et al., 2005). In addition to the above, a study by O’Donnell et 
al., 2005 showed that following reovirus infection in the CNS, NF-κB p50 (+/+) mice 
exhibited significant neuronal apoptosis, while p50 (-/-) mice displayed a minimal 
apoptotic response. On the other hand, reovirus infection in the heart induced minimal 
apoptosis in the NF-κB p50+/+ mice, while extensive apoptosis occurred in the heart of 
p50–/– mice (O'Donnell et al., 2005). This study provided two distinct roles for the NF-κB 
p50 subunit in the brain and heart, continuing to confirm the organ and cell type 
specificity of the NF-κB activity. The studies mentioned above provide two differing 
effects resulting from the disruption of the p50 subunit of NF-κB, hence, presenting  
researches with a difficult task of trying to conclusively elucidate the exact mechanisms 
of this key transcription factor (Lipton, 1997). 
It has been shown that NF-κB is redox regulated and that oxidative stress is an 
activator of NF-κB and a known regulator of gene transcription since most agents that 
that activate NF-κB, trigger the formation of reactive oxygen species (ROS) or are 
oxidants themselves, e.g. superoxide, hydrogen peroxide, hydroxyl radicals and 
peroxynitrite (Laskin and Pendino, 1995; Kim et al., 2000b; Chung et al., 2005). In 
addition, NF-κB activation can also be triggered by ROS in the absence of any stimulus, 
as is the case in the current study. The upstream processes for the activation of NF-κB 
have also been shown to involve a series of serine/threonine kinases and phosphatases 
that are regulated by the redox status of the cell, further emphasizing the interaction of 
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NF-κB and oxidative stress (Flohe et al., 1997). In the present study, we observed a 
significant decrease in the levels of oxidative stress as indexed by oxidative stress 
biomarkers, i.e., protein carbonyls, 3NT and lipid peroxidation product HNE in the brains 
of partially knocked out p50 (-/+) mice compared to those of the WT. It has previously 
been shown that 4-hydroxyhexenal (HHE), a reactive aldehdye similar to HNE, activates 
NF-κB which further activates p38, MAPK and extracellular signal regulated kinase 
(ERK) leading to various signaling cascades (Je et al., 2004). As a result, the reduced 
levels of HNE in the p50 (-/+) mice observed in the present study could thus inhibit the 
activation of NF-κB leading to a possible protective mechanism.  
The partial knock out of p50, i.e., p50 (-/+), generates a dysfunctional subunit, 
which as a result could lead to a possible compensatory mechanism from the other 
heterodimer member of the classical NF-κB transcription factor, p65. Since p65 has a 
transactivation domain and is responsible for the transcriptional activation of target 
genes, its compensatory role would therefore bring about a more functional NF-κB 
transcription factor and enhance activity (Kato et al., 2002). This proposed compensatory 
mechanism phenomenon has previously been documented in cytokine knockout mice 
where the redundancy of the cytokine cascade compensates for the deletion of a single 
cytokine gene (Kato et al., 2002). Various studies of p50 knockouts also continue to put 
forth the possible compensational role of p65. In a study of partial hepatectomy in p50 (-
/-) mice, there was an increased expression of the p65 protein in the nucleus which was 
believed to provide compensation for the absence of p50 leading to normal liver 
regeneration and repair following liver injury (Iimuro et al., 1998; Kato et al., 2002). It 
has also been shown that gene deletion of p50 does not alter hepatic inflammatory 
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response since the increased nuclei level of p65 protein in the p50 (-/-) mice compared to 
the p50 (+/+) mice was believed to compensate for sufficient transcriptional activation of 
relevant genes (Beg et al., 1995). It is also suggested that both p50 and p65 may have 
critical inhibitory functions and that the inhibitory functions of p65 are more clearly 
demonstrated in the absence of p50 (Gadjeva et al., 2004). In the same fashion, we 
hypothesis that the partial knock out of p50 leads to a dysfunctional heterodimer hence 
necessitating a compensatory response from p65 which then leads to the transcriptional of 
antioxidant genes and hence a reduction in the levels of oxidative stress. 
Other than the compensatory response mechanisms suggested for the reduction in 
oxidative stress levels in the p50 (-/+) mice, it is also possible that other pathways could 
be involved in activating the NF-κB leading to the observed reduction in the levels of 
oxidative stress observed in the present study. One potential pathway could be the 
involvement of nuclear factor-erythroid 2–related factor 2 (Nrf2). Just like NF-κB, Nrf2 
is also involved in the innate immune response and survival. In particular, Nrf2 regulates 
the basal and inducible expression of various antioxidant and other cytoprotective genes 
by binding to the antioxidant response element of DNA in conditions of oxidative stress 
(Motohashi and Yamamoto, 2004). It has been reported that there could be a possible 
cross-talk among redox-sensitive transcription factors NF-κB and Nrf2, in that there is 
dependency of key family members of AP-1 and NF-κB on Nrf2 (Yang et al., 2005). 
Thus, Nrf2 regulates NF- B activation largely by modulating its upstream signaling 
components (Thimmulappa et al., 2006). Under normal conditions, there are low nuclear 
levels of Nrf2; under stress conditions there is an increase in the nuclear accumulation of 
Nrf2 resulting in its binding to the antioxidant response element leading to enhanced 
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transcriptional activation of antioxidant target genes (Thimmulappa et al., 2006). A broad 
range of antioxidants has been known to inhibit the activation of NF-κB (Flohe et al., 
1997); however, oxidative stress induced activation of NF-κB leads to the up-regulation 
of antioxidant enzymes such as glutathione peroxidase and catalase among others 
(Messina et al., 2006). For the present study we believe that with the compensatory effect 
of p65, NF-κB could be activated and in turn it would activate Nrf2 leading to the up-
regulation of antioxidant enzymes resulting into the reduction in the level of oxidative 
stress observed.  Downstream effects of Nrf2 and NF-κB activity in the p50 (-/+) mice 
can be observed in the present study from the proteomics results obtained. In addition to a 
reduction in the levels oxidative damage in the p50 (-/+) mice in the current study, we 
also observed a significant increase in the expression of key proteins related to energy 
metabolism and cytoprotective activities. These proteins identified and their possible 
roles in survival are discussed as follows; 
Heat shock proteins (HSP) are a family of molecules that are highly conserved 
during evolution and involved in many cellular functions, such as protein folding. Some 
examples include HSP10, -27, -60, -70, -72 and -90. Mammalian heat shock protein 10 
(Hsp10) also known as chaperonin 10 is a mitochondrial protein involved in protein 
folding. It has been shown that HSP 10 forms a heptameric lid, which binds to a double-
ring toroidal structure that is composed of seven Hsp subunit rings (Xu et al., 1997). 
Increased expression of HSPs has recently been found to be associated with a number of 
neurodegenerative disorders, immunomodulatory activities among others (Flohe et al., 
2003; Poon et al., 2004b). It is believed that HSPs are exported to the plasma membrane 
and are released from apoptotic cells as a source of signaling to the innate and adaptive 
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immune system (Beg, 2002; Flohe et al., 2003). HSP10 and another chaperone HSP60 
interact in a two-step folding mechanism in the mitochondria of prokaryotic and 
eukaryotic cells (Beg, 2002) and it is hypothesized that HSP60 and HSP10 could possibly 
be a new diagnostic and prognostic tools for certain cancers (Triantafilou and 
Triantafilou, 2004). In the present study, we have shown that there is a significant 
increase in the expression of HSP10 in the p50 (-/+) mice compared to the wild type. The 
increased expression could mean enhanced activity leading to proper folding of proteins 
and more protection against oxidative stress and this could possibly contribute to the 
significant reduction of oxidative stress observed in these p50 (-/+) mice. 
The NADH: ubiquinone oxidoreductase also known as Complex I, couples the 
oxidation of NADH and the reduction of ubiquinone, to the generation of a proton 
gradient which is then used for generation of ATP in the mitochondria (Weiss et al., 
1991). This complex provides the input to the electron transport chain from the NAD-
linked dehydrogenases of the citric acid cycle. Dysregulation of this complex has been 
associated with various neurodegenerative disorders such as AD among others 
(Robinson, 1998; Loeffen et al., 2000). In the current study, we observed a significant 
increase in the expression of NADH: ubiquinone oxidoreductase in the p50 (-/+) mice 
compared to the wild type. The significance of this could imply increased activity and 
also provide an efficient mechanism for the generation of proton gradient that eventually 
leads to an increase in the production of ATP. 
Fructose Bisphosphate aldolase C (FBP) is a glycolytic enzyme that catalyses the 
reversible aldol cleavage or condensation of fructose-1, 6-bisphosphate into 
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dihydroxyacetone-phosphate and glyceraldehyde 3-phosphate (Perham, 1990). In 
vertebrates, three forms of this enzyme are found: aldolase A is expressed in muscle, 
aldolase B in liver, kidney, stomach and intestine, and aldolase C in brain, heart and 
ovary. The different isozymes have different catalytic functions: aldolases A and C are 
mainly involved in glycolysis, while aldolase B is involved in both glycolysis and 
gluconeogenesis (Perham, 1990). In the current study we observed a significant increase 
in the expression of FBP in the p50 (-/+) mice compared to the wild type that would lead 
to improved glycolytic function and enhanced energy metabolism. 
ATP synthase (Complex V) is a mitochondrial enzyme that utilizes the 
electrochemical proton gradient established across the inner mitochondrial membrane by 
the ETC for synthesis of ATP (Leyva et al., 2003). ATP synthase deficiency has been 
associated with an increase in oxidative stress (Basso et al., 2004). Our laboratory has 
shown that ATP synthase is oxidatively modified and is inactivated in the gracile axonal 
dystrophy (gad) mouse brain (Castegna et al., 2004). In the present study, ATP synthase γ 
chain expression was significantly increased in the p50 (-/+) mice compared to the wild 
type. The increased expression of this enzyme could presumably result in increased 
activity, hence enhancing the crucial cellular process of ATP generation. 
  Ubiquinol-cytochrome-C reductase also known as the bc1 complex or complex III 
is the central redox enzyme in the ETC. This complex catalyzes the oxidation of diverse 
quinols by high potential redox-carriers, in the process generating a proton gradient that 
is utilized for the generation of ATP (Mulkidjanian, 2005). In the current study the 
expression of the Ubiquinol-cytochrome-C reductase core protein 2 also known as 
complex III subunit II was found to be significantly increased. This is a component of the 
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Ubiquinol-cytochrome c reductase complex and the core protein 2 is required for the 
assembly of the Complex III. As a result, the increase in expression of three key proteins 
of the ETC, a glycolytic enzyme and a chaperone protein in the present study is very 
significant, in that this ensures not only sufficient generation of adequate ATP that would 
lead to improved cellular activities and hence survival in the p50 (-/+) mice, but also the 
proper folding of proteins.  
The present study and those discussed in this dissertation research underscore the 
complexity of the mechanism through which NF-κB is activated or repressed. It has been 
suggest that the ultimate biological effect of NF-κB activation will be dependent on a 
number of reasons; these include the stimulus responsible for this activation or 
repression, the subunit composition of the NF-κB, gene targets, the cell type and organ 
among many others (Culmsee et al., 2003). With these many variables to consider and 
different experimental approaches available, a wide variation in the interpretation of 
results will be expected. It should therefore be noted that whereas all these studies 
mentioned in this manuscript had various stimuli and the knockouts were homozygous, 
the present study had heterozygous knockout mice and there was no stimulus given. We 
believe that the differences in the knockout models are very subtle with the major 
difference being only on the lack of stimulus, which therefore should not undermine the 
importance of the present findings. Though speculative, we believe that the partial knock 
out of p50 subunit of NF-κB might be a pre-conditioning step preparing the mice against 
oxidative stress induced effects. The effect of various stimuli on the p50 (-/+) mice 
showing a reduced oxidative stress warrants further investigation since this might be a 
potential avenue for therapeutic interventions. We therefore provide additional insights 
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on the complexities of NF-κB activity especially in a stimulus-free environment. We also 
suggest that the p50 subunit of NF-κB plays a significant role in the oxidative stress-
related neurodegeneration and that it should be considered as a potential target in the 
development of therapeutics strategies involving oxidative stress and nuclear factor kappa 
B (NF-κB) activity. 
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Appendix C 
Data supporting figures and Tables 
  
Figure 4.1A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1B 
 
 
 
 
 
 
 
 
 
 
 
          
 
 
 
 
 
 
 
 
n CC EC CA EA 
     
1 415 485 260.5 320.5 
2 560 494 272 243 
3 393.5 343.5 405.5 360.5 
4 357.5 353.5 315 185 
5 360.5 361 458.5 289.5 
6 480.5  395 255 
     
Averages 427.833 407.4 351.083 275.583 
SEM 32.1796 33.6621 32.7565 25.2406 
% Control 100 95.224 82.0608 64.4137 
n CC EC CA EA 
     
1 491.667 319 371.5 379 
2 389.333 349 343.5 341 
3 407 389.5 347.5 308 
4 381 341 310 325 
5 320 332 323.5 321 
6 377  347 292 
     
Averages 394.333 346.1 340.5 327.667 
SEM 22.8494 11.9398 8.71875 12.2792 
% Control 100 87.7684 86.3483 83.0938 
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Figure 4.1C 
 
     
 
n CC EC CA EA 
1 381.5 469 361.5 434.5 
2 452 381.5 428 363 
3 371 348.5 398.5 352.5 
4 404.5 430.5 372.5 368.5 
5 449 361.5 343.5 388.5 
6 427  372 361.5 
     
Averages 414.16667 398.2 379.33333 378.08333 
SEM 13.944334 22.529758 12.163242 12.302044 
% Control 100 96.14487 91.58954 91.28773 
 
 
 
 
Table 4.3  
 
 CC EA %Control Sem 
1301 52.7658 9.295329 17.6162 7.592398 
2504 23.42602 6.361421 27.15537 5.339302 
3101 30.12821 6.159792 20.44526 5.697713 
4501 30.41586 7.046319 23.1666 6.583777 
9701 3.533036 0.562666 15.92585 0.325476 
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Figure 4.5  
  
 
Read 10 
Avg 
Read1 
Avg 
Change 
OD mg/ml Activity 
Specific 
activity 
CC1 1.003 0.8335 0.1695 8.8589552 0.1765625 0.0199304 
CC2 1.2705 1.064 0.2065 10.515477 0.2151042 0.020456 
CC3 1.334 1.1575 0.1765 9.5210958 0.1838542 0.0193102 
CC4 1.0765 0.958 0.1185 8.7279309 0.1234375 0.0141428 
CC5 1.049 0.8575 0.1915 7.4340659 0.1994792 0.0268331 
      0.0201345 
       
EA1 1.3435 1.075 0.2685 8.2108528 0.2796875 0.0340631 
EA2 1.525 1.2655 0.2595 9.6427613 0.2703125 0.0280327 
EA3 1.734 1.474 0.26 8.0213356 0.2708333 0.0337641 
EA4 1.472 1.2895 0.1825 7.8388374 0.1901042 0.0242516 
EA5 1.467 1.262 0.205 7.951144 0.2135417 0.0268567 
      0.0293937 
       
     CC EA 
   GST % Control 100 145.98653 
   
Change 
in OD mg/ml Activity 
Specific 
activity 
CC1 0.059 0.0725 0.0135 0.3129096 0.0047647 0.0696962 
CC2 0.07 0.0835 0.0135 0.1507208 0.0047647 0.1446953 
CC3 0.0535 0.0655 0.012 0.3211009 0.0042353 0.0603718 
CC4 0.061 0.074 0.013 0.3112713 0.0045882 0.0674681 
CC5 0.0605 0.0715 0.011 0.2621232 0.0038824 0.0677924 
      0.082005 
       
EA1 0.0755 0.1025 0.027 0.1982307 0.0095294 0.2200326 
EA2 0.064 0.091 0.027 0.3079948 0.0095294 0.1416167 
EA3 0.06 0.0785 0.0185 0.3964613 0.0065294 0.0753815 
EA4 0.059 0.0875 0.0285 0.2588467 0.0100588 0.1778674 
EA5 0.0645 0.08 0.0155 0.1965924 0.0054706 0.1273676 
      0.148453 
       
   SOD CC EA  
   
% 
control 100 181.0299  
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Figure 4.6  
 
 
 CC EA 
 250 342 
 146 360 
 231 340 
 191 362 
 226 331 
 311 409 
Average 225.83333 357.33333 
SEM 22.694223 11.441639 
%Control 100 158.2288 
 
 
 
 
 
Table 5.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CU/ZN 
SOD   FBP   CK   
  CC CE Control CE Control CA 
  5121 5601 4134 3455 6586 5470 
  2436 5762 2093 6386 4777 8022 
  1880 5401 2004 5531 1088 5448 
  1718 4621 2785 4075 4545 10010 
  2553 6549 1979 3243 4769 8252 
Average 2741.6 5586.8 2599 4538 4353 7440.4 
Fold 
change   2.037788   1.746056   1.709258 
 GLUD   GAPDH   
 Control CE Control EA 
 3337 3448 4289 7248 
 1615 3779 3902 12762 
 1905 3528 2668 9710 
 2412 3118 4189 7737 
 1757 2864 3306 5581 
Average 2205.2 3347.4 3670.8 8607.6 
Fold 
change   1.517958   2.344884 
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Figure 5.3 
 
 
 
      
Change 
in OD mg/ml Activity 
Specific 
activity 
CC1 0.059 0.0725 0.0135 0.3129096 0.0047647 0.0696962 
CC2 0.07 0.0835 0.0135 0.1507208 0.0047647 0.1446953 
CC3 0.0535 0.0655 0.012 0.3211009 0.0042353 0.0603718 
CC4 0.061 0.074 0.013 0.3112713 0.0045882 0.0674681 
CC5 0.0605 0.0715 0.011 0.2621232 0.0038824 0.0677924 
      0.082005 
       
EA1 0.0755 0.1025 0.027 0.1982307 0.0095294 0.2200326 
EA2 0.064 0.091 0.027 0.3079948 0.0095294 0.1416167 
EA3 0.06 0.0785 0.0185 0.3964613 0.0065294 0.0753815 
EA4 0.059 0.0875 0.0285 0.2588467 0.0100588 0.1778674 
EA5 0.0645 0.08 0.0155 0.1965924 0.0054706 0.1273676 
      0.148453 
                    SOD CC EA   
  %  Control 100 181.0299   
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Figure 5.4 
 
 
 
 
Case 
Treatment 
Group Aox Diet 
Env 
Enrich 
Black/White 
discrimination 
errors 
Black/white 
Reversal 
Errors 
Spatial 
errors CuZnSOD 
1521S 1 1 1 N/A N/A N/A 1718 
1510A 1 1 1 154 219 250 1880 
1508U 1 1 1 N/A N/A N/A 2436 
1543S 1 1 1 50 197 214 2553 
1494D 1 1 1 83 219 265 5121 
1506B 2 1 2 8 219 278 3761 
1529S 2 1 2 12 128 275 4286 
1523U 2 1 2 28 84 232 5486 
1542S 2 1 2 8 57 91 5815 
1518D 2 1 2 79 96.5 33 7477 
1491B 3 2 1 74 202 255 N/A 
1508A 3 2 1 74 146 60 N/A 
1509U 3 2 1 131 182 N/A N/A 
1523B 3 2 1 77 137 120 N/A 
1532S 3 2 1 108.5 202 223 N/A 
1542T 4 2 2 85 145 142 4621 
1541B 4 2 2 21 64 177 5401 
1502S 4 2 2 82 142 263 5601 
1521B 4 2 2 60 70 58 5762 
1581T 4 2 2 44 52 7 6549 
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Figure 6.1 
 
 
 Normal AD 
 596 413 
 511.5 462 
 448 552 
 487.5 489.5 
  542.5 
Average 510.75 491.8 
Stdev 62.57329 57.65696 
SEM 31.286645 23.062784 
 
 
 
 
 
Figure 6.2 
 
 
 
 
 IsoP (ng/ml) NeuroP (ng/ml) 
 Normal AD Normal AD 
 1.98 1.34 128.56 131.64 
 2.25 1.99 136.54 233.18 
 1.95 1.22 170.41 127.66 
 2.17 1.41 108.07 53.21 
  2.84  89.92 
Average 2.0875 1.76 135.895 127.122 
Stdev 0.145688 0.3424422 25.946959 73.905317 
%Control 100 84.311377 100 93.544281 
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Table 6.4  
 
  
    MDH   FBP   UCHL1 
  Normal AD Normal AD Normal AD 
  1711.2 1185.6 1632 3021.8 2124.8 3549.2 
  1898.5 1025.4 2037.1 2932 1915.2 3765.3 
  1754.2 1202.5 1884.2 2339.7 2792.8 4202.5 
  1954.2 1085.2 1896.1 2242.8 1951.7 3178.7 
Average 1829.53 1124.68 1862.35 2634.075 2196.125 3673.925 
Fold 
Change   0.6147371   1.4143824   1.6729125 
 
 
 
 
  GAPDH     ATP    PRDX 
              
  Normal AD Normal AD Normal AD 
  4734.3 10993.3 4305.8 45.3 3625.3 2113.6 
  6273.3 6132.1 2308.6 1072.4 3339 2708.3 
  4740.9 8798.7 2947.5 10.6 6012.8 1409.1 
  2614.2 6700.2 1772.2 2881.5 2516.3 1701.5 
Average 4590.675 8156.075 2833.525 1002.45 3873.35 1983.125 
Fold 
Change   0.5628535   0.353782   0.5119922 
 
 
 
Figure 7.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 RCR SD 
Ipsi 2.30 1.30 
Contra 7.10 1.40 
Sham 8.00 2.00 
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Figure 7.2 
 
 
 HNE  3NT  Carbonyl  
 CH IH CH IH CH IH 
 368.5 802 394.25 604 736.66667 1003.3333 
 502 779 460.5 565 698.66667 1142.6667 
 481.5 753.5 448 659.5 754 926.233 
 595.5 626.5 409 612 680.66667 890.66667 
Average 486.875 740.25 427.9375 610.125 717.5 990.72492 
% Control 100 152.04108 100 142.57339 100 138.08013 
Sem 46.609805 39.188912 15.695798 19.397568 16.859715 55.83915 
 
 
 
 
 
Table 7.3 
 
 
Cortex 
Contra 
blots/gels Ipsi blot/gels  
SSP Average Average % Control Sem 
3402 62.2 228.3 367.1 47.2 
5404 16.9 162.7 962.8 68.8 
6606 1.3 36.7 2742.7 85.9 
6609 0.02 0.06 318.8 30.0 
3303 0.06 1.28 2042.5 74.3 
 
 
Table 7.4  
 
Hippo 
Contra 
Blots/gels Ispi Blots/gels  
SSP Average Average 
% 
Control Sem 
3303 0.062485 0.851117 1362.103 38.55067 
4204 0.028807 0.351442 1220.004 31.80999 
6511 7.174938 42.21875 588.4197 37.7746 
6609 0.021081 0.109313 518.536 27.16987 
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Figure 7.7  
 
Complex I Mean SEM 
Contralateral 92.50 0.925 
Ipsilateral 52.90 12.5 
 
 
Complex IV Mean SEM 
Contralateral 96.76 6.11 
Ipsilateral 73.18 3.41 
 
 
PDH activity Mean SEM 
Contralateral 99.50 5.22 
Ipsilateral 84.10 13.97 
 
 
 
 
 
Figure A1 
 
 Ctrl Fe2+/H2O2 29 40 52 
 336 589 448 540 509 
 381 611 412 569 472.5 
 358.5 600 386 554.5 423 
 321 599 342 509 462 
 354 606 378 512 412 
 365.2 576 404 523 445 
Average 352.6167 596.8333 395 534.5833 453.9167 
Stdev 21.33639 12.6082 35.6595 24.12139 35.31914 
Sem 8.534557 5.043279 14.2638 9.648558 14.12766 
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Figure A3 
 
 Ctrl Fe2+/H2O2 D609 40 nM 
D609+ 40 nM 
DCC 
 336 589 225 436 306 
 381 611 242 509 293 
 358.5 600 233.5 472.5 299.5 
 321 599 221.5 462 311 
 354 606 263.2 421 285.1 
 365.2 576 241 488 279 
Average 352.6167 596.8333 237.7 464.75 295.6 
Stdev 21.33639 12.6082 14.97331 32.57875 12.27273 
Sem 8.534557 5.043279 5.989324 13.0315 4.909094 
 
 
 
 
Figure A4 
 
 Ctrl 29 40 52 
 104 107 137 114 
 124 125 171 121 
 65 130 175 99 
Average 97.66667 120.6667 161 111.3333 
% Control 100 123.5495 164.8464 113.9932 
Stdev 30.00556 12.09683 20.88061 11.23981 
SEM 20.0037 8.064554 13.92041 7.493207 
 
 
 
 
Figure A5 
 
 Ctrl 29 40 52 
 182 99 84 97 
 184 146 151 139 
 133 107 157 93 
Average 166.3333 117.3333 130.6667 109.6667 
% Control 100 70.54108 78.55711 65.93186 
Stdev 28.88483 25.14624 40.52571 25.48202 
Sem 16.69643 14.5354 23.42527 14.72949 
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Figure A6  
 
 CC 29nm 40nm 52nm 
 203 228 309 183 
 196 247 326 142 
 191 236 301 153 
 186 214 316 146 
Average 194 231.25 313 156 
%Control 100 119.201 161.3402 80.41237 
Stdev 7.25718 13.88944 10.61446 18.5652 
Sem 3.62859 6.944722 5.307228 9.2826 
 
 
 
 
Figure A7 
 
 C Fe2+/H202 370nM 700nM 1mM 
 401 538 380 333 307 
 328 512 371 326 306 
 353 498 375 329 298 
 336 502 362 336 310 
Average 354.5 512.5 372 331 305.25 
% Control 100 144.5698 104.9365 93.37094 86.10719 
Stdev 32.70576 17.99074 7.615773 4.396969 5.123475 
Sem 16.35288 8.995369 3.807887 2.198484 2.561738 
 
 
 
Figure B1 
 
 Carbonyl  HNE  3NT  
 wt ko wt ko wt ko 
 232.5 171 379.5 301.5 534.33333 365.66667 
 367.5 154 389.5 341.5 419 336.33333 
 271 191 355 269 423 432.33333 
 166 170.5 357.5 351.5 443.33333 429.33333 
 298.5 157 496.5 353 476.33333 434.66667 
Average 267.1 168.7 395.6 323.3 459.2 399.66667 
% Control 100 63.159865 100 81.723964 100 87.035424 
Stdev 74.9995 14.652645 58.260621 36.852069 47.740968 45.659975 
Sem 34.090682 6.6602931 26.482101 16.750941 21.70044 20.754534 
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Figure B2 
 
 
 WT KO 
Fold 
change p value 
ATP Synthase 959.14 1367.02 1.42526 0.0562 
Ubiquinol cyt c reductase 2113.84 8008.46 3.78858 0.01624 
HSP10 1340.64 2671.24 1.99251 0.04613 
FBP 1343.66 1609.08 1.19754 0.01913 
NADH-ubiquinone 345.9 780.54 2.25655 0.05324 
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